
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

38453898
1769
10.1038/s41392-024-01769-5
Review Article
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou Qian 12345
Meng Yu 12345
Li Daishi 12345
Yao Lei 6
Le Jiayuan 12345
Liu Yihuang 12345
Sun Yuming 7
http://orcid.org/0000-0001-6621-8131
Zeng Furong zengflorachn@hotmail.com

8
http://orcid.org/0000-0001-8187-636X
Chen Xiang chenxiangck@126.com

12345
http://orcid.org/0000-0002-4424-9727
Deng Guangtong dengguangtong@outlook.com

12345
1 grid.216417.7 0000 0001 0379 7164 Department of Dermatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China
2 National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, 87 Xiangya Road, Changsha, 410008 Hunan Province China
3 Furong Laboratory, 87 Xiangya Road, Changsha, 410008 Hunan Province China
4 https://ror.org/00f1zfq44 grid.216417.7 0000 0001 0379 7164 Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China
5 grid.452223.0 0000 0004 1757 7615 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 87 Xiangya Road, Changsha, 410008 Hunan Province China
6 grid.216417.7 0000 0001 0379 7164 Department of General Surgery, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China
7 grid.216417.7 0000 0001 0379 7164 Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China
8 grid.216417.7 0000 0001 0379 7164 Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan Province China
8 3 2024
8 3 2024
2024
9 5523 10 2023
21 1 2024
3 2 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Ferroptosis is a non-apoptotic form of regulated cell death characterized by the lethal accumulation of iron-dependent membrane-localized lipid peroxides. It acts as an innate tumor suppressor mechanism and participates in the biological processes of tumors. Intriguingly, mesenchymal and dedifferentiated cancer cells, which are usually resistant to apoptosis and traditional therapies, are exquisitely vulnerable to ferroptosis, further underscoring its potential as a treatment approach for cancers, especially for refractory cancers. However, the impact of ferroptosis on cancer extends beyond its direct cytotoxic effect on tumor cells. Ferroptosis induction not only inhibits cancer but also promotes cancer development due to its potential negative impact on anticancer immunity. Thus, a comprehensive understanding of the role of ferroptosis in cancer is crucial for the successful translation of ferroptosis therapy from the laboratory to clinical applications. In this review, we provide an overview of the recent advancements in understanding ferroptosis in cancer, covering molecular mechanisms, biological functions, regulatory pathways, and interactions with the tumor microenvironment. We also summarize the potential applications of ferroptosis induction in immunotherapy, radiotherapy, and systemic therapy, as well as ferroptosis inhibition for cancer treatment in various conditions. We finally discuss ferroptosis markers, the current challenges and future directions of ferroptosis in the treatment of cancer.

Subject terms

Cancer
Cell biology
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 82272849 82102803 82103183 Zeng Furong Deng Guangtong issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

Every living being eventually dies. Cell death is a key biological process inherent in complex organisms, serving as a crucial mechanism for the elimination of unwanted cells.1 Mammalian cell death encompasses accidental cell death, an uncontrolled biological event triggered by unexpected attacks and injuries, and regulated cell death (RCD), which is driven by a genetically encoded apparatus and can be modulated by drug or genetic interventions.2 The orderly progression of RCD in complex organisms is integral to its normal development and homeostasis,3 while the loss of controlled cell death contributes to human diseases such as cancers, characterized by the presence of abnormal cells exhibiting unlimited replication and immortality due to successful evasion of cell death regulation. Cancer treatment strategies consistently prioritize the selective eradication of cancer cells while minimizing harm to normal cells. RCD is an important channel for achieving this, as it enables the specific targeting of tumor cells and enhances the efficacy of drug-induced cell death, while simultaneously reducing adverse effects on normal cells.

Ferroptosis, a term coined by the laboratory of Brent R. Stockwell in 2012, is a distinct mode of RCD characterized by the iron-dependent lethal accumulation of membrane-localized lipid peroxides.4 Cells undergoing ferroptosis display distinct hallmarks compared to other extensively studied forms of RCD,5 such as apoptosis,6 pyroptosis,7 and necroptosis.5 Morphologically, ferroptotic cells exhibit dysmorphic small mitochondria with condensed membranes and decreased crista.4,8–10 Mechanically, unlike classical RCD involving specific executioner proteins of cell death (such as gasdermin D for pyroptosis, caspase for apoptosis, and mixed lineage kinase domain-like protein (MLKL) for necrosis), the identity of the cell death executioner proteins in ferroptosis remains unclear. While it is widely accepted that the execution of ferroptosis necessitates the oxidized phospholipids (PLs) containing polyunsaturated fatty acids (PUFA-PLs), the mechanisms by which these oxidized PUFA-PLs, beyond a certain threshold, lead to membrane permeabilization and cell death, as well as the downstream executioners that mediate the eventual execution event known as the ‘point of no return’ in ferroptosis, remain largely elusive.11 The process of ferroptosis involves ferrous iron accumulation, free radical production, antioxidant system dysfunction, and lipid peroxidation. Based on its distinctive features, a comprehensive panel of biomarkers and functional tests, including pharmacological inhibition, has been assembled to effectively differentiate ferroptosis from other types of RCD, providing suitable tools for investigating the pathophysiological functions of ferroptosis.12

In recent years, modulating ferroptosis to intervene in the occurrence and development of cancer has been a hotspot and focus of etiological research and treatment. Ferroptosis is tightly implicated in tumor biology. On the one hand, tumor suppressors have been found to execute part of their tumor-suppression function depending on ferroptosis induction. Ferroptosis seems to be an innate tumor-suppressive mechanism.12,13 On the other hand, cancer cells, in order to support their survival, can evolve several mechanisms to evade host ferroptosis, which provides vulnerable targets for ferroptosis-based therapy. Interestingly, mesenchymal and dedifferentiated cancer cells, which typically exhibit resistance to apoptosis and traditional treatment approaches, display a remarkable susceptibility to ferroptosis. Consequently, ferroptosis is recognized as an attractive target for cancer treatments, especially for refractory tumors. So far, a plethora of ferroptosis interventions have shown promising effectiveness in cancer treatment even overcoming resistance to traditional therapies,14–16 and ferroptosis is also involved in the tumor-suppressive functions of radiotherapy and immunotherapy.17–20 Combination therapy based on ferroptosis is a highly promising strategy for enhancing the effectiveness of conventional therapies, tackling resistant tumors, and preventing tumor recurrence. However, the role of ferroptosis in tumor suppression depends on the context, as it appears to have apparently paradoxical roles in different stages of some tumors. For instance, ferroptosis induction facilitates the progression of chronic liver diseases to hepatocellular carcinoma (HCC),21 while it can restrain the established HCC development.22 Moreover, a study found that ferroptosis inhibitors can effectively suppress tumor growth as long as they are administered early when the tumor is sufficiently small.23 Therefore, achieving a comprehensive and in-depth understanding of the role of ferroptosis in cancers is crucial for effectively guiding its application in cancer treatment.

Given the vigorous growth in ferroptosis, it is imperative to gain iterative insights into ferroptosis. Here, we review the major milestones and molecular machinery of ferroptosis, including drivers and defenses two systems. Then, we decipher the functions of ferroptosis in tumor biology, the classic cancer-related ferroptosis regulatory pathways and ferroptosis-mediated crosstalk between cancers and immune cells. Lastly, we summarize the potential ferroptosis-based therapy and ferroptosis markers and discuss the current limitations and future directions of ferroptosis in the treatment of cancer.

Major milestone of ferroptosis

In the past decade, we have witnessed a significant surge in research on ferroptosis24 (Fig. 1). Although the term ferroptosis was coined in 2012,4 the clues to ferroptosis date back much earlier. Iron-induced toxicity was first observed in 1908.25 The importance of cystine in the viability and growth of mouse fibroblast strain L and the HeLa cell was reported in 1955.26,27 Dietary cystine and selenium in 1959 were further found to significantly reduce peroxidation in the liver and muscle of vitamin E-deficient chicks.28 In 1977, Shiro Bannai and colleagues observed that withdrawal of cystine-induced cell death accompanied by glutathione (GSH) depletion could be rescued by antioxidant vitamin E supplementation.29 They further reported in 1980 that cystine could be taken up from the environment by the system xc- in exchange for glutamate.30 The identification of glutathione peroxidase 4 (GPX4), a selenoprotein, in 1982 as a GSH-dependent peroxidase to counteract lipid peroxidation in membranes, marked a significant milestone.31 Over the following decade, GPX4 was found to counteract cell death associated with lipid peroxidation.32 In 1989, it was observed that glutamate-induced cytotoxicity resulted from the cystine uptake inhibition, leading to decreased GSH levels, oxidative stress, and ultimate cell death.33 Antioxidant treatments, such as alpha-tocopherol (α-toc), as well as inhibition of iron-containing lipid dioxygenase arachidonate lipoxygenase 12 (ALOX12), in 1992 and 1997, respectively, were found to prevent this form of cell death.34,35 Remarkedly, in 2001, the concept of “oxytosis” was coined to characterize the non-apoptotic cell death in neurons that is induced by oxidative stress in response to glutamate toxicity.36 While both oxytosis and ferroptosis involve reactive oxygen species (ROS) production, ALOXs and GSH depletion,36 and could be suppressed by iron chelators and enhanced by various sources of iron,37 some special features in oxytosis including cyclic guanosine monophosphate (cGMP)-gated channels, mitochondrial swelling and DNA fragmentation,38 highlighted ferroptosis as a distinct form of RCD.Fig. 1 History of research on the discovery and development of ferroptosis. The term ferroptosis was coined in 2012, but the understanding of ferroptosis can be traced back as early as 1908. Since 2012, there has been a flourishing development in the research of ferroptosis and its regulatory mechanisms. ACSL4 acyl-CoA synthetase long-chain family member 4, DHODH dihydroorotate dehydrogenase, Fer-1 ferrostatin-1, FSP1 ferroptosis suppressor protein 1, GCH1 GTP cyclohydrolase 1, GPX4 glutathione peroxidase 4, HSC hematopoietic stem cells, MBOAT1/2 membrane-bound O-acyltransferase domain-containing 1 and 2, PL phospholipid, PMN-MDSC polymorphonuclear myeloid-derived suppressor cell, PUFA polyunsaturated fatty acid, VK vitamin K

The discovery of ferroptosis stemmed from the high-throughput screening of small molecules aimed at targeting oncogenic RAS mutations. In 2003, erastin was identified as a selective inducer of non-apoptotic cell death in cancer cells dependent on ST- and RASG12V,39 along with the involvement of the RAS/BRAF/MEK/MAPK pathway and voltage-dependent anion channel (VDAC) that mediate oxidative stress and mitochondrial dysfunction, respectively.40 Another small molecule compound, RSL3, was discovered in 2008 through the same screening system, which could activate an iron-dependent form of cell death.41 In the same year, the inactivation of GPX4 was reported to induce a non-apoptotic cell death that could be suppressed by alpha-tocopherol and ALOX12/15 inhibitors.42 It was only in 2012 that the term “ferroptosis” was coined to describe this form of cell death, due to its dependence on iron, unique morphology, biochemical traits, and genetic features that distinguish it from other forms of regulated cell death.4 Erastin was discovered to block cystine uptake by inhibiting system xc- to induce ferroptosis, while ferrostatin-1 was identified as a powerful inhibitor of ferroptosis in cancer cells.4 In the following decades, breakthroughs in ferroptosis yielded a comprehensive insight into the mechanisms responsible for the execution and regulation of this process.

In 2014, GPX4 was identified as the central regulator of RSL3- and erastin-induced ferroptosis, and RSL3 directly inactivates GPX4, leading to lipid peroxidation and ultimately ferroptosis.43 Moreover, knockout of GPX4 causes cell death, while liproxstatin-1, a potent spiroquinoxalinamine derivative, is reported to suppress ferroptosis.8 In 2015, through the extensive use of massive insertional mutagenesis on haploid KBM7 cells, the inactivation of acyl-coenzyme A (CoA) synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) was shown to render these cells resistant to ferroptosis. Meanwhile, the most commonly mutated tumor suppressor protein, p53, suppresses solute carrier family 7 members 11 (SLC7A11) expression and cystine uptake, sensitizing cells to ferroptosis.13 In 2016, ferroptosis was found to rely on PUFA oxidation by ALOXs via a phosphorylase kinase G2 (PHKG2)-dependent iron pool and the covalent inhibition of the catalytic selenocysteine in GPX4 hinders the removal of PUFA hydroperoxides.44 Simultaneously, it has been reported that FIN56 not only induces the degradation of GPX4 but also depletes ubiquinone (CoQ10) through the mevalonate pathway to enhance ferroptosis sensitivity.45 In 2017, ACSL4 was further identified as an essential component for ferroptosis execution by promoting arachidonic acid (AA) or adrenic acid (AdA) esterification into phosphatidylethanolamines (PEs).46 A further study in 2018 underlined the requirement for selenium utilization by GPX4 to inhibit hydroperoxide-induced ferroptosis.45 In 2019, CD8+ T cells were shown to induce tumor ferroptosis during cancer immunotherapy.19 In the meantime, E-cadherin-mediated intercellular contacts control ferroptosis sensitivity through the Merlin/Hippo/Yes-associated protein 1(YAP) pathway to regulate the expression of ACSL4 and transferrin receptor (TFR1) in response to cell-cell contacts.47 Moreover, using unbiased genetic screens, ferroptosis suppressor protein (FSP1), previously named apoptosis-inducing factor mitochondria-associated 2 (AIFM2), was independently discovered as a novel ferroptosis resistance gene capable of complementing the loss or inhibition of GPX4.48,49

Two groups in 2020 independently identified GTP cyclohydrolase-1 (GCH1) as a suppressor of ferroptosis.50,51 Mechanistically, GCH1 suppresses ferroptosis through two main mechanisms. First, it produces the lipophilic antioxidant tetrahydrobiopterin (BH4), which aids in the prevention of lipid peroxidation. Second, GCH1 increases the abundance of the reducing agent CoQ10, which further protects against ferroptosis. This dual action of GCH1 contributes to the suppression of lipid peroxidation and the maintenance of cellular redox balance.50,51 Moreover, Zou et al. identified the oxidative organelles peroxisomes as a crucial factor in driving susceptibility to and evasion from ferroptosis through the synthesis of polyunsaturated ether PLs (PUFA-ePLs), which serve as substrates for lipid peroxidation.52 The administration of the engineered enzyme cyst(e)inase demonstrated a viable method to trigger ferroptosis in pancreatic ductal adenocarcinoma (PDAC) by depleting cysteine and cystine.53 Additionally, Ubellacker et al. found that melanoma cells in the lymph are prone to forming metastases in blood because lymph protects metastasizing melanoma cells from ferroptosis.54 In 2021, dihydroorotate dehydrogenase (DHODH) was discovered to be a mitochondrial suppressor of ferroptosis through its ability to decrease mitochondrial CoQ10 levels, and DHODH inhibitors had ferroptosis-sensitizing effects which was argued by Mishima et al. that DHODH inhibitors enhance sensitivity to ferroptosis through the inhibition of FSP1.55 In 2022, it was discovered that pathologically activated neutrophils, known as polymorphonuclear (PMN) myeloid-derived suppressor cells (MDSCs), undergo spontaneous ferroptosis, which contributes to immune suppression in cancer, highlighting the role of ferroptosis in immune regulation within the tumor microenvironment.23 Furthermore, FSP1 was further discovered to efficiently reduce vitamin K to its hydroquinone, providing protection against harmful lipid peroxidation and ferroptosis.56 Further studies in 2023 demonstrated that FSP1-dependent phase separation is crucial for ferroptosis induction.57 Besides, Zhao et al. found that low protein synthesis rates increased the susceptibility of hematopoietic stem cells to ferroptosis.58 Strikingly, through a whole-genome CRISPR activation screen, sex hormone-driven membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) expressions were reported to prevent ferroptosis in cancer cells lacking the two main ferroptosis defense systems GPX4 and FSP1.59 Collectively, these studies contribute to a deeper understanding of the mechanisms and regulation of ferroptosis, highlighting its significance in the potential for therapeutic interventions.

Molecular mechanisms of ferroptosis

Ferroptosis reflects a redox imbalance between its drivers and defenses system.24,60 Here, we briefly outline its core mechanisms, with a specific emphasis on its driving and defense mechanisms (Fig. 2). For a more comprehensive and detailed understanding of the molecular pathways and intricate mechanisms underlying ferroptosis, we recommend referring to several recent reviews in the field.12,24,60–64Fig. 2 Molecular mechanisms of ferroptosis. Ferroptosis is driven by PUFA-PLs synthesis, lipid peroxidation and iron toxicity. Major defense systems of ferroptosis include the GPX4 antioxidant system, FSP1/ubiquinol (CoQH2), DHODH/CoQH2, GCH1/tetrahydrobiopterin (BH4) systems, monounsaturated fatty acid (MUFA)-PLs synthesis, and the ESCRT-III-mediated membrane repair systems. When ferroptosis-promoting activities significantly surpass the detoxification capabilities provided by the defense systems, a fatal accumulation of lipid peroxides on the cellular membranes ultimately results in membrane rupture and ferroptotic cell death. ABCB7 ATP binding cassette subfamily B member 7, ACC acetyl-CoA carboxylase, ALOX lipoxygenase, CISD1 CDGSH iron sulfur domain 1, CoQ coenzyme Q, Cys cysteine, Cys2 cystine, FTMT ferritin mitochondrial, GCL glutamate-cysteine ligase, GSH glutathione, GSSG oxidized glutathione, iPLA2b phospholipase A2 group VI, LIP labile iron pool, LPCAT3 lysophosphatidylcholine acyltransferase 3, NAD(P)H nicotinamide adenine dinucleotide phosphate, POR cytochrome P450 oxidoreductase, SCD1 stearoyl-CoA desaturase 1, SFA saturated fatty acid, SLC25A37, solute carrier family 25 member 37, SLC25A28 solute carrier family 25 member 28, SLC40A1 solute carrier family 40 member 1, STARD7 StAR-related lipid transfer domain containing 7, TF transferrin, TFR1 transferrin receptor, VDAC voltage-dependent anion channel. This figure was created with BioRender.com

Drivers of ferroptosis

PUFA-PLs synthesis

PUFAs are highly prone to lipid peroxidation due to the presence of weak C-H bonds at the bis-allylic positions.44,65 Recent studies mainly focus on ω-6 PUFAs, such as linoleic acid (18:2), gamma-linolenic acid (18:3), dihomo-gamma-linolenic acid (20:3), AA (20:4) and AdA (22:4), as well as ω-3 PUFAs, including alpha-linolenic acid (18:3), eicosapentaenoic acid (20:5) and docosahexaenoic acid (22:6).66,67 Among them, AA (20:4) and AdA (22:4), are the primary substrates of lipid peroxidation during ferroptosis.68 Notably, free PUFAs are not the direct drivers of ferroptosis, and they need to be esterified into membrane PLs to exhibit lethality after peroxidation.46,68,69 ACSL4 and LPCAT3 are responsible for the biosynthesis and esterification of PUFA-PLs. Taking AA (20:4) as a case in point, ACSL4 catalyzes the combination of free AA (20:4) and CoA to form a CoA-AA (20:4) intermediate, which is subsequently esterified into PEs by LPCAT3 to generate AA (20:4)-PE (PE-AA),46,68,69 which are necessary for the execution of ferroptosis. Consistently, malonyl-CoA generated by acetyl-CoA carboxylase (ACC)-catalyzed carboxylation of acetyl-CoA is critical for the synthesis of certain PUFAs and is therefore necessary for ferroptosis.60 The peroxisome-mediated biosynthesis of plasmalogens has been suggested as an additional pathway for the production of PUFAs involved in lipid peroxidation, favoring ferroptosis onset.52,70 On the contrary, phospholipase A2 group VI (iPLA2β) cleaves oxidized PUFA tails from PLs to suppress p53-driven ferroptosis.71 Remarkedly, deuterated PUFAs (D-PUFAs) at bis-allylic position retards the radical chain reaction of lipid peroxidation to protect against RSL3- or erastin-induced ferroptosis,44 suggesting the significance of the structure of PUFAs in its activity.

Lipid peroxidation

Lipid peroxidation is the hallmark of ferroptosis.4 PUFA-PLs are highly susceptible to peroxidation because of the presence of bis-allylic moieties in PUFAs. The oxidation of PUFA-PLs occurs through both enzymatic reactions and non-enzymatic autoxidation driven by the Fenton reaction.44,72 Enzymatic lipid peroxidation of PUFA-PLs primarily involves the action of ALOXs and cytochrome P450 oxidoreductase (POR).73 ALOXs are enzymes containing nonheme iron, which directly introduce oxygen to PUFAs and PUFA-containing lipids within biological membranes. For example, ALOX12 is essential for p53-dependent ferroptosis, while ALOX15 is involved in erastin- or RSL3-induced ferroptosis through complexing with PE binding protein 1 (PEBP1), specifically recognizing stearoyl-AA-PE to generate lipid peroxides.74 Moreover, ALOXE3, ALOX5, ALOX12B, and ALOX15B have been implicated in ferroptosis induction.75–78 Several ALOX inhibitors have been shown to possess antioxidant properties, effectively shielding cells from lipid peroxidation.35,42 However, genetic deletion of Alox15 in Gpx4 knockout mice failed to avert ferroptosis in vivo,8 and Alox12/15 failed to restore the viability of Gpx4 deficient T cells,79 suggesting the existence of alternative mechanisms in certain contexts of ferroptosis. As expected, POR directly supplies electrons to the P450 enzyme, which catalyzes the peroxidation of PUFA-PLs in an ALOX-independent manner.73,80 These studies suggested that several iron-dependent enzymes can promote lipid peroxidation and ferroptosis. Future investigations are needed to determine the potential involvement of other oxygenases, such as cyclooxygenases and peroxygenases, in lipid peroxidation. Non-enzymatic lipid peroxidation of PUFA-PLs is driven by the Fenton reaction, with iron serving as a catalyst.72,81 In this process, once the initial phospholipid hydroperoxides (PLOOHs) are generated (via enzymatic reactions or other cellular metabolic processes) and are not promptly reduced by GPX4, they can interact with ferrous iron to yield alkoxyl and peroxyl radicals (Fenton reaction), initiating PLOOHs production.82,83

Iron metabolism and toxicity

As noted above, lipid peroxidation requires both iron-dependent enzymes and iron-mediated Fenton reactions, thereby at least partly providing the iron-dependent nature of ferroptosis. Thus, interventions targeting iron metabolism have an impact on the vulnerability to ferroptosis. Ferric iron is the primary form of iron in circulation and binds to transferrin (TF).84 It is delivered into cells and localized in endosomes with the assistance of TFR1, a membrane protein.85 Within the endosome, ferric iron is reduced to ferrous iron by the six-transmembrane epithelial antigen of the prostate 3 (STEAP3).86 The endocytosed ferrous iron is later released into the cytoplasm via solute carrier family 11 member 2 (SLC11A2), forming the labile iron pool (LIP), which catalyzes the generation of hydroxyl radicals and triggers ferroptosis.87 Excess intracellular iron is typically sequestered within the ferritin protein, which consists of two subunits: ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL).41 Ferritin undergoes degradation via ferritinophagy, facilitated by nuclear receptor coactivator 4 (NCOA4), resulting in the release of substantial amounts of iron.88,89 Additionally, excess cytoplasmic ferrous iron can be exported from the cell through solute carrier family 40 member 1 (SLC40A1).90 Consistently, deletion of TF, TFR1, SLC11A2 and NCOA1, and overexpression of FTH1, FTL and SLC40A1 suppresses ferroptosis by decreasing the LIP.91 Therefore, interventions that modulate the import, storage, and export of iron in the cytoplasm contribute to an increase in susceptibility to ferroptosis.

In addition to the cytoplasm, mitochondria, which is the primary site of iron utilization and the main source of ROS, plays a major role in modulating redox-active reactions and ferroptosis.92,93 To reach the mitochondria, iron must traverse both the outer and inner mitochondrial membranes to enter the matrix through SLC11A2,94 and solute carrier family 25 member 37 (SLC25A37) or solute carrier family 25 member 28 (SLC25A28), respectively.95–97 Moreover, recent studies highlighted the key role of CDGSH iron sulfur domain 1 (CISD1) in regulating iron homeostasis in mitochondria.98,99 CISD1 knockdown significantly increases the content of erastin-induced mitochondrial ferrous irons and promotes mitochondrial lipid peroxidation and ferroptosis.100 CISD1 can also bind with VDAC proteins and regulate their gating in a redox-dependent manner.101 Inhibiting VDAC proteins can prevent mitoCISD1-dependent mitochondrial iron accumulation and erastin-induced ferroptosis.40,101–103 Ferritin mitochondrial (FTMT) serves as the iron-storage protein in mitochondria, inhibiting ferroptosis by reducing total and chelatable iron levels.104–106 ATP binding cassette subfamily B member 7 (ABCB7) is involved in the transfer of iron from mitochondria to cytosol.107–109 Although mitochondrial iron accumulation can be observed in the absence of ABCB7,107 ABCB7 loss does not lead to an increase in mitochondrial ROS and ferroptosis.110 On the contrary, ABCB8 can facilitate mitochondrial iron export.111,112 Overexpression of ABCB8 reduces mitochondrial iron and protects against ferroptosis-related I/R damage and doxorubicin-induced cardiomyopathy.113,114 Collectively, these results provide strong evidence that diverse factors controlling iron metabolism regulate susceptibility to ferroptosis.

Defenses of ferroptosis

GPX4 antioxidant system

Erastin and RSL3 are the representative two types of ferroptosis inducers (FINs) through directly inhibiting the activity of xc- system and GPX4, respectively.4,43 The system xc- containing subunits SLC7A11 and solute carrier family 3 member 2 (SLC3A2) mediates the exchanges of intracellular glutamate for extracellular cystine.115,116 Intracellular cystine is quickly converted to cysteine, playing a vital role as a cellular antioxidant and acting as the limiting factor for the synthesis of glutamate-cysteine ligase (GCL)-mediated GSH synthesis.117,118 The availability of cellular GSH closely regulates the cellular GPX4 activity.119,120 Thus, the inactivation of GPX4 by both erastin and RSL3, either directly or indirectly, underscores the significance of GPX4 as a key repressor of ferroptosis.

GPX4 is the sole member of the GPX family that acts as a phospholipid hydroperoxidase, directly reducing PLOOH to their corresponding phospholipid alcohols (PLOH).31,121 GPX4’s catalytic reaction operates according to a ping-pong mechanism, where the enzyme’s active site shuttles between oxidation and reduction states. Firstly, the PLOOH oxidizes the active site selenol in GPX4 (GPX4-SeH) to form the selenenic acid intermediate (GPX4-SeOH). Secondly, this intermediate undergoes a reaction with GSH, resulting in the formation of the selenium-glutathione adduct (GPX4-Se-SG). Thirdly, through a reaction with a second GSH molecule, GPX4-Se-SG undergoes conversion to GPX4-SeH, generating oxidized glutathione (GSSG).122,123 By examining the crystal structure of seleno-GPX4, researchers observed the existence of seleninic acid (GPX4-Se-OO-) within the enzyme’s active site.124 This finding implies the possibility of an alternative reaction mechanism that encompasses three distinct redox states (GPX4-SeH, GPX4-SeOH, GPX4-Se-OO-) of the catalytically active selenocysteine. These studies have also emphasized the essential role of selenocysteine in the expression and activity of GPX4, which is in line with Ingold et al.’s findings that the substitution of a cysteine residue for selenocysteine (U46C) in GPX4 is required to prevent hydroperoxide-induced ferroptosis.125

GPX4 exists in three isoforms: mitochondrial, cytosolic, and nuclear GPX4. While derived from the same GPX4 gene, the isoforms of GPX4 have distinct transcription initiation sites.126–129 Early embryonic lethality occurs when the cytosolic GPX4 gene is genetically ablated or expresses an inactive form.130 The rescue of the lethal phenotype in Gpx4-null mutant mice was achieved by re-expression of cytoplasmic GPX4, rather than mitochondrial or nuclear GPX4, indicating the crucial role of cytosolic GPX4 in preventing embryonic lethality.131,132 Disruption of mitochondrial GPX4 in mice does not result in lethality but instead causes male infertility due to abnormal sperm development.130,133 It seems that only cytosolic GPX4 could suppress ferroptosis, which is challenged by recent studies that mitochondrial GPX4, but not cytoplasmic GPX4, could potently suppress lipid peroxidation and ferroptosis in DHODH or glycerol-3-phosphate dehydrogenase 2 (GDP2) knockout cells.134,135 Therefore, these organelle-specific forms of GPX4 may independently inhibit local lipid hydroperoxides and ferroptosis, although the potential role of nuclear GPX4 requires further investigation. Notably, GPX4 depletion also mediates apoptosis, necroptosis and pyroptosis in mice, suggesting that GPX4 depletion-induced lipid peroxidation occupies a central position at the intersection of these forms of RCD. Thus, the detection of multiple markers is essential for definitively identifying ferroptosis in addition to lipid peroxidation.

Radical-trapping antioxidant system

As mentioned above, GPX4 is a central suppressor of ferroptosis, and other mechanisms that regulate the activity or expression of GPX4 also control susceptibility to ferroptosis.43,45,136–138 However, some cancer cells survived GPX4 inhibition, suggesting the existence of alternative mechanisms of ferroptosis resistance. In recent years, three GPX4-independent systems that capture free radicals to exert their antioxidative effects and suppress ferroptosis have been identified. These systems include FSP1/ ubiquinol (CoQH2), DHODH/CoQH2, and GCH1/BH4. Coenzyme Q (CoQ) is an endogenous antioxidant and exists in three forms: CoQ10, semiquinone, and CoQH2, wherein CoQH2 traps lipid peroxyl radicals to protect cells from ferroptosis.15,49 The synthesis and cellular distribution of CoQ10 are linked to StAR related lipid transfer domain containing 7 (STARD7), which transports CoQ10 from mitochondria, where it is synthesized, to the plasma membrane.139 In 2020, two independent teams found that N-myristylation-dependent recruitment of FSP1 to the plasma membrane resists ferroptosis in the plasma membrane.48,49,140 Mechanistically, FSP1 suppresses lipid peroxidation by catalyzing the reduction of CoQ10 to CoQH2 with the consumption of nicotinamide adenine dinucleotide phosphate (NAD(P)H).48 Moreover, FSP1 was identified as a vitamin K reductase to generate its associated hydroquinone, which inhibits lipid peroxidation at the expense of NAD(P)H.56 A recent study also suggested that phase separation of FSP1 plays a role in promoting ferroptosis which requires N-terminal myristoylation, as well as specific amino acid residues and essentially disordered, low-complexity regions in FSP1.57 Analogous to the function of FSP1 in the plasma membranes, DHODH detoxifies lipid peroxides by reducing CoQ10 to CoQH2, thereby inhibiting ferroptosis specifically in the mitochondria.134 Furthermore, GCH1 has been identified as a suppressor of ferroptosis through a two-pronged mechanism.48,50 On one hand, GCH1 produces the lipophilic antioxidant BH4 preventing lipid peroxidation; on the other hand, GCH1 induces lipid remodeling as a protective measure against ferroptosis by selectively safeguarding PLs with two polyunsaturated fatty acyl tails from depletion.48,50 However, the subcellular compartments wherein the GCH1/BH4 system functions still need further investigation.

MUFA-PLs synthesis

Different from PUFAs, monounsaturated fatty acids (MUFAs) are less susceptible to peroxidation owing to a lack of bis-allylic positions. Exogenous MUFAs can prevent ferroptosis by displacing PUFAs from membrane lipids.44,141 The biosynthesis of anti-ferroptosis MUFA-PLs is mainly regulated by stearoyl-CoA desaturase 1 (SCD1) and acyl-CoA synthetase long-chain family member 3 (ACSL3).141,142 SCD1 introduces a double bond in the cis-Δ9 position of the de novo synthesized saturated fatty acids (SFAs), particularly palmitic acid (C16:0) and stearic acid (C18:0), resulting in the formation of palmitoleic acid (C16:1) and oleic acid (C18:1), respectively.142 As a result, overexpression of SCD1 enhances MUFA synthesis and protects cells from ferroptosis, while inhibition of SCD1 enhances the sensitivity to ferroptosis.59,142 Moreover, MUFAs are reported to enhance both the number of lipid droplets and the number/function of peroxisomes, leading to a reduction in ether lipids and lipid oxidation.143 However, oleic acid does not lower the propensity of cells to succumb to ferroptosis in ACSL3-depleted cells.54 ACSL3 converts MUFAs into their acyl-CoA esters, facilitating their incorporation into membrane PLs.141 Thus, similar to PUFAs, MUFAs need to be inserted into the membrane to exhibit antioxidant properties. Interestingly, MBOAT1/2 has recently been identified to selectively transfer MUFAs into lyso-PE, resulting in an increase in cellular PE-MUFA and a corresponding decrease in cellular PE-PUFA, ultimately resisting ferroptosis.59 On all accounts, the anti-ferroptosis role of MBOAT1/2 operates independently of GPX4 and FSP1 through a surveillance mechanism mediated by PL remodeling.

Membrane repair system

The rupture of the plasma membrane is involved at the terminal stage of ferroptosis. Membrane damages in ferroptosis cover a loss of plasma membrane integrity,88 and rupture of the outer mitochondria membrane.4,8 Consequently, membrane repair systems have been proposed and demonstrated to prevent ferroptosis. Among these systems, the Endosomal Sorting Complex Required for Transport-III (ESCRT-III) has gained attention as a common mechanism for membrane repair, acting as a defense against various forms of RCD, including ferroptosis.144–146 Mechanistically, ferroptosis leads to an elevation in cytosolic Ca2+ levels due to an osmotic imbalance triggered by the opening of small nanopores.147 In response to the influx of Ca,2+ subunits of ESCRT-III known as charged multivesicular body proteins (CHMPs), specifically CHMP5 and CHMP6, are recruited and assembled at the location of damage to facilitate membrane repair processes. Erastin and RSL3, which are known as ferroptosis activators, lead to the buildup of CHMP5 and CHMP6 in the plasma membrane of pancreatic cancer cells, and the knocking out of CHMP5 or CHMP6 intensifies the susceptibility of cancer cells to ferroptosis.146 Furthermore, in certain cases, FSP1 inhibits ferroptosis by promoting the accumulation of CHMP5 and CHMP6 on the plasma membrane.148 Overall, these findings highlight the critical role of ESCRT-III activation in preventing ferroptosis.

Functions of ferroptosis in cancer biology

Oxygen (O2)-driven metabolism is vital for the survival of organisms and the execution of biological activities, achieved via a sequence of redox reactions.149 The transition metal iron is the key element to catalyze these redox processes, leading to the generation of ROS, which encompasses various oxygen derivatives, including ferroptosis divers PLOOHs. Accumulating evidence indicates ferroptosis in tumor biology.

Ferroptosis induction in tumor suppression

Ferroptosis appears to function as an innate mechanism for tumor suppression, mediating the anticancer activity of several tumor suppressor genes. Tumor suppressors such as p53, BRCA1-associated protein 1 (BAP1), fumarate hydratase (FH), Kelch-like ECH-associated protein 1 (KEAP1), and the epigenetic regulator MLL4 have been shown to exert their tumor-suppressive functions, at least partially, by inducing ferroptosis in tumor cells.

The tumor suppressor TP53, widely regarded as the most critical barrier to cancer development, effectively exerts its ferroptosis-mediated tumor-suppression function by suppressing the cystine transporter SLC7A11 in an ALOX12-dependent manner.13,150,151 While the acetylation-defective mutant p533KR (K117R, K161R, K162R) loses its conventional functions of promoting cell-cycle arrest, apoptosis, and senescence, it still retains its tumor-suppressive ability by promoting ferroptosis.13 By contrast, the mutant p534KR (K98R+3KR) lack ferroptosis regulatory activity and consequently lose their tumor-suppressive functions,152,153 suggesting the significance of acetylation in ferroptosis. Moreover, the TP53 single-nucleotide polymorphism P47S found in many people of pre-menopausal African-American women has an increased risk of breast cancer.152,154 Mechanistically, p53P47S is defective in promoting ferroptosis and repressing tumor development through increasing the cellular levels of CoA and GSH.154 These findings indicate that ferroptosis is at least partly responsible for TP53-mediated tumor suppression.

BAP1 encodes a deubiquitinase responsible for removing ubiquitin from histone 2A and frequently exhibits inactivating mutations and deletions in various sporadic cancers.155 Interestingly, BAP1 suppresses tumorigenesis partly through ferroptosis by repressing SLC7A11 via reducing histone 2A ubiquitination (H2Aub) occupancy on the SLC7A11 promoter.156 Deletions and mutations of BAP1 result in the loss of its ability to repress SLC7A11, enabling cells to evade ferroptosis and promoting tumor formation.156 BAP1 re-expression in a BAP1-deficient background significantly inhibited tumor development with condensed mitochondria and increased 4-hydroxynonenal (4-HNE) protein expression, which could be partially restored by the ferroptosis inhibitor liproxstatin-1,156 suggesting that ferroptosis at least partly contribute to BAP1’s tumor suppression in vivo.

FH is an enzyme involved in the tricarboxylic acid (TCA) cycle, which has been confirmed as a bona fide tumor suppressor in renal cancer.157 Genetic mutation of FH has been detected in both benign and malignant renal cancer lesions.157–159 Notably, renal cancer cells with FH mutations display resistance to ferroptosis and maintain their viability and ability to proliferate even when deprived of cystine. In contrast, wild-type FH cancer cells are unable to proliferate under these conditions.160 These findings confer the tumorigenic advantage of the loss of FH function under oxidative stress through suppressing ferroptosis, supporting the notion that ferroptosis may serve as a physiologically relevant mechanism to suppress tumors.

KEAP1, a ubiquitinated enzyme, is commonly mutated or inactivated in lung cancers.161,162 KEAP1 binds to nuclear factor erythroid 2-related factor 2 (NRF2) and triggers its proteasomal degradation, thereby inhibiting tumor development.163 Loss of KEAP1 function leads to increased tumor burden and accelerates tumor growth,163,164 because its mutants or deficiency in lung cancers upregulate the expression of FSP1 by stabilizing NRF2 proteins, resulting in ferroptosis resistance.165 Moreover, KEAP1 knockdown protects glioma cells from ferroptosis and promotes their proliferation by upregulating NRF2-mediated expression of SLC7A11.166 These findings indicate that the ferroptosis-promoting role of KEAP1 potentially at least partly accounts for its tumor-suppressive function.

The epigenetic regulator MLL4 is one of the most commonly mutated genes in cancer biology.167,168 It can activate key ALOXs genes, such as ALOX12, promoting epidermal differentiation and barrier formation and, in turn, inhibiting cutaneous squamous cell carcinomas through ferroptosis.169 Epidermal MLL4 deficiency results in impaired skin differentiation, the development of precancerous neoplasms and resistance to ferroptosis, accompanied by downregulation of pro-ferroptosis genes ALOXs (ALOX12, ALOX12B, and ALOXE3) and the upregulation of anti-ferroptosis genes (GPX4, SLC7A11, and SCD1).169 This suggests that MLL4-mediated ferroptosis serves as a critical natural mechanism in promoting epidermal differentiation, maintaining skin homeostasis, and preventing cutaneous carcinomas formation.

Ferroptosis evasion in tumor progression

Despite the presence of the ferroptosis-mediated tumor suppression mechanism, tumors inevitably arise and progress uncontrollably, indicating the existence of the mechanism of ferroptosis evasion in tumor. Building upon the core driver and defense mechanism of ferroptosis. We will briefly discuss the mechanisms through which tumor cells have evolved to evade ferroptosis and support tumor development.

Tumor cells exhibit heightened antioxidant capacity as an adaptive response to increased levels of ROS caused by metabolic and signaling abnormalities.170 Stabilizing and overexpressing the anti-ferroptotic systems are crucial mechanisms evolved by tumor cells to avert ferroptosis and promote tumor progression. The upregulation of the SLC7A11/GSH/GPX4 axis, a key ferroptosis defense system, is a significant evasion mechanism evolved by tumor cells. SLC7A11 is overexpressed in multiple cancers, and it is one of the extensively studied mechanisms by which tumor cells evade ferroptosis.53,171,172 For instance, its upregulation by the inactivation of tumor suppressors like TP53, BAP1, and ARF confers ferroptosis evasion and promotes tumor growth.13,156,173 Moreover, Oncogenic KRAS activation has also been shown to upregulate SLC7A11 expression, defending against ferroptosis and promoting lung adenocarcinoma (LUAD) development.174 GSH, an antioxidant that functions as the cofactor of GPX4, is frequently elevated in tumors, accelerating tumor progression and therapy resistance.170,175–179 GPX4, the essential antioxidant peroxidase of ferroptosis, has also been found to be highly expressed in various tumors.180,181 Several cancer phenotypes characterized by stem cell-like or dedifferentiated states exhibit highly dependent GPX4 for survival, indicating its crucial role in evading ferroptosis and supporting tumor cell surviva.15,182 The radical-trapping antioxidant system mechanisms of ferroptosis, which are mediated by the FSP1 and GCH1, are also upregulated in some cancers and contribute to ferroptosis evasion and tumor development.50,165 Additionally, NRF2, a master regulator of antioxidant defense, which is upregulated in multiple cancers and is considered a driver of cancer progression, metastasis, and therapy resistance,183 regulates components of the ferroptosis cascade, including SLC7A11, GPX4 and FSP1, to defend against ferroptosis contribute to tumor progression and therapy resistance.165,184–188

Tumor cells also employ mechanisms that limit pro-ferroptotic systems to evade ferroptosis. Downregulation of peroxidized PUFA-PLs and reduction of the LIP within cancer cells have been associated with ferroptosis evasion and tumor progression.189 For instance, iPLA2β, which cleaves and detoxifies peroxidized lipids to avert ferroptosis, is overexpressed in some human cancers and is involved in inhibiting p53-mediated ferroptosis and tumor suppression.190 Sterol regulatory element-binding protein 2 (SREBP2)-driven iron homeostatic pathways are overexpressed in melanoma circulating tumor cells, reducing intracellular iron pools and conferring resistance to ferroptosis, contributing to cancer progression, metastasis, and drug resistance.191 Proteins involved in the iron-sulfur clusters (ISCs) synthesis and assembly, such as NFS1, Frataxin, and CISD2, have been found to be highly expressed in tumors, enabling cancer cells to evade ferroptosis and contribute to tumor progression by reducing the LIP.192–194 Breast cancer cells detaching from the extracellular matrix increase the expression of prominin 2, stimulating iron export and reducing the LIP to evade ferroptosis.195

Strikingly, tumor microenvironment functions in ferroptosis evasion in tumor progression. For example, the lymphatic environment, which contains an abundant amount of oleic acid, can enhance the synthesis of MUFA-phospholipids (MUFA-PLs) in melanoma cells through an ACSL3-dependent pathway, leading to resistance to oxidative stress and ferroptosis. This facilitates the migration and survival of cancer cells in lymphatics and enhances their ability to survive during subsequent metastasis via the bloodstream.54 Moreover, mammary adipocytes provide protection for triple-negative breast cancer (TNBC) cells against ferroptosis by secreting oleic acid,196 providing a unique micro-environment for cancer cell survival. Additionally, sex hormones could regulate ferroptosis surveillance.59 MBOAT1 and MBOAT2 could be regulated by estrogen receptors (ER) and androgen receptors (AR), respectively. Both of them could catalyze the incorporation of MUFAs into PL to mediate the ferroptosis defense mechanism independently of GPX4 and the radical-trapping antioxidant system, suggesting the potential role of ferroptosis suppression in specific contexts related to sex hormone signaling. These findings also indicate that sex differences need to be considered, and ER or AR antagonists should combine with FINs to inhibit the ER+ cancer or AR+ prostate tumor growth, respectively.59,197

Cancer-related pathway in ferroptosis

RAS signaling

The RAS family are the most frequently mutated oncogenes in human cancers, comprising three major mutation variants: KRAS, HRAS, and NRAS.198,199 RAS is the first oncogene associated with ferroptosis, due to erastin and RSL3 were initially discovered from RAS synthetic lethal screen.39–41 Inhibiting RAS or the downstream RAF/MEK/MAPK axis can reverse the erastin or RSL3-induced selective cytotoxicity in engineered RAS-mutant tumor cells, possibly because mutant RAS signaling enhances the cellular basal iron by modulating the expression of iron metabolism-related genes.40,41 Mutations in epidermal growth factor receptor (EGFR), the RAS signaling upstream, increase the sensitivity of ferroptosis in non-small cell lung cancer (NSCLC) cells and human mammary epithelial cells.200 Notably, mutant KRAS has been reported to evade ferroptosis, establishing a targetable vulnerability in KRAS-mutant lung cancer174,201 (Fig. 3a). Mutant KRAS upregulate the NRF2/SLC7A11 axis, resulting in the selective SLC7A11 inhibition killing in KRAS-mutant cancer cells.174 Mutant KRAS can also elevate FSP1 by activating MAPK and NRF2 pathways to protect KRAS-mutant cells from ferroptosis during tumor initiation.202 Combining FSP1 in ferroptosis-inducing therapy represents an effective strategy for treating KRAS-mutant tumors.202 Moreover, mutant KRAS lung cancer has been found to upregulate fatty acid synthase (FASN) and escape from ferroptosis by promoting the synthesis and availability of SFA/MUFA, potentially through an ACSL3-dependent mechanism.201 ACSL3, downstream of FASN, is essential for tumorigenesis in mutant KRAS lung cancer.203 Targeting FASN represents an effective therapeutic strategy for inducing ferroptosis in mutant KRAS lung cancer.Fig. 3 Cancer-related pathways in ferroptosis. a RAS signaling governs upregulation of SCL7A11, FASN, and FSP1 to evade ferroptosis, establishing a targetable vulnerability. b NRF2 protects cancer cells from ferroptosis primarily through transcriptional regulation of downstream target genes involved in iron metabolism, GSH metabolism and ROS detoxification enzymes. c mTOR signaling primarily inhibits the sensitivity to ferroptosis through autophagy, promoting GPX4 protein synthesis, and upregulating the SREBP1/SCD and KEAP1/NRF2 axis. d Hypoxia plays a dual role in regulating ferroptosis by inducing the expression of its primary regulators HIF1α and HIF2α. e EMT reshapes the metabolic status granting mesenchymal tumor cells vulnerability to ferroptosis. f p53 transcriptionally suppresses SLC7A11 expression or modulates metabolism-related genes to promote ferroptosis. g The YAP/TAZ pathway plays a crucial role in regulating cell density-mediated and D-lactate-induced ferroptosis. h Ferroptosis serves as a type of autophagy-dependent cell death involving ferritinophagy, lipophagy, mitophagy, clockophagy, and chaperone-mediated autophagy. i Mitochondrial TCA cycle, ETC and glutamate are required for cystine deprivation-induced ferroptosis. PPP generate NADPH to implicate in ferroptosis process. Energy stresses facilitate tumor defense against ferroptosis by activating AMPK to enhance ACC-mediated MUFA formation. 4EBP 4E (eIF4E)-binding proteins, α-KG α-Ketoglutaric acid, ACSL5 acyl-CoA synthetase long chain family member 5, AKT AKT serine/threonine kinase, ASS1 argininosuccinate synthase 1, AKR1C1 aldo-keto reductase family 1 member C1, ANGPTL4 angiopoietin-like 4, ARNTL aryl hydrocarbon receptor nuclear translocator like, AMPK protein kinase AMP-activated catalytic subunit alpha 1, ATM ataxia-telangiectasia mutated, BAMBI BMP and activin membrane bound inhibitor, BRAF B-Raf proto-oncogene, serine/threonine kinase, CDKN1A cyclin dependent kinase inhibitor 1A, CDK7 cyclin dependent kinase 7, CHAC1 ChaC glutathione specific gamma-glutamylcyclotransferase 1, DPP4 dipeptidyl peptidase 4, DPP9 dipeptidyl peptidase 9, EGLN2 egl-9 family hypoxia inducible factor 2, EMP1 epithelial membrane protein 1, EMT epithelial-mesenchymal transition, FABP3/7 fatty acid binding protein 3/7, FASN fatty acid synthase, FTH1 ferritin heavy chain 1, GCLC glutamate-cysteine ligase catalytic subunit, GCLM glutamate-cysteine ligase modifier subunit, GFPT1 glutamine--fructose-6-phosphate transaminase 1, GINS4 GINS complex subunit 4, GLS glutaminase, GLUD1 glutamate dehydrogenase 1, HDAC Type-2 histone deacetylase 2, HIF1α hypoxia inducible factor 1 subunit alpha, HIF2α hypoxia inducible factor 2 subunit alpha, HILPDA hypoxia inducible lipid droplet associated, HMOX1 heme oxygenase 1, HSP90 heat shock protein 90, HSC70 heat shock cognate 71 kDa protein, Keap1 Kelch-1ike ECH- associated protein l, KDM5A lysine demethylase 5A, *KRAS mutant KRAS, KRAS, KRAS proto-oncogene, GTPase, LATS1 large tumor suppressor kinase 1, LAMP2A lysosomal-associated membrane protein 2, LC3 MAP1LC3A microtubule associated protein 1 light chain 3 alpha, LDHD lactate dehydrogenase D, LKB1 Lkb1 kinase, MEK MAP kinase-ERK kinase, MDM2 proto-oncogene, MDMX MDM4 regulator of p53, MEX3A mex-3 RNA binding family member A, mTOR rapamycin target protein, MT1G metallothionein 1G, MPC1 mitochondrial pyruvate carrier 1, MST macrophage stimulating, MYC MYC proto-oncogene, bHLH transcription factor, NCOA4 nuclear receptor coactivator 4, NRF2 nuclear factor erythroid 2-related factor 2, NF2 neurofibromin 2, NOX2 NADPH oxidase 2, NOX4 NADPH oxidase 4, OXPHOX oxidative phosphorylation, PI3K phosphoinositide 3-kinase, PPARGC1A PPARG coactivator 1 alpha, PRMT5 protein arginine methyltransferase 5, RAB7A member RAS oncogene family, SCD5 stearoyl-Coenzyme A desaturase 5, SREBP1 sterol regulatory element-binding protein 1, SESN2 sestrin 2, E-cad E-cadherin, SLC40A1 solute carrier family 40 member 1, SLC7A11 solute carrier family 7 member 11, SOD1 superoxide dismutase 1, SQSTM1 sequestosome 1, TAZ Tafazzin, TXNRD1 thioredoxin reductase 1, TCA cycle tricarboxylic acid cycle, WTAP WT1 associated protein, YAP1 Yes1 associated transcriptional regulator, ZEB1 zinc finger E-box binding homeobox 1, ZNF498 zinc finger and SCAN domain containing 25. This figure was created with BioRender.com

NRF2 signaling

NRF2 is a crucial transcription factor involved in cellular defense against oxidative and electrophilic stress.204 NRF2 acts as a suppressor of tumor initiation in the early stages of cancer.205–207 However, once oncogenic driver mutations occur, the high expression status of NRF2 in cancer cells may promote tumor progression and therapeutic resistance,208,209 partly through its ability to defend against ferroptosis. NRF2 primarily defends against ferroptosis through the transcriptional regulation of downstream target genes involved in iron metabolism (including SLC40A1, metallothionein 1G (MT1G), heme oxygenase 1 (HMOX1), and FTH1), GSH metabolism (including SLC7A11, glutamate-cysteine ligase catalytic subunit (GCLC), glutamate-cysteine ligase modifier subunit (GCLM), and ChaC glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1)) and ROS detoxification enzymes (including thioredoxin reductase 1 (TXNRD1), aldo-keto reductase family 1 member C 1/2/3 (AKR1C1/2/3), sestrin 2 (SESN2), glutathione S-transferase pi 1 (GSTP1), and NAD(P)H quinone dehydrogenase 1(NQO1)), thus suppressing oxidative damage induced by ferroptotic stress210,211 (Fig. 3b). This transcriptional regulation mechanism relies heavily on the stability of NRF2, which is negatively regulated by the ubiquitin ligase scaffold protein KEAP1, a tumor suppressor frequently mutated in NSCLC, via the ubiquitin-proteasome pathway.212 Protein arginine methyltransferase 5 (PRMT5) inhibits NRF2 by methylating and stabilizing KEAP1.213 p62 and dipeptidyl peptidase 9 (DPP9) disrupt the interaction between KEAP1 and NRF2 by competitively binding to KEAP1 to maintain the NRF2 stability and promote the transcription of its downstream iron metabolism and antioxidant genes, resulting in ferroptosis-mediated sorafenib resistance.187,214 mTORC1 and disulfiram/copper (DSF/Cu)-activated p62 phosphorylation, along with mitochondrial translocator protein (TSPO)-mediated p62 accumulation by inhibiting its autophagy, enhance the competitive inhibition of p62 on KEAP1, resulting in increased NRF2 accumulation and ferroptosis resistance.215–217 In addition to KEAP1-mediated degradation, other oncogenes such as KRASG12D, BRAFV619E and MycERT2 can transcriptionally induce NRF2 expression, ensuring the maintenance of stable cellular antioxidant programs to reduce intracellular ROS accumulation and potentially provide defense against ferroptosis.208 Nevertheless, a recent study has revealed that the regulatory function of NRF2 in ferroptosis is influenced by cellular ferrous ions in cancer cells.213 Overexpression of NRF2 can promote RSL3-induced cell death in TNBC cells, which harbor high levels of ferrous ions.213 Further research is needed to investigate the role of NRF2 in mediating ferroptosis under different conditions.

mTOR signaling

The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase,218 is a key target in cancer research due to its involvement in the PI3K/AKT/mTOR signaling pathway, which is frequently activated in human cancers and is often associated with therapeutic resistance.219 Both mTORC1 and mTORC2 have been implicated in ferroptosis in human cancers. mTORC2 inhibits the cystine-glutamate reverse transport activity and promotes ferroptosis by phosphorylating serine at position 26 of SLC7A11.20 Nevertheless, mTORC1 primarily inhibits ferroptosis sensitivity through three mechanisms (Fig. 3c): inhibition of autophagy, promotion of GPX4 protein synthesis, and upregulation of the sterol regulatory element-binding protein 1 (SREBP1)/SCD axis.220 mTORC1 acts as a potent autophagy inhibitor via the phosphorylation-dependent inhibition of autophagy-related gene (ATG) complexes. Large tumor suppressor 1/2 (LATS1/2) kinases, core components of the Hippo pathway, are activated under high cell density conditions, leading to mTORC1 phosphorylation and subsequent inhibition of autophagy-induced degradation of SLC7A11, ultimately suppressing ferroptosis.221 Cysteine, mediated by SLC7A11, participates not only in GSH biosynthesis but also activates Rag/mTORC1/eukaryotic initiation factor 4E (eIF4E)-binding proteins (4EBPs) signaling pathway to promote GPX4 protein synthesis, revealing a novel mechanism of ferroptosis resistance through GPX4 metabolism.222 Oncogenic mutations in the PI3K/AKT pathway activate mTORC1, but not mTORC2, to promote SREBP1 expression, which in turn induces SCD1-mediated MUFAs synthesis and inhibit ferroptosis.217 We also reported that lorlatinib sensitizes ferroptosis by inhibiting PI3K/AKT/mTOR-mediated SREBP1/SCD1 signaling axis via targeting insulin-like growth factor 1 receptor (IGF1R) and synergizes with RSL3 to inhibit melanoma.223 Argininosuccinate synthase 1 (ASS1), a key enzyme in the urea cycle, can activate the mTORC1/SREBP1/SCD5 signaling pathway to promote the synthesis of MUFAs, thereby suppressing ferroptosis.224 Notably, mTORC1 can modulate the KEAP1/NRF2 signaling pathway by promoting the binding of p62 and KEAP1, indicating a crosstalk between the PI3K/AKT/mTOR and the KEAP1/NRF2 signaling pathways.217

Hypoxia signaling

Hypoxia, a common characteristic of cancer, is present in approximately 90% of solid tumors, and it promotes tumor progression and therapy resistance.225–227 The hypoxic response is mainly mediated by hypoxia-inducible factors (HIFs) that are widely upregulated in human cancers and play a critical role in enabling cancer cells to adapt to hypoxic environments.228–230 HIFs seem to play a dual role in modulating ferroptosis and subsequently affecting therapeutic efficacy in cancers (Fig. 3d). In human fibrosarcoma and lung cancer cells, hypoxia pretreatment has been demonstrated to limit RSL3/FIN56-induced ferroptosis by inducing HIF1α expression.231 Mechanistically, hypoxia-induced HIF1α expression transcriptionally upregulates fatty acid-binding proteins 3 and 7 (FABP3/7), promoting lipid droplet formation via enhancing fatty acid uptake and lipid storage to evade ferroptosis.231 Hypoxia can enhance intracellular lactate accumulation and increase cystine uptake by promoting HIF1α-mediated transcription of lactate dehydrogenases (LDH) and SLC7A11, ultimately promoting resistance to ferroptosis in solid tumors in a lactate/GPX4-dependent manner.232 Additionally, under hypoxic conditions, WTAP-mediated m6A modification modulates the PPARGC1A/BAMBI/ACSL5 axis, suppressing ROS production and subsequent lipid peroxidation to inhibit ferroptosis.233 FASN, which is significantly upregulated in cancers with treatment-resistant features, can bind to HIF1α and inhibit its ubiquitination and degradation, facilitating the nuclear translocation of HIF1α and subsequently promoting the transcription of SLC7A11, leading to resistance to ferroptosis and sorafenib treatment in HCC.234 Therefore, inhibiting hypoxia-activated HIF1α signaling may be an effective strategy to reverse drug resistance by enhancing ferroptosis. Notably, hypoxia also can confer ferroptosis susceptibility to colorectal cancer cells by increasing the expression of lipid and iron-regulatory genes in a HIF2α-dependent manner.235 Similarly, the activation of HIF2α increases hypoxia-inducible lipid droplet-associated protein (HILPDA) expression, driving the accumulation of PUFAs and subsequent lipid peroxidation, which contributes to the vulnerability of clear-cell carcinomas to ferroptosis.236 This evidence reveals the complex mechanisms through which hypoxia regulates ferroptosis in cancer and emphasizes the importance of targeting hypoxia signaling as a crucial approach in anticancer therapies.

Epithelial-mesenchymal transition

Epithelial-mesenchymal transition (EMT) is a major driver of cancer progression, as it involves the reorganization of cellular cytoskeleton, acquisition of mesenchymal features, and distant metastasis.237–240 Notably, EMT not only promotes the colonization of tumor cells in distant sites through a metastatic cascade but also renders these mesenchymal-like cells resistant to multiple treatment strategies.241–243 Interestingly, tumor cells with mesenchymal characteristics are more sensitive to ferroptosis compared to epithelial cells, partly due to the upregulation of zinc finger E-box binding homeobox 1 (ZEB1).20,240,244,245 ZEB1 is an EMT-related transcription factor that promotes the maintenance of mesenchymal phenotype which can be induced by TGFβ.246 ZEB1 enhance PUFA-PLs accumulation partially via direct transcriptional activation of the lipid biology regulator peroxisome proliferator-activated receptor gamma (PPARG), endowing susceptibility to ferroptosis.247 (Fig. 3e). Moreover, iron metabolism reprogramming may also contribute to the ferroptosis vulnerability of mesenchymal cells. CD44-mediated hyaluronate-dependent iron endocytosis pathway is enhanced during EMT. Endocytosed iron acts as a catalyst to relieve epigenetic suppression of mesenchymal-related proteins, thereby sustaining cellular mesenchymal characteristics and supporting ferroptosis vulnerability.248 This finding reveals the connection between epigenetic regulation of EMT and ferroptosis vulnerability. Notably, EMT could be induced by histone deacetylase inhibitor with increased intracellular iron accumulation and reduced expression of the iron export protein ferroportin, thereby enhancing vulnerability to ferroptosis.249 Erlotinib-tolerant persistent cancer cells also maintain mesenchymal characteristics with increased glutaminolysis induced by histone lysine demethylase 5 A (KDM5A) mediated mitochondrial pyruvate carrier 1 (MPC1) inhibition.250 Consequently, these cells become susceptible to ferroptosis. These findings shed light on the potential to selectively eliminate multidrug-resistant cancer cells with mesenchymal-like phenotypes using ferroptosis-inducing drugs, which may lay the foundation for significant advances in the field of cancer therapy resistance.

TP53 signaling

As noted above, P53 mediates tumor suppression partly through SLC7A11 inhibition-induced ferroptosis13,150,152–154 (Fig. 3f). Consistently, cell cycle promoter GINS4 suppresses ferroptosis in LUAD via inhibiting p53 acetylation and promoting SLC7A11 expression.251 MDM2/MDMX, MEX3A, and ZNF498 inhibit p53’s transcriptional activity through post-translational modifications in different subtype cancer cells, thereby suppressing p53-mediated ferroptosis.252–254 However, p53 can also inhibit ferroptosis in a context-dependent manner. Upon cystine deprivation, p53 induces cyclin-dependent kinase inhibitor 1 A (CDKN1A)/p21 expression and reduces the ferroptosis sensitivity of tumor cells in a GSH-dependent manner by affecting cysteine metabolism.255,256 Additionally, p53 directly binds to dipeptidyl-peptidase-4 (DPP4), blocking its activity, thus inhibiting DPP4/ NADPH oxidase 1 (NOX1) complex-mediated lipid peroxidation and erastin-induced ferroptosis.257 Notably, TP53 null cancer cells can still undergo ferroptosis via p53-independent pathways,173,258 which may indicate the potential limitation of p53 as a regulator of ferroptosis.

YAP/TAZ signaling

Cancer cells show density-dependent vulnerability to ferroptosis, with increased resistance observed in spheroids,47 suggesting the impact of cell density and cell-cell connections on ferroptosis sensitivity independent of genetic factors. The Hippo pathway, the primary regulator of intercellular communication and mechanical forces, plays a critical role in modulating density-mediated ferroptosis susceptibility.259 (Fig. 3g). Specifically, high cell density induces E-cadherin-mediated recruitment of NF2 and activation of the MST1/2-LATS1/2 cascade, which phosphorylates and retains YAP/TAZ in the cytoplasm, inhibiting their transcriptional activation of ACSL4 and TFR1, ultimately contributing to ferroptosis resistance.47,260 Consistently, various post-transcriptional modifications regulate the expression and activity of YAP protein, impacting ferroptosis susceptibility. Cyclin-dependent kinase 7 (CDK7) independently promotes nuclear YAP phosphorylation at the S127 and S397 sites, inducing downstream LDHD protein expression and D-lactate-induced ferroptosis resistance in esophageal squamous cell carcinoma (ESCC).261 Glutamine-fructose-6-phosphate transaminase (GFPT1) maintains YAP stability through o-GlcNAcylation, countering Hippo pathway suppression. Inhibition of system xc- impairs this process, reducing ferritin levels, increasing intracellular iron, and enhancing ferroptosis sensitivity.262 Furthermore, TAZ can activate NOX2/4 to promote ferroptosis by upregulating angiopoietin-like 4 (ANGPTL4) in ovarian cancers or epithelial membrane protein 1 (EMP1) in renal cancers.259,263,264 However, the ferroptosis sensitivity of the Burkitt lymphoma cell lines, which do not express YAP or its homolog TAZ, can still be influenced by cell density, indicating an alternative mechanism and the limited role of YAP/TAZ in cell density-mediated ferroptosis vulnerability.47

Autophagy pathway

Ferroptosis exhibits a dependence on autophagy in various induction mechanisms,265 referring to ferritinophagy, lipophagy, mitochondrial autophagy, clockophagy, and chaperone-mediated autophagy (CMA) (Fig. 3h). Ferritinophagy involves autophagic degradation of ferritin, facilitated by NCOA4 binding and subsequent delivery to lysosomes.266 Ataxia telangiectasia mutated (ATM) phosphorylates NCOA4 to enhance ferritinophagy, promoting ferroptosis by increasing intracellular labile iron.267 Conversely, tripartite motif-containing protein 7 (TRIM7) ubiquitinates and degrades NCOA4, inhibiting ferritinophagy and tumor cell sensitivity to ferroptosis.268 Lipophagy targets lipid droplets for lysosomal degradation, providing substrates for lipid peroxidation.269 RAB7A, member of the RAS oncogene family, enhances lipophagy-mediated ferroptosis by promoting autophagosome formation.269,270 Progesterone receptor membrane component 1 (PGRMC1) enhances ferroptosis susceptibility through silent information regulator 1 (SIRT1) activation-mediated lipophagy.271 Mitophagy and clockophagy selectively degrade mitochondria and ARNTL, respectively, promoting ferroptosis by inducing mitochondrial depletion and inhibiting fatty acid uptake and lipid storage.231,272,273 CMA, a highly selective autophagy pathway independent of vesicles, relies on chaperone proteins and lysosome-associated membrane protein 2a (LAMP2A) to deliver ferroptosis-related proteins to lysosomes for degradation, regulating ferroptosis in tumor cells.274 GPX4, a common substrate protein, undergoes CMA degradation facilitated by heat shock cognate 71 kDa protein (HSC70) and heat shock protein 90 (HSP90), enhancing the sensitivity of tumor cells to ferroptosis.275,276 Creatine kinase B (CKB) inhibits CMA-mediated GPX4 degradation by phosphorylating GPX4 and preventing its interaction with HSP70, providing protection against ferroptosis.276 However, most studies supporting the autophagy dependence of ferroptosis focus on the late stages of the ferroptosis process. This adds uncertainty to the concept of autophagy dependence in ferroptosis, as, in the late stages of oxidative damage, the mixed forms of cell death involving autophagy may become more common.277–280 Therefore, further research is required to clarify the permissive or regulatory role of autophagy in the process of ferroptosis.

Metabolism pathway

Energy metabolism is responsible for sustaining fundamental biological activities. Mitochondria serves as the primary energy production and acts as the main regulator for ROS stress and antioxidant defense.281,282 Glutaminolysis, TCA cycle and electron transport chain (ETC) are crucial for cysteine starvation-induced ferroptosis160 (Fig. 3i). Glutaminolysis metabolism fuels the TCA cycle by converting intracellular glutamine to glutamate via glutaminase (GLS), which is further metabolized to alpha-ketoglutarate (αKG) in mitochondria via glutamate dehydrogenase 1 (GLUD1). Glutaminolysis inhibition disrupts cystine deprivation-induced ferroptosis, whereas TCA metabolites downstream of αKG, including succinate, fumarate and malate can restore the role of glutamine in ferroptosis.160,283,284 Inhibiting the mitochondrial ETC also attenuates ferroptosis induced by cystine deprivation, as does depletion of mitochondria,160 partly due to the less leakage of electrons that produce superoxide and H2O2, which can then react with ferrous iron to drive Fenton chemistry and lipid peroxidation.12 The pentose phosphate pathway (PPP) contributes to ferroptosis by generating NADPH, which is involved in various defense mechanisms against ferroptosis, including GSH reduction,285 and the synthesis of thioredoxin and CoQ10.116,286 Inhibition of PPP-related enzymes impedes erastin-induced ferroptosis.4 Furthermore, glucose deprivation-induced energy stress activates AMP-activated protein kinase (AMPK), inhibiting PUFA biosynthesis and conferring ferroptosis resistance via ACC phosphorylation.287 The activation of AMPK in response to energy stress could also be regulated by liver kinase B1 (LKB1), which negatively regulates ferroptosis through AMPK/ACC-mediated PUFA inhibition.287,288

Lipid, amino acid, and vitamin metabolism also regulate ferroptosis sensitivity. As noted above, lipid droplet degradation, PUFA/MUFA phospholipid activation/synthesis, and PUFA-PL oxidation are essential in ferroptosis.4,44,141,269–271 Moreover, high-fat diet downregulates ACSL4 and promotes tumor cell invasiveness and resistance to ferroptosis.289 Chronic exposure to 27-hydroxycholesterol enhances GPX4 expression in ER-breast cancer cells, counteracting metabolic stress and leading to ferroptosis resistance.290 Adipokine inhibits ferroptosis by suppressing fatty acid oxidation and maintaining lipid levels via HIF2α activation.291 Additionally, cysteine starvation and glutamine supplementation induce or promote ferroptosis.292,293 Interestingly, prolonged methionine deprivation prevents GSH depletion from ferroptosis, whereas short-term methionine starvation promotes ferroptosis by stimulating CHAC1 transcription.294 Tryptophan facilitates cancer cells to escape from ferroptosis through its metabolites serotonin and 3-hydroxyanthranilic acid as radical-trapping antioxidants.295 Kynurenine, a product of tryptophan oxidation, also inhibits ferroptosis by scavenging ROS and activating NRF2 activity.296 Vitamin E is a well-known inhibitor of ferroptosis, both in vivo and in vitro, due to its powerful antioxidant properties.191,297,298 Vitamin K also inhibits ferroptosis by reducing to hydroquinone via FSP1 and vitamin K epoxide reductase complex subunit 1 like 1 (VKORC1L1).56,299

Ferroptosis-mediated crosstalk within the tumor microenvironment (TME)

The TME is a dynamic and complex ecosystem comprising cancer cells, stromal cells, diverse subpopulations of immune cells, the blood and lymphatic vasculature, and various acellular components.300 In the TME, bidirectional communication between cancer cells and their microenvironment is critical for tumor growth.301 In particular, dying cancer cells communicate with immune cells through the exposure or release of multiple signals during ferroptosis, thus modulating the anti-tumor immune responses. Simultaneously, mediators released by immune cells also have a crucial impact on regulating the susceptibility of cancer cells to ferroptosis. Pharmacologic screening identifies that CD8+ T cells exhibited a higher sensitivity to FINs than cancer cells,302 suggesting that pro-ferroptotic stimuli could elicit ferroptosis not only in cancer cells but also in tumor-infiltrating immune cells. Correspondingly, the occurrence of ferroptosis in immune cells will affect their survival and immunomodulatory function, ultimately reprograming tumor progression in the TME. Therefore, the versatile and complex roles of ferroptosis in the crosstalk between tumor cells and nonmalignant cells, particularly immune cells, within the TME are discussed below.

Immunomodulatory role of ferroptotic cancer cells

The emission of immunomodulatory signals by ferroptotic cancer cells, such as damage-associated molecular patterns (DAMPs), MHC class I molecules, cytokines, and lipid metabolites, exerts a significant and multifaceted impact on tumor growth by activating distinct immune responses (Fig. 4a).Fig. 4 Ferroptosis-mediated crosstalk in the tumor microenvironment (TME). a Ferroptotic cancer cells in the TME exhibit dual immunoregulatory effects, encompassing both immunostimulatory and immunosuppressive roles. The emission of various immunomodulatory signals by ferroptotic cancer cells activates different immune responses regulating tumor development. b The pro-ferroptotic and anti-ferroptotic impact on cancer cells mediated by immune cells and adipocytes in the TME. c The mechanisms and tumor-modulating effects of ferroptotic immune cells in the TME, including CD8+ T cells, dendritic cells (DCs), natural killer (NK) cells, tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). AA arachidonic acid, AGER advanced glycosylation end product-specific receptor, CAF cancer-associated fibroblast, CRT calreticulin, FATP2 fatty acid transport protein 2, FIN ferroptosis inducer, HMGB1 high-mobility group box 1, IFNγ interferon gamma, 8-OHG 8-hydroxy-2-deoxyguanosine, oxLDL oxidized low-density lipoproteins, STING stimulator of interferon genes, TGF-β, transforming growth factor beta, TLR2 Toll-like receptors 2, ULBP UL16 binding protein. This figure was created with BioRender.com

Immunostimulatory activities of ferroptotic cancer cells

Cancer cells undergoing RCD, including ferroptosis, could elicit protective anticancer immunity by emitting a series of endogenous adjuvant signals that are generally referred to as DAMPs.303 Under pro-ferroptotic stress, the intracellular DAMPs, including double-stranded DNA and mitochondrial DNA, can activate the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway, leading to the release of interferon β (IFNβ).304–306 Subsequently, IFNβ enhances dendritic cell (DC) maturation, macrophage phagocytosis, and the infiltration of cytotoxic CD8+ T cells, thereby resulting in tumor regression in preclinical cancer models.304–306 Additionally, oxidative stress triggers the upregulation and translocation of the calreticulin on the surface of ferroptotic cancer cells.306–308 Calreticulin serves as an ‘eat-me’ signal, promotes DC maturation, and increases the infiltration of cytotoxic CD8+ T cells into tumors, thus boosting anti-tumor immune responses.306–308 Likewise, oxidized PE, 1-steaoryl-2-15-HpETE-sn-glycero-3-phosphatidylethanolamine (SAPE-OOH), another ‘eat-me’ signal, accumulates on the membranes of ferroptotic cancer cells and could be directly recognized by its counterpart, the macrophage Toll-like receptors 2 (TLR2).309 This process promotes macrophage-mediated phagocytosis and elimination of ferroptotic cancer cells, thereby inhibiting tumor growth.309 Ferroptotic tumor cells also secrete high-mobility group box 1 (HMGB1) and ATP, the best-characterized DAMPs involved in immunogenic cell death.306,308,310,311 Notably, only early (1-3 hours), but not late (24 hours) ferroptotic cells release sufficient ATP and HMGB1 to stimulate DC maturation and elicit a vaccination-like anti-tumor immune response.310 Hence, further investigation is required to understand the immunostimulatory properties of these signals at different stages of ferroptotic cancer cells, which may contribute to the advancement of cancer vaccines based on ferroptosis.

In addition to DAMPs, pro-ferroptotic stimulation can upregulate other immunoregulatory molecules on the surface of ferroptotic tumor cells or regulate the secretion of cytokines into the TME, thereby boosting anti-tumor immune responses. For instance, inhibition of alpha 1,3-mannosyltransferase (ALG3) stimulates ferroptosis in cancer cells, which leads to the upregulation of MHC class I molecules on the cell surface,312 facilitating the infiltration of cytotoxic CD8+ T cells and subsequent tumor reduction.312 Furthermore, the interaction between the NK cells activating receptor NKG2D and its ligand UL16 binding protein (ULBP) is implicated in ferroptosis-mediated anti-tumor surveillance.313 Mechanistically, pro-ferroptosis nanoparticle promotes the upregulation of ULBP on the tumor cell surface, further activate NK cells with increased IFNγ secretion and lytic degranulation, and thus inhibit tumor growth in vivo.313 Cytokines secreted by cancer cells play a significant role in manipulating immune functions and guiding cancer progression.314 The cytokine transforming growth factor β (TGFβ) is responsible for cancer-associated fibroblast (CAF) formation and the establishment of an immunosuppressive TME after tumorigenesis.315,316 Recently, gastrointestinal cancer cells with anoctamin 1 (ANO1) high expression can release TGFβ through inhibiting ferroptosis to facilitate CAF recruitment and cripple CD8+ T cell-mediated anti-tumor immunity.317 Inhibition of ANO1 promotes an immune-activated TME with impaired TGFβ secretion, which can be restored by ferroptosis inhibitors in vivo, highlighting the significant role of ferroptosis in regulating cytokine release and orchestrating the TME.317 In summary, tumor cells could modulate the exposure or release of DAMPs, immunostimulatory molecules, and cytokines upon stimulation by ferroptosis, ultimately enhancing anti-tumor immunity and leading to tumor suppression.

Immunosuppressive activities of ferroptotic cancer cells

Intriguingly, the release of DAMPs triggered by cancer cells undergoing ferroptosis is a double-edged sword that not only boosts anti-tumor immune cell function but also enhances tumor-promoting responses of immunosuppressive cells in specific contexts.318 Ferroptotic damage induces the release of 8-OHG from pancreatic cells, which is a marker of oxidative DNA damage and serves as a DAMP.319,320 The released 8-OHG activates the STING-dependent DNA sensor pathway that enhances the infiltration and M2 polarization of macrophages, facilitating pancreatic carcinogenesis.319 In addition, the KRAS oncoprotein with G12D mutation is also released as a DAMP by ferroptotic pancreatic cancer cells and can be engulfed by macrophages via the advanced glycosylation end product-specific receptor (AGER) and promotes fatty acid oxidation driven by signal transducer and activator of transcription 3 (STAT3)-dependent in macrophages.321 Activation of the AGER-STAT3 pathway ultimately leads to pro-carcinogenic M2 macrophage polarization, and blocking this pathway or ferroptosis with ferrostatin-1 could inhibit TAM-mediated pancreatic tumor growth.321 In a hepatocellular tumorigenic model, GPX4 deletion-induced ferroptosis results in the release of high levels of HMGB1, thereby promoting the recruitment of immunosuppressive MDSCs.322 GPX4-deficient liver tumors also increase the expression of programmed cell death ligand 1 (PD-L1). Thus, MDSC infiltration and the concomitant PD-L1 upregulation counteract the cytotoxic CD8+ T cell response elicited by ferroptotic liver tumor cells, ultimately leading to no significant tumor suppression.322

Ferroptotic cancer cells could also release immunosuppressive lipid mediators that favor immunosuppressive responses. It is well-established that PTGS2, a gene that encodes cyclooxygenase-2 and determines the production of prostaglandin E2 (PGE2), is upregulated during ferroptosis in cancer cells.43 PGE2 is an immunosuppressive prostanoid lipid that could impair the anti-tumor activity of conventional type 1 DC (cDC1), NK cells, and effector T cells.323–325 Meanwhile, PGE2 can activate immunosuppressive cells such as MDSCs and regulatory T cells (Tregs), contributing to immune escape.325,326 Overall, ferroptotic tumor cells could emit multiple immunosuppressive signals, especially DAMPs and lipid metabolites, thereby facilitating tumorigenesis and tumor growth.

Effect of immune cells on cancer cells ferroptosis

Anti-tumor immune cells exert their functions partially by releasing mediators such as cytokines, which can enhance the susceptibility of tumor cells to ferroptosis (Fig. 4b). IFNγ released by cytotoxic CD8+ T cells binds to its receptor and activates the Janus kinase (JAK)/signal transducer and activator of transcription 1 (STAT1) pathway in cancer cells, leading to the suppression of transcription and expression of SLC3A2 and SLC7A11, the two subunits of the cystine antiporter system xc.-19,327,328 Hence, system xc- downregulation dampens the import of cystine and enhances lipid peroxidation, thereby rendering cancer cells vulnerable to ferroptosis triggered by pharmacological manipulations.19,329 Subsequent research has shown that CD8+ T cell-released IFNγ cooperates with AA to directly cause cancer cell ferroptosis in an ACSL4-dependent manner.330 Mechanistically, IFNγ activates the JAK/STAT1/interferon regulatory factor 1 (IRF1) signaling pathway and promotes IRF1 to bind to the IFN-stimulated response elements in the ACSL4 promoter region, ultimately leading to ACSL4 transcriptional upregulation in cancer cells.330,331 ACSL4 functions by facilitating the incorporation of PUFAs (including AA) into PLs on the plasm membrane.46 Therefore, it is not surprising that IFNγ released by activated cytotoxic CD8+ T cells reprograms lipid patterns in the presence of AA via ACSL4, thereby inducing and enhancing ferroptosis in cancer cells and resulting in tumor reduction.332,333 These studies suggest that IFNγ and AA induce ferroptosis in cancer cells.19 In addition to activated CD8+ T cells, NK cells are also significant producers of IFNγ.334 A recent study has indicated that chimeric antigen receptor (CAR)-modified NK cells, genetically engineered immune cells, could promote cancer cell ferroptosis by releasing IFNγ. Similar to CD8+ T cells, IFNγ produced by CAR NK cells enhances ferroptosis seemingly through downregulating the system xc- subunits (SLC3A2 and SLC7A11) in cancer cells.335 Nevertheless, the precise mechanism by which CAR NK cells inhibit their expression requires further investigation. In summary, tumor-infiltrating activated CD8+ T cells and CAR-modified NK cells can kill cancer cells by enhancing their vulnerability to ferroptosis through the production and release of IFNγ.

Immunosuppressive TAMs have been reported to hinder the ferroptosis of tumor cells by secreting cytokines and microRNAs into the TME, thereby supporting tumor growth. For instance, TAMs can release the cytokine TGFβ1, which binds to its receptor and promotes SMAD family member 3 (SMAD3) on the promoter region of hepatic leukemia factor (HLF) in TNBC cells.336 Increased HLF transcription, in turn, enhances the transcription of gamma-glutamyltransferase 1 (GGT1), an enzyme that increases intracellular cysteine availability for GSH synthesis.337 Accordingly, TAM-derived TGFβ1 suppresses ferroptosis by boosting the GGT1/GSH/GPX4 axis in TNBC cells. Intriguingly, in addition to GGT1, HLF also induces interleukin 6 (IL6) transcription, activating the JAK2/STAT3 axis to augment TGFβ1 secretion by TAMs, ultimately constituting a feedforward circuit to promote TNBC tumor growth.336 In addition, TAMs package the miRNA-660-5p into exosomes, which are secreted into the TME and internalized by cervical cancer cells to interfere with ALOX15 expression.338 Downregulation of ALOX15 is involved in cervical cancer cell resistance to ferroptosis.338 Furthermore, the role of cancer-associated adipocytes in fueling cancer has gained increasing attention, and this pro-tumor effect may be associated with ferroptosis resistance.196,339 Mammary adipocytes secrete oleic acid, a MUFA, which impairs lipid peroxidation and ferroptosis in TNBC cells through an ACSL3-dependent mechanism.196 Taken together, TAMs and cancer-associated adipocytes could secrete cytokines, microRNAs, and lipid metabolites to shield cancer cells from ferroptosis and promote tumor progression.

Effects of ferroptotic immune cells on cancer cells

Emerging evidence has revealed the occurrence of ferroptosis in immune cells within the TME, in addition to cancer cells. This ferroptotic process affects not only the survival of tumor-infiltrating immune cells but also their immunoregulatory properties, ultimately regulating cancer behavior. Herein, a comprehensive understanding of the role of ferroptotic immune cells, including CD8+ T cells, B cells, DCs, NK cells, TAMs, Tregs, and MDSCs, in cancer progression will help develop ferroptosis-targeted immunotherapeutic strategies (Fig. 4c).

CD8+ T cells are essential for effective anti-tumor immune responses, and ferroptosis-associated lipid metabolism reprogramming contributes to the impairment of CD8+ T cells in the TME.340 Fatty acids, particularly AA from the TME, facilitate lipid peroxidation and ferroptosis in tumor-infiltrating CD8+ T cells through the fatty acid transporter CD36.341 This CD36-mediated ferroptosis hampers cytotoxic cytokine production and anti-tumor function of CD8+ T cells, with decreased levels of IFNγ, TNFα, and perforin.341 Adoptive transfer of CD8+ T cells treated with the ferroptosis inhibitor ferrostatin-1 improves the survival of tumor-bearing mice and reduces tumor burden, suggesting that targeting ferroptosis in CD8+ T cells could enhance anti-tumor efficacy in vivo.341 In addition to AA, CD36 can enhance the absorption of oxidized low-density lipoproteins (OxLDL) into intratumoral CD8+ T cells, which induces lipid peroxidation and dysfunction in CD8+ T cells.342 Importantly, compared to Tc1 cells, IL-9-secreting CD8+ Tc9 cells could activate the IL-9/STAT3/fatty acid oxidation pathway, which protects against tumor- or ROS-induced lipid peroxidation and ferroptosis within the TME.343 Consistently, STAT3 inhibitor-treated Tc9 cells exhibit increased lipid peroxidation and compromised anti-tumor ability, whereas ferroptosis inhibitor-treated Tc9 cells display reduced iron levels and lipid peroxidation, as well as stronger anti-tumor ability in vivo.343 These findings suggest that inhibiting ferroptosis in CD8+ T cells can augment anti-tumor immunity and kill tumor cells better.

B cells exhibit remarkable heterogeneity and play complex roles within the TME.344 Up to now, the role of ferroptosis in regulating the homeostasis and immune responses of tumor-infiltrating B cells has not been extensively reported. Emerging evidence indicates that marginal zone B cells and B1 cells, but not follicular B2 cells, are susceptible to GPX4 inhibition-induced ferroptosis due to their high expression of CD36 and consequent fatty acid uptake.345 Moreover, ferroptosis has been observed in B cells from both systemic lupus erythematosus patients and mice, suggesting that it may regulate B cell differentiation and plasma cell formation to participate in the pathogenesis of lupus.346 These studies highlight the significance of ferroptosis in the survival and function of B cells, but the impact of ferroptosis on tumor-infiltrating B cells and B cell-mediated tumor immunity remains to be further investigated.

DCs are recognized as antigen-presenting cells and powerful initiators of T-cell responses that eliminate tumor cells within the TME.347 Recent evidence indicates that pro-ferroptotic regulators can impair the anti-tumor function of tumor-infiltrating DCs. Damaging molecules, including ROS and lipid peroxidation byproduct 4-HNE, the marker of ferroptosis, accumulate in ovarian cancer-associated DCs.348,349 This accumulation promotes endoplasmic reticulum stress response and X-box binding protein 1 (XBP1) activation, ultimately impairing the ability of tumor-associated DCs to present antigens and initiate anti-tumor T-cell responses.348,350 Intriguingly, GPX4 inhibitor, but not SLC7A11 inhibitor, could trigger ferroptosis in DCs in a PPARG-dependent manner.351 Genetic inhibition of PPARG significantly restores the impaired anti-tumor activities of ferroptotic DCs in vivo.351 Besides, in an inflammatory model, the enzymatic production of lipid peroxides mediated by ALOX12/15 disrupts the maturation and activation of DCs via NRF2, but the exact role of ALOX12/15-triggered dysfunction of DCs in anti-tumor immunity within the TME requires further clarification.352 Collectively, ferroptosis can occur in DCs and cripple their normal anti-tumor function.

Dysfunction of NK cells, a subset of natural cytotoxic lymphocytes, in the TME due to lipid peroxidation-associated oxidative stress favors tumor growth.353 L-kynurenine (L-KYN), a tryptophan metabolite in gastric cancer TME, has been reported to trigger lipid peroxidation and ferroptosis in NK cells, thereby facilitating tumor growth in vivo.354 Overexpression of GPX4 confers resistance of NK cells to ferroptosis induced by L-KYN within the TME and augments NK cell-mediated tumoricidal effects in vivo.354 These findings suggest that TME can render NK cells susceptible to ferroptosis and lead to their dysfunction, highlighting the therapeutic potential of inhibiting NK cell ferroptosis within the TME for cancer therapy.

TAMs exhibit strong plasticity and can differentiate into either immunostimulatory M1 phenotype or immunosuppressive M2 phenotype.355 Notably, M1 macrophages display increased resilience against ferroptosis compared to the M2 phenotype despite similar expression levels of GPX4, ACSL4, and LPCAT3 between the two subtypes.356 This resistance is attributed to the elevated levels of inducible nitric oxide synthase (iNOS) and NO• in M1 macrophages, which can substitute for GPX4 and inhibit ALOX15-mediated lipid peroxidation and ferroptosis.356 GPX4 inhibitor RSL3 effectively induces ferroptosis in M2 macrophages while sparing M1 macrophages.356 In addition, pro-ferroptotic stimuli can re-educate TAMs into an anti-tumorigenic M1 phenotype through multiple reprogramming pathways during ferroptosis, thereby inhibiting tumor progression. For instance, inhibition of apolipoprotein C1 (APOC1) or SLC7A11 promotes ferroptosis in TAMs, which is characterized by increased iron content, downregulated anti-ferroptosis mediators (GPX4, NRF2, SLC7A11, and GSH), and significant ferroptosis-associated mitochondrial changes.357,358 These pro-ferroptosis modifications by APOC1 and SLC7A11 further increase CD86 expression of the M1 phenotype and decrease the expression of CD206, CD163, and ARG1 of M2 phenotype in TAMs, thus inhibiting pro-tumoral M2 polarization and the development of HCC.357,358 Additionally, several pro-ferroptosis nanoparticles, such as iron-based metal-organic frameworks loaded with FINs (RSL3 or dihydroartemisinin), drive multiple signaling pathways to shift TAMs from the M2 to M1 phenotype.359–361 Ultimately, the shift from M2 to M1 phenotype provokes strong anti-tumor activities of TAMs with phagocytic killing and metastasis inhibition.359,360,362 These studies highlight that targeting ferroptosis in TAMs is promising to eliminate pro-tumorigenic M2 macrophages or reprogram TAMs towards a tumoricidal M1 type, thereby inhibiting tumor progression.

Activated Tregs represent a crucial barrier against autoimmunity as well as anti-tumor immunity.363 Gpx4-deficient activated Tregs are susceptible to ferroptosis and exhibit enhanced production of the proinflammatory cytokine IL-1β, leading to a promotion of T helper cell 17 (Th17) responses. This process compromises the immunosuppressive function of Tregs within the TME and limits tumor growth in vivo.364 Ferroptosis inhibitor administration indeed restores tumor burden in mice with Treg-specific deletion of GPX4. Collectively, targeting ferroptosis by inhibiting GPX4 in intratumoral Tregs seems to be a promising strategy for reprogramming the TME and treating cancer. However, it is worth mentioning that non-selective deletion of GPX4 in Tregs not only elicits anti-tumor immunity but also detrimental autoimmunity, such as significant inflammation in the colon.364 Therefore, future studies should further determine how to selectively target tumor-infiltrating Tregs without affecting Tregs in healthy tissues when inducing ferroptosis to avoid systemic loss of immune tolerance.

MDSCs are pathologically activated immature cells with potent immunosuppressive effects and great heterogeneity.365 They can be identified as two subgroups: PMN- and monocytic (M)-MDSCs.366 Tumor-infiltrating PMN-MDSCs, but not M-MDSCs, are vulnerable to ferroptosis or even experience spontaneous ferroptosis within the TME.23 Increased AA uptake through the fatty acid transport protein 2 (FATP2) and hypoxia-mediated downregulation of GPX4 both contribute to this susceptibility to ferroptosis.23 Although ferroptosis reduces the number of PMN-MDSCs, the increased release of immunosuppressive molecules, such as PGE2 and oxidized lipids, from ferroptotic PMN-MDSCs promotes tumor growth by restricting anti-tumor T cells and supporting the suppressive activity of TAMs.23,367 These findings suggest ferroptosis induction could decrease the viability of MDSCs, but the complex immunoregulatory nature of ferroptosis in MDSCs, as well as TME, must be considered in further research.

Therapeutic strategies of ferroptosis in cancer

As noted above, ferroptosis is tightly interwoven with cell metabolic and oxidative burdens, suggesting the possibility that cancer cells may have higher predispositions to FINs for their overall more active metabolism, higher ROS levels and iron requirements.11,368,369 Intriguingly, mesenchymal and dedifferentiated cancer cells, which are usually resistant to apoptosis and traditional therapies, are exquisitely vulnerable to ferroptosis.182,247,370 Therefore, FINs hold promise in cancer treatment.371 However, due to the immunosuppressive regulatory role and the tissue-damaging ability of ferroptosis, ferroptosis inhibition also proves to be an effective strategy to prevent tumor initiation, inhibit tumor progression, improve tissue damage-mediated cachexia in advanced tumors, and alleviate the side effects of traditional therapies. For these reasons, a comprehensive understanding of the current applications of both ferroptosis induction and inhibition in cancer will pave the way for their clinical implementation.

Ferroptosis induction

In addition to immunotherapy and radiotherapy,19,372 a diverse range of systemic drugs, including but not limited to targeted therapy,214 chemotherapy,138,373 lipid-lowering drugs,374,375 and anti-inflammatory drugs,376,377 have been identified as FINs and possess tumor-suppressive abilities.60 (Table 1). Here, we will describe in detail FINs that have previously entered clinical trials and briefly discuss the main tool compounds used to induce ferroptosis (Fig. 5) (Table 2).Table 1 Clinical trial drugs inducing ferroptosis for antitumor treatment

Drugs	Target	Cancer type	Indication	NCT	Phase	References (PMID)	
Sorafenib	SLC7A11	HCC

GC

CCRC

	HCC

AML

Neuroblastoma

Lung cancer

	NCT03794440

NCT03247088

NCT02559778

NCT00064350

	Marketed	26403645

36473315

31899616

37713596

	
Sulfasalazine	SLC7A11	Prostate cancer

Lymphoma

Lung cancer

CRC

HNC

PDAC

OCCC

	GBM

GBM

Breast cancer

Solid tumor

	NCT04205357

NCT01577966

NCT03847311

NCT01198145

	Marketed as an anti-inflammatory agent, in oncology phase I trials	11587223

31949285

37190291

37132587

27477897

28130223

37511540

	
Lapatinib	Iron	Breast cancer	Breast cancer

Breast cancer

Breast cancer

	NCT03085368

NCT00356811

NCT00667251

	Marketed	27441659	
Neratinib	Iron	Breast cancer	Breast cancer

CRC

CRC

	NCT04366713

NCT03377387

NCT03457896

	Marketed	37596261	
Artesunate	Iron	NHL

HCC

	Breast cancer

CRC

	NCT00764036

NCT03093129

	Marketed as an antimalarial drug, in oncology phase II trials	37326033

32699265

	
Cisplatin	GSH	GC

HNC

NSCLC

	NSCLC

Bladder cancer

Cervical cancer

Pancreas cancer

	NCT01656551

NCT04574960

NCT01561586

NCT03649321

	Marketed	27477897

28012440

35534546

35784745

	
Gemcitabine	GPX4	PDAC

LUAD

	Pancreatic cancer

BTC

Solid Tumor

	NCT06015659

NCT05357196

NCT05147272

	Marketed	36225575

28130223

	
Withaferin A	GPX4	Neuroblastoma HCC	Ovarian cancer

Advanced cancer

Osteosarcoma

	NCT05610735

NCT04092647

NCT00689195

	Phase II	29939160

36707233

	
Lovastatin	HMGCR	NSCLC	Prostate cancer

Ovarian Cancer

	NCT00580970

NCT00585052

	Marketed as lipid-lowering agents, in oncology	35943796	
Simvastatin	HMGCR	TNBC	Multiple myeloma	NCT00281476	phase II trials	34627266	
Haloperidol	DRD2	GBM	Advanced cancer	NCT04833023

NCT03743649

NCT00124930

	Marked for the treatment of psychiatric disorders, phase IV for the treatment of cancer	37249604	
Zalcitabine	DNA stress	Pancreatic cancer	AIDS-related Kaposi sarcoma	NCT00000954	Marketed for the treatment of HIV, phase I for the treatment of cancer	32186434	
β-Elemene	TFEB	NSCLC	NSCLC

GBM

	NCT03123484

NCT02629757

	Marketed	37689240	
BSO	GCL	TNBC	Neuroblastoma

Neuroblastoma

	NCT00005835

NCT00002730

	Phase I	37563614

37256771

	
Brequinar	DHODH	Cervical cancer

Colon cancer

Fibrosarcoma

Lung cancer

	AML	NCT03760666	Phase II	33981038

37291265

36672495

	
Curcumenol	FTH1	Lung cancer	Cancer	NCT00475683	Phase III	35224289	
NCT national clinical trial, N/A not applicable, BSO buthionine sulfoxide amine, GPX4 glutathione peroxidase 4, GSH glutathione, SLC7A11 solute carrier family 7 member 11, HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase, DRD2 dopamine D2 receptor, TFEB transcription factor EB, GCL glutamate-cysteine ligase, DHODH dihydroorotate dehydrogenase, FTH1 ferritin heavy chain 1, HCC hepatocellular carcinoma, GC gastric cancer, CCRC clear cell renal cell carcinoma, HNC head and neck cancer, NSCLC non-small-cell lung cancer, PDAC pancreatic ductal adenocarcinoma, LUAD lung adenocarcinoma, CRC colorectal cancer, OCCC ovarian clear cell carcinoma, TNBC triple-negative breast cancer, NHL non‑Hodgkin lymphoma, AIDs acquired immunodeficiency syndrome, BTC biliary tract cancer, AML acute myeloid leukemia, GBM glioblastoma

Fig. 5 Ferroptosis induction for cancer therapy. a Radiotherapy induces ferroptosis to suppress tumor through the following three mechanisms: ① Radiotherapy-induced DNA damage activates the ATM and cGAS/STING/ATF3 axis, leading to SLC7A11 inhibition and subsequent triggering of ferroptosis.② Radiotherapy upregulates the expression of ACSL4, facilitating the PUFA-PLs formation and inducing ferroptosis. ③ RT-MPs induce ferroptosis in neighboring unirradiated cells relying on the bystander effect. After immunotherapy treatment, activated CD8+ T cells release IFNγ, sensitizing tumor cells to ferroptosis by inhibiting SLC7A11, and promoting ACSL4-mediated PUFA-PLs formation, ultimately triggering ferroptosis. Immunotherapy and radiotherapy synergistically inhibit tumors by suppressing SLC7A11. b, c Major systemic drugs and experimental tool compounds for effective treatment of tumors through ferroptosis induction. ATF3 activation transcription factor 3, cGAS cyclic GMP-AMP synthase, cGAMP cyclic 2’,3’-GMP-AMP, DHA dihydroartemisinin, DHODH dihydroorotate dehydrogenase, FSP1 ferroptosis suppressor protein 1, FTH1 ferritin heavy chain 1, GCL glutamate-cysteine ligase, IFNγ interferon gamma, IKE imidazole ketone erastin, RT-MPs irradiated tumor cell-derived microparticles, STING stimulator of interferon genes. This figure was created with BioRender.com

Table 2 Classical pharmacological agents inducing ferroptosis for antitumor treatment

Compounds	Target	Mechanism	Cancer type	References (PMID)	
Erastin	SLC7A11	GSH depletion by inhibiting SLC7A11 activity	HCC

Melanoma

NSCLC

LUAD

Ovarian cancer

Anaplastic thyroid cancer

	31974380

37277863

31897145

33882617

31800616

36442849

36895980

	
IKE	SLC7A11	GSH depletion by inhibiting SLC7A11 activity	DLBCL

Sarcoma

GBM

NSCLC

	24439385

30799221

31899616

37752118

37957645

	
Cyst(e)inase	Cyst(e)ine	GSH depletion by degrading cysteine and cystine	Prostate cancer

Breast cancer

Lung cancer

Pancreatic tumors

Ovarian cancer

	27869804

29168506

32241947

31043744

	
RSL3	GPX4	GPX4 inactivation	Fibrosarcoma

TNBC

HCC

Lung cancer

Anaplastic thyroid cancer

	24439385

30545638

36257316

37596261

31556117

36895980

	
M162	GPX4	GPX4 inactivation	TNBC

Anaplastic thyroid cancer

	36257316

36895980

	
ML210	GPX4	GPX4 inactivation	HNC

TNBC

NSCLC

Anaplastic thyroid cancer

	33741422

34623753

37655031

36895980

	
FIN56	GPX4	GPX4 degradation	GBM

Lung cancer

	34659551

31949285

	
FINO2	Iron and

GPX4

	Iron oxidation and GPX4 inactivation	Fibrosarcoma	29610484	
Hemin	Iron	Iron loading	Lung cancer	36228518	
icFSP1	FSP1	Phase separation of FSP1	Melanoma	37380771	
iFSP1	FSP1	FSP1 inhibition	TNBC

NSCLC

HCC

	37432874

36893885

	
IKE imidazole ketone erastin, SLC7A11 solute carrier family 7 member 11, GPX4 glutathione peroxidase 4, FSP1 ferroptosis suppressor protein 1, GSH glutathione, HCC hepatocellular carcinoma, NSCLC non-small-cell lung cancer, LUAD lung adenocarcinoma, DLBCL diffuse large B-cell lymphoma, TNBC triple-negative breast cancer, GBM glioblastoma, HNC head and neck cancer

Immunotherapy

Immunotherapy with immune checkpoint inhibitors (ICIs) is a promising approach that targets explicitly dysfunctional immune systems and mainly activates CD8+ T cells to eradicate tumor cells effectively.378 The advent of ICIs, specifically anti-CTLA4 and anti-PD-1/PD-L1 antibodies, have brought about a paradigm shift in cancer therapy and represent a significant breakthrough in oncology.379 As described above, on one hand, IFNγ derived from CD8+ T cells activates the JAK/STAT1 pathway to downregulate SLC7A11 and SLC3A2, thereby sensitizing tumor cells to ferroptosis19,380; on the other hand, IFNγ can transcriptionally stimulate ACSL4 expression to promote the integration of TME-associated AA into PLs by STAT1/IRF1 signaling, ultimately inducing ferroptosis in tumor cells.330 Therefore, ferroptosis induction contributes to the anti-tumor effects of CD8+ T cells, and immunotherapy can promote cancer cell ferroptosis in vivo. As expected, inhibiting ferroptosis by liproxstatin-1 diminishes the effectiveness of ICIs in controlling tumor growth.19 Additionally, the resistance of tumor cells to ferroptosis is associated with unresponsiveness to ICIs. Restoring their sensitivity to ferroptosis could enhance immunotherapy efficacy. TYRO3high tumors, which are resistant to ICIs, can be re-sensitized to anti-PD1 therapy by restoring ferroptosis via inhibiting TYRO3-mediated AKT/NRF2 pathway.381

Owing to the immunomodulatory effect of ferroptotic cells and the involvement of ferroptosis in ICIs anti-tumor effect, ferroptosis induction holds promise as an anti-tumor strategy to enhance the efficacy of ICIs. A growing body of evidence has demonstrated that combining ICIs and ferroptosis-inducing agents synergistically inhibits tumor growth in vitro and vivo.19,309,382 For example, the combined treatment of GPX4 inhibitors and anti-PD-1 blockade significantly suppressed tumor growth and induced a pronounced immune response with increased proportions of activated CD8+ T cells in TNBC tumor-bearing immunocompetent mice.382 IL-1β sustains Fe-S cluster maintenance to repress iron accumulation and ferroptosis. The combination of IL-1β blockade and anti-PD-1 antibody leads to enhanced tumor inhibition compared to monotherapy, but this effect could be reversed by liproxstatin-1, indicating the involvement of ferroptosis.383 Moreover, we also found that bromodomain containing 4 (BRD4) is upregulated in ICB-resistant melanoma patients, and inhibiting BRD4/AKR1C2 axis by bromodomain and extra-terminal motif (BET) inhibitors has been shown to enhance the susceptibility of melanoma to ferroptosis and immunotherapy.384 Nevertheless, the intricate impact of ferroptosis on the TME limits the applicability of this combination strategy due to immunosuppressive activities triggered by ferroptosis. For example, although GPX4 inhibition-induced ferroptosis in HCC cells increased CD8+ T cell infiltration, this effect was counteracted by PD-L1 upregulation on tumor cells.322 Synchronously, ferroptosis triggered immunosuppressive MDSC infiltration through increased release of HMGB1 from hepatocytes. The triple combination of pharmacological FINs, checkpoint blockade, and MDSC suppression effectively inhibits primary liver tumors and liver metastasis.322 Hence, the specific components of multidrug combination therapy based on ferroptosis-inducing agents and immunotherapy could be customized to counteract the immunosuppression triggered by ferroptosis, so as to evoke robust anti-tumor immune responses and enhance the efficacy of anti-tumor treatment.

Radiation therapy

Radiotherapy, a widely employed cancer treatment modality, involves precisely administering ionizing radiation (IR) to target and eliminate tumor cells selectively.385,386 Radiotherapy directly induces diverse forms of DNA damage and is capable of inducing ferroptosis to inhibit tumor growth.327,387 The mechanisms through which radiotherapy induces ferroptosis are multifaceted.18 Firstly, radiotherapy-induced DNA double-strand breaks (DSBs) downregulate SLC7A11expression in an ATM-dependent manner, resulting in reduced cystine uptake, and enhanced ferroptosis.327 Moreover, radiotherapy-induced DNA damage also can activate the cGAS/STING pathway to trigger tumor ferroptosis via activating transcription factor 3 (ATF3) /SLC7A11/GPX4 axis.304 Secondly, radiotherapy induces the expression of ACSL4 to promote the integration of PUFAs into PLs, resulting in the formation of PUFA-PLs, ultimately resulting in ferroptosis.372 Thirdly, irradiated tumor cell-derived microparticles (RT-MPs) induce a bystander effect via inducing ferroptosis, which causes the generation of oxidative stress and DNA damage in neighboring unirradiated cells.388 The mechanism by which RT-MPs induce ferroptosis is not yet fully understood, but the colocalization of RT-MPs membranes with lysosomes and mitochondria provides a direction for understanding its potential mechanisms.388

The occurrence of radioresistance, which leads to the failure of radiotherapy, is undeniably linked to metastasis, cancer recurrence, and unfavourable prognosis.389 Ferroptosis has also been implicated in radioresistance. IR can induce SLC7A11 and GPX4 upregulated as an adaptive response to safeguard cells against ferroptosis and contribute to radioresistance,372,390,391 suggesting that inhibiting SLC7A11 or GPX4 sensitizes radioresistant cancers to IR. As expected, the combination of class I FINs that inhibit SLC7A11 or class II or III FINs that inhibit or deplete GPX4 with IR demonstrated synergistic effects in inducing lipid peroxidation and ferroptosis.372 Moreover, suppressors of cytokine signaling 2 (SOCS2) were screened out as a potential biomarker predicting radiosensitivity of HCC. Mechanistically, SOCS2 transfers the attached ubiquitin to SLC7A11 and promotes K48-linked polyubiquitination degradation of SLC7A11.391 Conversely, stanniocalcin 2 (STC2) activate PRMT5, leading to upregulation of SLC7A11 and resistance to ferroptosis, thus playing a role in ESCC radioresistance.390 Other mechanisms that inhibit ferroptosis also contribute to radioresistance. For example, KEAP1 mutant lung cancers, which are refractory to most therapies, including radiotherapy, exhibit the upregulation of the NRF2/FSP1 anti-ferroptosis axis, resulting in resistance to ferroptosis and radiotherapy.165 Targeting FSP1 confers vulnerability to ferroptosis and enhances radiosensitivity in KEAP1 mutant lung cancers.165 IR-induced downregulation of copper metabolism MURR1 domain 10 (COMMD10) contributes to the radioresistance because COMMD10 inhibition represses ferroptosis through reducing iron concentration and facilitating HIF1α/SLC7A11 axis.392 These findings suggested that ferroptosis inhibition contributes to radioresistance, and combining FINs and IR synergistically induces ferroptosis.

Systemic drugs

Sorafenib, the first tyrosine kinase inhibitor authorized for the treatment of patients with unresectable HCC, advanced renal cell carcinoma, and differentiated thyroid cancer,210 has been shown to trigger ferroptosis by inhibiting system xc- and increasing intracellular iron levels.393–395 Therefore, increased SLC7A11 expression and the inhibition of ferritin autophagy contribute to resistance against sorafenib.234,396,397 For example, YAP/TAZ maintains the protein stability, nuclear localization, and transcriptional activity of ATF4, synergistically encouraging the expression of SLC7A11 and resulting in resistance against sorafenib-induced ferroptosis.397 Activation of ATF2 can inhibit protein degradation of SLC7A11 and mediate resistance to sorafenib-induced ferroptosis in gastric cancer.396 Moreover, CISD2 dissociates Beclin-1 from the PI3K-III complex and therefore leads to the inhibition of autophagy and resistance against sorafenib-induced ferroptosis.398 Depletion of PTBP1 leads to resistance against sorafenib-induced ferroptosis through disrupting NCOA4 translation and avoiding ferritin autophagy.399 However, sorafenib-induced ferroptosis is context-dependent, because sorafenib fails to trigger ferroptosis in various tumor cell lines,400 and whether these cells have acquired resistance against sorafenib-triggered ferroptosis needs to be clarified.

Lapatinib and neratinib are both tyrosine kinase inhibitors approved for the treatment of breast cancer. In lapatinib-resistant NSCLC cells, the activation of mTORC1 leads to the upregulation of GPX4 expression and inhibits lapatinib-induced ferroptosis. Therefore, inhibition of GPX4 or mTOR can overcome lapatinib resistance and facilitate lapatinib-induced ferroptosis.401 Moreover, the combination of lapatinib and siramesine, a lysosomal destabilizing lysosomotropic drug, synergistically induces ferroptosis through regulating iron homeostasis.402,403 Neratinib facilitates ferroptosis and suppresses brain metastasis in human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a neoadjuvant therapy through the elevation of intracellular iron levels.404 Moreover, neratinib inhibits acute myeloid leukemia cell proliferation by activating autophagy-dependent ferroptosis.405 A recent study revealed that neratinib effectively tackled resistance to RSL3 in non-HER2 amplified luminal breast cancer, and combination treatment with RSL3 and neratinib enhances ferroptosis by increasing mitochondrial iron-dependent ROS production and lipid peroxidation.406

Cisplatin is a platinum-based chemotherapeutic agent approved by the Food and Drug Administration (FDA) for oncology use in 1978.407 Cisplatin-based regimens remain the mainstay of treatment for a wide range of solid tumors.408 The anti-tumor mechanism of cisplatin is mainly mediated by the production of nuclear DNA adducts, which ultimately leads to apoptosis.409 However, recent studies have shown that cisplatin can also induce ferroptosis by depleting GSH and inactivating GPX4, providing an alternative mechanism for inhibiting tumor growth.373 Consistently, NRF2/SLC7A11 signaling pathway is activated in cisplatin-resistant cancer cells, and inhibiting this pathway could trigger ferroptosis and overcome cisplatin resistance.410–413 Combining cisplatin with FINs also may be a better strategy to improve the therapeutic effect of cisplatin.414,415 Notably, cisplatin-mediated tumor cell ferroptosis can promote the anti-tumor efficacy of ICI therapy by reprogramming TME characterized by the N1 neutrophil polarization and increased T-cell infiltration and Th1 differentiation in NSCLC.416

Gemcitabine (GEM) undergoes a complex intracellular conversion into gemcitabine diphosphate and triphosphate nucleotides, which induce DNA chain termination and interfere with DNA synthesis, conferring potent anti-tumor activity across a wide spectrum of tumors.417 The anticancer activity of GEM is associated with the Hsp70 member 5 (HSPA5)/GPX4 pathway-mediated ferroptosis induction.138,254 Epigallocatechine gallate or sulfasalazine enhances the sensitivity of gemcitabine in PDAC by inhibiting the HSPA5/GPX4 pathway, thereby disinhibiting ferroptosis.138 Consistently, the combination of GEM and IKE shows a synergistic antiproliferative effect on LUAD.418 Moreover, PDAC-associated fibroblasts can secrete exosome-derived miR-3173-5p, which inhibits ferroptosis and promotes gemcitabine resistance by targeting ACSL4.419

Sulfasalazine (SAS), a clinical anti-inflammatory drug used in rheumatoid arthritis,420 induces ferroptosis by inhibiting cystine/glutamate antiporter SLC7A11.376,377 Similar to classical system xc- inhibitors such as erastin/IKE, SAS effectively induces ferroptotic cell death in chemotherapy-resistant cells and improves chemotherapy response.410 SAS also enhances the therapeutic effectiveness of front-line therapies, such as anthracycline daunorubicin, in acute myeloid leukemia,421 as well as paclitaxel in ovarian clear cell carcinoma.422 Moreover, SAS, as a radiosensitizer, enhances the therapeutic efficacy of radiotherapy by promoting ferroptosis.327,372,423 Notably, a specially designed injectable hydrogel drug delivery system loaded with SAS demonstrates remarkable therapeutic efficacy in combating peritoneal dissemination and malignant ascites in advanced HCC, which is resistant to systemic therapies,424,425 particularly when combined with anti-PD-1 immunotherapy.426

Statins, a class of clinical drugs aimed at reducing blood cholesterol levels,427 including fluvastatin,428 atorvastatin,429 pravastatin,430 lovastatin,431 and simvastatin,375 are considered attractive FINs in daily practice due to their favorable safety profile.430 Statins induce ferroptosis by inhibiting the GSH/GPX4 and FSP1/CoQ10/NAD(P)H axes via the mevalonate pathway.247,375 Simvastatin inhibits the expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) to downregulate the mevalonate pathway and GPX4, thereby inducing cancer cell ferroptosis.375 Lovastatin induces ferroptosis and converts the immuno-cold phenotype to an inflammatory phenotype in NSCLC by downregulating PD-L1 expression in lung cancer cells, making the tumors more responsive to immunotherapy.431

Artemisinin, derived from the Chinese herb Artemisia annua,432 has been found to have anti-tumor effects in various types of tumors through ferroptosis.433 Mechanistically, artemisinin promotes ferritinophagy and increases intracellular free iron levels, and finally leads to ferroptosis and tumor inhibition.434,435 Artesunate, as an artemisinin derivative, has demonstrated efficacy in suppressing sunitinib-resistant renal cell carcinoma cells through ferroptosis and cell cycle arrest.435 Expectedly, artesunate synergistizes with sorafenib to induce ferroptosis in HCC and non-Hodgkin lymphoma cells.436,437 Consistently, dihydroartemisinin, the metabolite of artemisinin,438 inhibits lung cancer cells by suppressing the PRIM2/SLC7A11 axis,439 and enhances the cytotoxicity of gefitinib in LUAD cells,440 sorafenib in HCC,441 and cisplatin in PDAC.442

Haloperidol, a specific antagonist of dopamine receptor D2 (DRD2) extensively used for the treatment of psychiatric disorders,443 exhibits inhibitory effects in cancers by inducing ferroptosis.444,445 However, the precise mechanism by which it induces ferroptosis remains unclear, and there may be a potential association with autophagy.446 Haloperidol demonstrates synergistic activity with temozolomide in the growth inhibition of glioblastoma multiforme (GBM) through enhancing temozolomide-induced autophagy-mediated ferroptosis by inhibiting DRD2.444 Haloperidol can also sensitize the erastin- and sorafenib-induced ferroptosis in HCC by inhibiting the sigma 1 receptor (S1R).447

Zalcitabine, also known as 2’, 3’-dideoxycytidine, is used for the treatment of patients infected with the human immunodeficiency virus (HIV) by targeting mitochondrial DNA polymerase gamma (POLG).448 Zalcitabine induces autophagy-mediated ferroptosis in pancreatic cancer cells by activating mitochondrial DNA stress and the STING1/TMEM173-dependent DNA sensing pathway.449

β-Elemene (β-ELE), derived from Curcuma wenyujin, is widely used to treat NSCLC in clinical settings in China.450 β-ELE binds to transcription factor (TFEB), which is the key regulator of lysosome biogenesis, and notably activates TFEB-mediated lysosome degradation of GPX4, thus inducing NSCLC ferroptosis and resulting tumor suppression.451

Withaferin A (WA) is a bioactive compound derived from the ashwagandha plant, Withania somnifera.452 WA eradicates high-risk neuroblastoma tumors and suppresses relapse rates by inducing ferroptosis via GPX4 targeting and inactivation.453 WA also attenuated sorafenib resistance and metastatic potential by KEAP1/NRF2-associated EMT and ferroptosis.454 Moreover, a triple combination of withaferin A, the CXCR2 inhibitor and anti-PD-1 immunotherapy greatly improves the survival of wild-type mice with liver tumors and reduces liver metastasis of colorectal cancer. This effect may be attributed to the triggering of GPX4-associated ferroptotic hepatocyte death, leading to an adaptive immune response characterized by the activation of CD8+ T cells, upregulation of PD-L1 on tumor cells, and infiltration of immunosuppressive MDSCs.322

Buthionine sulfoxide amine (BSO) activates ferroptosis by targeting GCL for de novo GSH elimination.455 BSO induces ferroptotic cell death in lung cancer and HCC.192,456 BSO enhances the therapeutic effect of traditional chemotherapy regimens455 and radiotherapy in TNBC by promoting ferroptosis.457

Brequinar, a DHODH inhibitor, serves as a potential agent to treat GPX4low cancers by triggering ferroptosis,134 whereas combined administration of brequinar and sulfasalazine synergistically suppresses GPX4high tumors growth.134 Moreover, AMPK activation enhances the assembly of pyrimidinosomes, rendering cancer cells more reliant on DHODH-mediated ferroptosis defense to counteract AMPK-associated stresses.458 The combination of brequinar and AMPK activators exhibit synergistic efficacy in tumor suppression through ferroptosis.458

Curcumenol, an effective compound found in Wenyujin, has been discovered to inhibit the growth of lung cancer tumors by inducing ferroptosis through lncRNA H19/miR-19b-3p/FTH1 axis.459

Others

In addition to FINs that have previously entered clinical trials, a wide range of experimental tool compounds have been employed in preclinical studies of ferroptosis (Table 2). These compounds could be classified into four classes.12,460–462 Classical I FINs are identified through the depletion of GSH to trigger ferroptosis, such as erastin, its derivatives imidazole ketone erastin (IKE),460,463,464 and cyst(e)inase, which depletes GSH by degrading cysteine and cystine.465 Classical II FINs directly inhibit GPX4 to induce ferroptosis, such as RSL3, ML162 and ML210.43,269,382 Classical III FINs deplete the GPX4 protein and CoQ10 to induce ferroptosis, such as FIN56.45,466–469 Class IV FINs induce ferroptosis by augmenting the LIP, such as FINO2.136 These tool compounds have made significant contributions to the understanding of the mechanism of ferroptosis due to their specificity towards ferroptosis.

Moreover, the drug delivery system has gained increasing interest in tumor treatment due to its effective delivery and precise control of drug release. Nowadays, three delivery systems, including nanoparticles, hydrogels, and liposomes, have been utilized to improve the efficiency and selectivity of FINs in targeting tumors while minimizing toxicity to normal organs. For example, the acidity-activatable dynamic nanoparticles BNP@R were developed to specifically deliver RSL3 to tumors and enable acid-activatable photodynamic therapy, thereby promoting RSL3-induced ferroptosis and ultimately inhibiting tumor growth.470 The tumor-suppressing effect of RSL3 in vivo was also potentiated when delivered in an injectable alginate hydrogel RTFG@SA.471 Brequinar-loaded mitochondrial-targeted liposomes BQR@MLipo were employed to enhance brequinar-mediated mitochondrial ferroptosis, effectively inhibiting bladder cancer growth.306 The continuous advancements in drug delivery systems targeting ferroptosis contribute to the clinical applications of FINs in cancer treatment.

Ferroptosis inhibition

The heterogeneity of tumors and the immune microenvironment complicates the role of ferroptosis in tumor suppression. Under some conditions, ferroptosis is even conducive to tumor initiation and progression: 1) The inflammation resulting from ferroptosis-induced tissue damage contributes the onset of necroinflammation-driven tumors.21,148; 2) The vulnerability of immune cells to ferroptosis compromises their anti-tumor function or enhances their pro-tumor effect, leading to tumor growth.23,354,449; 3) The immunosuppressive activities of ferroptotic cancer cells promotes the tumor progression.321 Moreover, it is worth noting that ferroptosis inhibition could also be considered an effective means to suppress the side effects mediated by traditional therapy-induced ferroptosis, due to the tissue-damaging ability of ferroptosis. Thus, ferroptosis inhibition seems to be a potential context-dependent strategy for cancer treatment.

Inhibition of ferroptosis is advantageous in suppressing the initiation of necroinflammation-driven tumors. Liver-related diseases, including steatohepatitis, can trigger the initiation of hepatocyte stress, excessive cell death, subsequent necroinflammation, and compensatory proliferation, which are considered to be the aetiologies of hepatocellular carcinogenesis.472,473 A recent study has revealed that ferroptosis stands out as the most pertinent form of hepatocyte death, leading to HCC-promoting necroinflammation and compensatory proliferation.21 By contrast, the activation transcription factor 4 (ATF4) attenuates the progression from steatohepatitis to HCC by upregulating SLC7A11 to block stress-related ferroptosis, thereby blunting HCC onset. Moreover, high-iron diets or depletion of Gpx4-induced ferroptosis promotes pancreatitis and pancreatic tumorigenesis. Inhibiting ferroptosis through the administration of liproxstatin-1 reduces the formation of spontaneous pancreatic cancer and reverses the promotion of PDAC development by high-iron diets or GPX4 depletion.319 The initiation of ferroptosis-driven pancreatic cancer may be associated with macrophage infiltration and activation, which is mediated by the release of 8-OHG caused by ferroptotic damage and subsequent activation of the STING-dependent DNA sensor pathway in macrophages.319

Ferroptosis inhibition rescues immune cells from undergoing ferroptosis and affects their immune regulatory ability, thereby impeding tumor development. CD36-mediated ferroptosis hampers the effector function of intratumoral CD8+ T cells and diminishes their ability to combat tumors. Consequently, genetic deletion of CD36 or inhibition of ferroptosis with ferrostatin-1 in CD8+ T cells can effectively restore their anti-tumor effects.449 NK cells also undergo ferroptosis induced by various triggers in the TME, including L-KYN released by tumor cells and CAF-derived follistatin-like protein 1 (FSTL1) and iron.354,474 Overexpression of GPX4 in NK cells effectively inhibits ferroptosis and prevents their reduction within the TME, thereby suppressing tumor growth.354 Consistently, the combination of FSTL1-neutralizing antibody and deferoxamine significantly inhibits NK cell ferroptosis, enhancing the cytotoxicity of NK cells against tumor cells.474 In addition, tumor-associated PMN-MDSCs undergo ferroptosis spontaneously.23 Intriguingly, although this ferroptotic process decreases PMN-MDSC numbers, their immunosuppressive activity is enhanced due to the increased release of immunosuppressive molecules.23 Inhibition of ferroptosis by liproxstatin-1 could alleviate the immune suppression mediated by PMN-MDSCs and reduce tumor growth, especially when combined with immunotherapy.23 These studies indicate that ferroptosis in several immune cell types exerts tumor-supportive effects, raising the possibility for future investigation into selectively inhibiting ferroptosis in immune cells through cell-specific delivery to inhibit tumor growth effectively.

Ferroptosis inhibition counteracts the immunosuppressive activities of ferroptotic cancer cells to restrict tumor progression. For example, mutated KRAS protein derived from ferroptotic PDAC cells is packaged into exosomes, which are then engulfed by adjacent macrophages, promoting their subsequent polarization into an M2 tumor-promoting state.321 Administration of ferrostatin-1 can inhibit the tumor-promoting growth arising from peripheral blood mononuclear cell-derived macrophages (PBMCMs) in immunodeficient mice.321 However, the impact of ferroptosis inhibition on PDAC tumor progression has not been investigated in immunocompetent mice. It is crucial to consider that inhibiting ferroptosis may also suppress the tumoricidal effect of cancer cell ferroptotic death and affect the immunoregulatory role of immune cells within the TME. Therefore, the application of ferroptosis-based approaches in cancer treatment should be applied with caution. More studies are needed to fully understand the complex interplay between ferroptosis, tumor progression, and immune response, to make informed decisions regarding the application of ferroptosis modulation in cancer therapy.

Because of the link between the anti-tumor effects of traditional therapy and ferroptosis induction, as well as the potential tissue-damaging properties of ferroptosis, ferroptosis inhibition is considered an effective approach to suppress the side effects mediated by traditional therapy-induced ferroptosis. For instance, cisplatin-induced ferroptosis was implicated in chemotherapy-induced ovarian damage, and the administration of antioxidant NAC can alleviate cisplatin-induced toxicity in normal ovarian cells by inhibiting ferroptosis and oxidative stress.475 Cisplatin-induced acute kidney injury and doxorubicin-induced cardiomyopathy also could be inhibited by ferroptosis inhibitor ferrostatin-1.476,477 The FDA-approved iron chelator dexrazoxane protects against doxorubicin-induced cardiotoxicity by chelating mitochondrial iron.114 Moreover, ferroptosis is also implicated in radiation-induced intestinal injury, which can be alleviated by administering ferrostatin-1.478 Ferroptosis inhibition appears to be a potential target for mitigating treatment side effects, potentially enhancing treatment tolerance, and prolonging the life quality of patients. However, it also raises concerns regarding whether the administration of ferroptosis inhibitors to mitigate the ferroptosis-related side effects induced by traditional therapy might also inhibit its therapeutic effect. In addition, the occurrence of ferroptosis was observed in wasting tissues during advanced tumors cachexia. It is reported that tissue-infiltrating neutrophils-secreted LCN2 induces ferroptosis and wasting tissues in lung cancer cachexia. Liproxstatin-1 has been shown to mitigate tissue wasting in lung cancer cachexia, improve symptoms, and extend the survival of cachectic mice by inhibiting ferroptosis.479

Collectively, ferroptosis inhibition holds promise as a strategy for suppressing tumor growth, attenuating adverse effects of traditional therapies and improving cachexia. Ferroptosis inhibitors generally encompass four classes120: 1) Radical-trapping antioxidants including ferrostatin-1, liproxstatin-1 and vitamin E.4,8,298 2) Iron chelators such as deferoxamine, cyclipirox, and deferiprone.4,120 3) Inhibitors of ferroptosis-promoting enzymes, such as ACSL4 inhibitor (thiazolidinediones and triacsin C.46,68 4) Inhibitors of protein degradation in the ferroptosis defense system, such as 5-(tetradecyloxy)-2-furoic acid (TOFA) and dopamine for preventing GPX4 protein degradation.45,480 Additionally, compounds, like CoQ10, N-acetylcysteine (NAC) and β-mercaptoethanol (2ME) that disrupt the pathways involved in ferroptosis excitation can also be potential inhibitors.120 Several clinical trials are pending to assess the effectiveness of ferroptosis inhibitors, such as deferoxamine (DFO) and deferasirox (DFX) in anti-tumor treatment (Table 3). However, further investigations are required to ascertain whether their anti-tumor potential is dependent on their ability to inhibit ferroptosis.Table 3 Ferroptosis inhibitors used for cancer research

Drugs/Compounds	Target	Mechanism	Indication	NCT	Phase	Reference (PMID)	
RTAs	
Ferrostatin-1	RTA	Inhibits lipid peroxidation	N/A	N/A	N/A	36996941	
Liproxstatin-1	RTA	Inhibits lipid peroxidation	N/A	N/A	N/A	36385526

36973755

33311482

	
Vitamin E	RTA/ALOXs	Inhibits lipid peroxidation

and may inhibit ALOXs

	PDAC

Prostate Cancer

CRC

NSCLC

	NCT01446952

NCT00809458

NCT00905918

NCT01871454

	I

III

I

II

	24439385

27159577

	
XJB-5-131	RTA	Nitroxide-based mitochondrial

lipid peroxidation mitigators

	N/A	N/A	N/A	27725964	
JP4-039	RTA	Nitroxide-based mitochondrial

lipid peroxidation mitigators

	N/A	N/A	N/A	27725964	
Iron chelator	
Deferoxamine	Iron	Reduces intracellular iron	TNBC

HCC

Solid tumors

	NCT05300958

NCT03652467

NCT05184816

	II

I

I

	31519186	
Deferasirox	Iron	Reduces intracellular iron	MDS	NCT00940602	II	32203980	
2,2-bipyridyl	Iron	Reduces intracellular iron	N/A	N/A	N/A	22632970	
Ciclopirox	Iron	Reduces intracellular iron	HCC	NCT00990587	I	19589922	
Enzyme inhibitors	
Zileuton	5-LOX	Inhibits 5-LOX activity	NSCLC

HNC

	NCT00070486

NCT00056004

	II

II

	18281656

22425913

	
Troglitazone	ACSL4	Inhibits ACSL4	Sarcoma	NCT00003058	II	27842070	
Rosiglitazone	ACSL4	Inhibits ACSL4	Solid tumor

Prostate cancer

Sarcoma

	NCT04114136

NCT00182052

NCT00004180

	II

III

II

	27842070	
Pioglitazone	ACSL4	Inhibits ACSL4	Thyroid Cancers

Breast cancer

	NCT01655719

NCT05013255

	II

II

	27842070	
2-acetylphenothiazine	NOXs	Inhibits NOXs	N/A	N/A	N/A	28813679	
GKT137831	NOXs	Inhibits NOXs	N/A	N/A	N/A	22632970	
Linagliptin	DPP4	Inhibits NOX1-mediated

lipid peroxidation

	NSCLC	NCT03337698	II	28813679	
Vildagliptin	DPP4	Inhibits NOX1-mediated

lipid peroxidation

	Thyroid Cancer	NCT02862470	N/A	28813679	
Alogliptin	DPP4	Inhibits NOX1-mediated

lipid peroxidation

	N/A	N/A	N/A	28813679	
Baicalein	ALOX	Inhibits 12/15-LOX	N/A	N/A	N/A	27037021	
PD146176	ALOX	Inhibits 15-LOX-1	N/A	N/A	N/A	27842066	
AA-861	ALOX	Inhibits 5-LOX	N/A	N/A	N/A	27506793	
Protein degradation inhibitors	
Dopamine	Neurotransmitter	Increases the stability of GPX4	HNC	NCT02241083	IV	27793671	
TOFA	ACC	Inhibits GPX4 degradation	N/A	N/A	N/A	27159577	
Others	
β-mercaptoethanol	Reducing agent	Promotes cystine uptake

through bypassing xCT

	N/A	N/A	N/A	22632970	
CoQ10/idebenone	Antioxidant	Inhibits lipid peroxidation	Breast cancer

HCC

	NCT00976131

NCT01964001

	I

III

	31634900

27159577

	
NAC	GSH	GSH synthesis regulator	Lymphoma	NCT05081479	I	32203980	
MUFAs	Fatty acids	Decreases oxidizable PUFAs	Malignancy	NCT00924937	N/A	30686757

31270077

	
NCT national clinical trial, N/A not applicable, RTAs radical-trapping antioxidants, TOFA 5-(tetradecyloxy)-2-furoic acid, NAC N-acetylcysteine, MUFAs monounsaturated fatty acids, ALOXs arachidonate lipoxygenases, 5-LOX 5-lipoxygenase, ACSL4 acyl-CoA synthetase long-chain family member 4, NOXs NADPH oxidase, DPP4 dipeptidyl-peptidase-4, ACC Acetyl-CoA carboxylase, GSH glutathione, xCT system xc-, PUFAs polyunsaturated fatty acids, PDAC pancreatic ductal adenocarcinoma, CRC colorectal cancer, NSCLC non–small-cell lung cancer, TNBC triple-negative breast cancer, HCC hepatocellular carcinoma, MDS myelodysplastic syndromes, HNC head and neck cancer

Markers of ferroptosis

A standardized set of identification hallmarks for ferroptosis enables us to determine its occurrence in physiological and pathological conditions, facilitating further investigation into its role in cancer. Currently, four classes of markers, including lipid peroxidation, mitochondria morphological alteration, gene expression change, and TFR1 re-localization, have been considered suitable for detecting and accurately distinguishing ferroptosis from other forms of RCD.12 First, the core of ferroptosis occurrence is the peroxidation of membrane-localized lipids and their lethal accumulation. There are five methods available to detect lipid peroxidation, including BODIPY 581/591 C11 fluorescent probes, lipidomics, thiobarbituric acid reactive substances (TBARS), malondialdehyde (MDA) and 4-HNE staining. Among those, flow cytometry following BODIPY 581/591 C11 staining is a sensitive and convenient method for detecting lipid peroxidation. Second, multiple organelles are involved in ferroptosis. Endoplasmic reticulum-related oxidative stress,481–487 mitochondria-induced cysteine starvation,134,160 lysosome dysfunction,138,275,488–491 peroxisomes-mediated ether lipids peroxidation,52 and Golgi stress-related lipid peroxidation all contribute to ferroptosis induction.492,493 Among these organelles, the morphological alterations in mitochondria, characterized by shrinkage, increased density, and decreased cristae, are considered the morphological features of ferroptosis and can be observed using transmission electron microscopy. Nevertheless, these mitochondria alterations are not specific, as they can be observed in oxidative stress and mitochondrial stress, and mitochondria are not indispensable for ferroptosis induction in some conditions.12,481 Third, specific gene expression changes, such as increased CHAC1, PTGS2, SLC7A11 and ACSL4 can be detected in cells undergoing ferroptosis. However, these changes may not be universally observed in all contexts of ferroptosis.12,494 Moreover, a recent study has identified hyperoxidized peroxiredoxin 3 (PRDX3) protein as a novel marker of ferroptosis in vitro and in vivo, specifically detectable in ferroptosis, rather than mitochondrial oxidative stress or other forms of RCD, such as apoptosis, necroptosis and cuproptosis.495 Fourth, the re-localization of TFR1, which imports extracellular ferric into cells by endocytosis, contributing to the liable iron pool required for ferroptosis, has been demonstrated as a marker of ferroptosis.86 The relocation of TFR1 from the region surrounding Golgi to the plasma membrane can be observed through staining with the 373-FMA antibody. This method provides a potential avenue for selectively staining ferroptotic cells in tissue sections.

To accurately determine the occurrence of ferroptosis, multiple markers are needed, which must be detected before cell demise. The selection of an appropriate time point is important in detecting ferroptosis markers. Among these markers, lipid peroxidation is essential, while other indicators may not be fully detected. Additionally, pharmacological rescue experiments using ferroptosis inhibitors are also crucial. In evaluating the efficacy of ferroptosis-based therapies, appropriate markers for detecting ferroptosis within tumor tissue are necessary. Although staining for 4-HNE, hyperoxidized PRDX3, MDA and TFR1 shows relatively promising prospects in their applicability for ferroptosis detection in tumor tissue sections, these markers could not be used in a living organism. Blood, urine, and feces are regularly checked in clinic practice, and whether or not using these samples to detect ferroptosis levels in patients is worth exploring, because ferroptotic cells could release some specific substances into their microenvironment. Deciphering the changes in iron, lipids, metabolites, and immune mediators may provide guidance for the development of these techniques.

Conclusions and perspectives

Ferroptosis is a distinct form of cell death characterized by iron-dependent phospholipid peroxidation, which is strictly controlled at multiple levels. Pharmacologically targeting ferroptosis holds great promise as an anticancer strategy. However, to realize the prospects of ferroptosis drugs in clinical practice, several additional challenges remain to be overcome in future research.

Firstly, there is a lack of well-established animal models to evaluate cancer ferroptosis in vivo. Current models mainly rely on the use of FINs, such as IKE and cyst(e)inase,43,53,192,465,496 to treat xenograft tumors. However, the timing and frequency of administration vary in practice, and the side effects of long-term administration and potential drug resistance are not well understood. Additionally, generating CRISPR/Cas9-mediated GPX4 knockout cancer cells for xenograft models fails to evaluate the efficacy and safety effects of ferroptosis drugs. Therefore, standardized animal models are needed to improve our understanding of ferroptosis biology in cancer and ease the comparison of studies between research laboratories and clinicians.

Secondly, the complex biological effects of ferroptosis in cancer present another challenge. In some cases, ferroptosis induction initially promotes tumor formation but later leads to tumor cell demise and suppression.21,319 Tumor formation is a complex process involving metabolic disorders. For example, our team first put forward that melanoma is a metabolically driven and metabolically remodeled cancer.497,498 Given the coexistence of established tumor cells and cells transitioning into tumor cells,23 solely using ferroptosis inhibitors or inducers may not effectively control early-stage tumors. Therefore, it is crucial to determine the appropriate therapeutic time window for FINs.

Thirdly, the lack of effective and specific drugs that can safely induce ferroptosis in cancer cells poses an additional challenge. Although several compounds have been discovered to induce ferroptosis, their in vivo potential is limited due to poor bioavailability and insufficient targeting. Developing small molecules compatible with in vivo conditions and exploring targeted protein degradation technologies, such as proteolysis-targeting chimaeras (PROTACs)499,500 and lysosome-targeting chimaera,499,501 offer promising strategies. Moreover, reducing the toxicity of FINs remains a challenge in clinical oncology. Shifting the focus of developing ferroptosis-targeting drugs from completely abrogating master regulators, such as GPX4, to other controlling complexes with lower toxicity, and developing combination treatment strategies based on ferroptosis are all viable approaches to mitigate its toxicity.

Fourthly, ferroptosis induction may have negative impacts on anti-tumor immunity, posing a challenge in achieving complete tumor elimination. It is essential to promptly neutralize the factors that contribute to the immunosuppression induced by ferroptotic cancer cells. Moreover, FINs could potentially kill anti-tumor immune cells. Therefore, the development of cell-specific precision targeting strategies is crucial for maximizing the efficacy of ferroptosis-induced therapy.

Lastly, identifying the patient population that would benefit most from ferroptosis therapy is crucial for successful clinical trials. The sensitivity of different cancer types to ferroptosis varies based on tumor origin and genotype. Integrating genetic information from the cancer genome can aid in predicting tumor response to specific ferroptosis drugs.

In conclusion, we are on the verge of an exciting era in the realm of ferroptosis research. Overcoming the challenges above will pave the way for successful translation into clinical cancer treatment, enabling the development of personalized ferroptosis-related anticancer strategies. We anticipate that novel ferroptosis-based therapies, guided by standardized animal models and precise evaluation of therapeutic time windows, will be developed and implemented in the near future.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant Nos. 82103183 to FZ, 82102803, 82272849 to GD), National Natural Science Foundation of Hunan Province (Grant Nos. 2022JJ40767 to FZ) and Natural Science Fund for Outstanding Youths in Hunan Province (2023JJ20093 to GD). We thank Biorender (https://www.biorender.com/) for the assistance for the illustration.

Author contributions

G.D., X.C., and F.Z. designed the review; Q.Z., Y.M., D.L., L.Y., and J.L., searched for literature and wrote the manuscript; Y.M., D.L., and L.Y., drew the figures; Y.L., and Y.S, helped edit and revise the manuscript. G.D., and F.Z., provided funding support. All authors have read and approved the article and agree with publication in this journal.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Qian Zhou, Yu Meng, Daishi Li, Lei Yao, Jiayuan Le
==== Refs
References

1. Hotchkiss RS Strasser A McDunn JE Swanson PE Cell death N. Engl. J. Med 2009 361 1570 1583 10.1056/NEJMra0901217 19828534
Hotchkiss, R. S., Strasser, A., McDunn, J. E. & Swanson, P. E. Cell death. N. Engl. J. Med 361, 1570–1583 (2009).19828534 10.1056/NEJMra0901217
2. Galluzzi L Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 Cell Death Differ. 2015 22 58 73 10.1038/cdd.2014.137 25236395
Galluzzi, L. et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 22, 58–73 (2015).25236395 10.1038/cdd.2014.137
3. Green DR The coming decade of cell death research: five riddles Cell 2019 177 1094 1107 10.1016/j.cell.2019.04.024 31100266
Green, D. R. The coming decade of cell death research: five riddles. Cell 177, 1094–1107 (2019).31100266 10.1016/j.cell.2019.04.024
4. Dixon SJ Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 1072 10.1016/j.cell.2012.03.042 22632970
Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).22632970 10.1016/j.cell.2012.03.042
5. Kung G Konstantinidis K Kitsis RN Programmed necrosis, not apoptosis, in the heart Circ. Res 2011 108 1017 1036 10.1161/CIRCRESAHA.110.225730 21493924
Kung, G., Konstantinidis, K. & Kitsis, R. N. Programmed necrosis, not apoptosis, in the heart. Circ. Res. 108, 1017–1036 (2011).21493924 10.1161/CIRCRESAHA.110.225730
6. Feldmann G Liver apoptosis J. Hepatol. 1997 26 1 11 10.1016/S0168-8278(97)80491-6 9204404
Feldmann, G. Liver apoptosis. J. Hepatol. 26, 1–11 (1997).9204404 10.1016/S0168-8278(97)80491-6
7. Fang Y Pyroptosis: A new frontier in cancer Biomed. Pharmacother. 2020 121 109595 10.1016/j.biopha.2019.109595 31710896
Fang, Y. et al. Pyroptosis: A new frontier in cancer. Biomed. Pharmacother. 121, 109595 (2020).31710896 10.1016/j.biopha.2019.109595
8. Friedmann Angeli JP Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice Nat. Cell Biol. 2014 16 1180 1191 10.1038/ncb3064 25402683
Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).25402683 10.1038/ncb3064
9. Koskenkorva-Frank TS Weiss G Koppenol WH Burckhardt S The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress Free Radic. Biol. Med 2013 65 1174 1194 10.1016/j.freeradbiomed.2013.09.001 24036104
Koskenkorva-Frank, T. S., Weiss, G., Koppenol, W. H. & Burckhardt, S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic. Biol. Med 65, 1174–1194 (2013).24036104 10.1016/j.freeradbiomed.2013.09.001
10. Cao JY Dixon SJ Mechanisms of ferroptosis Cell Mol. Life Sci. 2016 73 2195 2209 10.1007/s00018-016-2194-1 27048822
Cao, J. Y. & Dixon, S. J. Mechanisms of ferroptosis. Cell Mol. Life Sci. 73, 2195–2209 (2016).27048822 10.1007/s00018-016-2194-1
11. Jiang X Stockwell BR Conrad M Ferroptosis: mechanisms, biology and role in disease Nat. Rev. Mol. Cell Biol. 2021 22 266 282 10.1038/s41580-020-00324-8 33495651
Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266–282 (2021).33495651 10.1038/s41580-020-00324-8
12. Stockwell BR Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications Cell 2022 185 2401 2421 10.1016/j.cell.2022.06.003 35803244
Stockwell, B. R. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401–2421 (2022).35803244 10.1016/j.cell.2022.06.003
13. Jiang L Ferroptosis as a p53-mediated activity during tumour suppression Nature 2015 520 57 62 10.1038/nature14344 25799988
Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).25799988 10.1038/nature14344
14. Zhang C Ferroptosis in cancer therapy: a novel approach to reversing drug resistance Mol. Cancer 2022 21 47 10.1186/s12943-022-01530-y 35151318
Zhang, C. et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol. Cancer 21, 47 (2022).35151318 10.1186/s12943-022-01530-y
15. Friedmann Angeli JP Krysko DV Conrad M Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion Nat. Rev. Cancer 2019 19 405 414 10.1038/s41568-019-0149-1 31101865
Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019).31101865 10.1038/s41568-019-0149-1
16. Chen JJ Galluzzi L Fighting resilient cancers with iron Trends Cell Biol. 2018 28 77 78 10.1016/j.tcb.2017.11.007 29223642
Chen, J. J. & Galluzzi, L. Fighting resilient cancers with iron. Trends Cell Biol. 28, 77–78 (2018).29223642 10.1016/j.tcb.2017.11.007
17. Beretta GL Zaffaroni N Radiotherapy-induced ferroptosis for cancer treatment Front Mol. Biosci. 2023 10 1216733 10.3389/fmolb.2023.1216733 37388241
Beretta, G. L. & Zaffaroni, N. Radiotherapy-induced ferroptosis for cancer treatment. Front Mol. Biosci. 10, 1216733 (2023).37388241 10.3389/fmolb.2023.1216733
18. Lei G Ferroptosis, radiotherapy, and combination therapeutic strategies Protein Cell 2021 12 836 857 10.1007/s13238-021-00841-y 33891303
Lei, G. et al. Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell 12, 836–857 (2021).33891303 10.1007/s13238-021-00841-y
19. Wang W CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy Nature 2019 569 270 274 10.1038/s41586-019-1170-y 31043744
Wang, W. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270–274 (2019).31043744 10.1038/s41586-019-1170-y
20. Zhao L Ferroptosis in cancer and cancer immunotherapy Cancer Commun. 2022 42 88 116 10.1002/cac2.12250
Zhao, L. et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 42, 88–116 (2022).10.1002/cac2.12250
21. He F ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis J. Hepatol. 2023 79 362 377 10.1016/j.jhep.2023.03.016 36996941
He, F. et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J. Hepatol. 79, 362–377 (2023).36996941 10.1016/j.jhep.2023.03.016
22. Tang D Kroemer G Kang R Ferroptosis in hepatocellular carcinoma: from bench to bedside Hepatology 2023 10.1097/HEP.0000000000000390 37820061
Tang, D., Kroemer, G. & Kang, R. Ferroptosis in hepatocellular carcinoma: from bench to bedside. Hepatology10.1097/HEP.0000000000000390 (2023).37820061 10.1097/HEP.0000000000000390
23. Kim R Ferroptosis of tumour neutrophils causes immune suppression in cancer Nature 2022 612 338 346 10.1038/s41586-022-05443-0 36385526
Kim, R. et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612, 338–346 (2022).36385526 10.1038/s41586-022-05443-0
24. Tang D Chen X Kang R Kroemer G Ferroptosis: molecular mechanisms and health implications Cell Res. 2021 31 107 125 10.1038/s41422-020-00441-1 33268902
Tang, D., Chen, X., Kang, R. & Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 31, 107–125 (2021).33268902 10.1038/s41422-020-00441-1
25. Moore B Hawkes JL An investigation of the toxic actions of dilute solutions of the salts of certain heavy metals (viz.: Copper, Iron, Nickel, Cobalt, Manganese, Zinc, Silver, and Lead) upon the Bacillus Typhosus, with a view to practical application in the Purification of Shell-fish Biochem J. 1908 3 313 345 10.1042/bj0030313 16742106
Moore, B. & Hawkes, J. L. An investigation of the toxic actions of dilute solutions of the salts of certain heavy metals (viz.: Copper, Iron, Nickel, Cobalt, Manganese, Zinc, Silver, and Lead) upon the Bacillus Typhosus, with a view to practical application in the Purification of Shell-fish. Biochem J. 3, 313–345 (1908).16742106 10.1042/bj0030313
26. Eagle H The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture J. Exp. Med. 1955 102 37 48 10.1084/jem.102.1.37 14392239
Eagle, H. The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture. J. Exp. Med. 102, 37–48 (1955).14392239 10.1084/jem.102.1.37
27. Eagle H Nutrition needs of mammalian cells in tissue culture Science 1955 122 501 514, 10.1126/science.122.3168.501 13255879
Eagle, H. Nutrition needs of mammalian cells in tissue culture. Science 122, 501–514, (1955).13255879 10.1126/science.122.3168.501
28. Bieri JG An effect of selenium and cystine on lipide peroxidation in tissues deficient in vitamin E Nature 1959 184 1148 1149 10.1038/1841148a0
Bieri, J. G. An effect of selenium and cystine on lipide peroxidation in tissues deficient in vitamin E. Nature 184, 1148–1149 (1959).10.1038/1841148a0
29. Bannai S Tsukeda H Okumura H Effect of antioxidants on cultured human diploid fibroblasts exposed to cystine-free medium Biochem Biophys. Res. Commun. 1977 74 1582 1588 10.1016/0006-291X(77)90623-4 843380
Bannai, S., Tsukeda, H. & Okumura, H. Effect of antioxidants on cultured human diploid fibroblasts exposed to cystine-free medium. Biochem Biophys. Res. Commun. 74, 1582–1588 (1977).843380 10.1016/0006-291X(77)90623-4
30. Bannai S Kitamura E Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture J. Biol. Chem. 1980 255 2372 2376 10.1016/S0021-9258(19)85901-X 7358676
Bannai, S. & Kitamura, E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J. Biol. Chem. 255, 2372–2376 (1980).7358676 10.1016/S0021-9258(19)85901-X
31. Ursini F Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides Biochim. Biophys. Acta 1982 710 197 211 10.1016/0005-2760(82)90150-3 7066358
Ursini, F. et al. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochim. Biophys. Acta 710, 197–211 (1982).7066358 10.1016/0005-2760(82)90150-3
32. Geiger PG Thomas JP Girotti AW Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases Arch. Biochem. Biophys. 1991 288 671 680 10.1016/0003-9861(91)90250-M 1898056
Geiger, P. G., Thomas, J. P. & Girotti, A. W. Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases. Arch. Biochem. Biophys. 288, 671–680 (1991).1898056 10.1016/0003-9861(91)90250-M
33. Murphy TH Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress Neuron 1989 2 1547 1558 10.1016/0896-6273(89)90043-3 2576375
Murphy, T. H. et al. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2, 1547–1558 (1989).2576375 10.1016/0896-6273(89)90043-3
34. Schubert D Kimura H Maher P Growth factors and vitamin E modify neuronal glutamate toxicity Proc. Natl Acad. Sci. USA 1992 89 8264 8267 10.1073/pnas.89.17.8264 1387712
Schubert, D., Kimura, H. & Maher, P. Growth factors and vitamin E modify neuronal glutamate toxicity. Proc. Natl Acad. Sci. USA 89, 8264–8267 (1992).1387712 10.1073/pnas.89.17.8264
35. Li Y Maher P Schubert D A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion Neuron 1997 19 453 463 10.1016/S0896-6273(00)80953-8 9292733
Li, Y., Maher, P. & Schubert, D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19, 453–463 (1997).9292733 10.1016/S0896-6273(00)80953-8
36. Tan S Schubert D Maher P Oxytosis: A novel form of programmed cell death Curr. Top. Med Chem. 2001 1 497 506 10.2174/1568026013394741 11895126
Tan, S., Schubert, D. & Maher, P. Oxytosis: A novel form of programmed cell death. Curr. Top. Med Chem. 1, 497–506 (2001).11895126 10.2174/1568026013394741
37. Kang Y Cellular protection using Flt3 and PI3Kalpha inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity Nat. Commun. 2014 5 3672 10.1038/ncomms4672 24739485
Kang, Y. et al. Cellular protection using Flt3 and PI3Kalpha inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. Nat. Commun. 5, 3672 (2014).24739485 10.1038/ncomms4672
38. Albrecht P Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target CNS Neurol. Disord. Drug Targets 2010 9 373 382 10.2174/187152710791292567 20053169
Albrecht, P. et al. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol. Disord. Drug Targets 9, 373–382 (2010).20053169 10.2174/187152710791292567
39. Dolma S Lessnick SL Hahn WC Stockwell BR Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells Cancer Cell 2003 3 285 296 10.1016/S1535-6108(03)00050-3 12676586
Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285–296 (2003).12676586 10.1016/S1535-6108(03)00050-3
40. Yagoda N RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels Nature 2007 447 864 868 10.1038/nature05859 17568748
Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864–868 (2007).17568748 10.1038/nature05859
41. Yang WS Stockwell BR Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells Chem. Biol. 2008 15 234 245 10.1016/j.chembiol.2008.02.010 18355723
Yang, W. S. & Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15, 234–245 (2008).18355723 10.1016/j.chembiol.2008.02.010
42. Seiler A Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death Cell Metab. 2008 8 237 248 10.1016/j.cmet.2008.07.005 18762024
Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237–248 (2008).18762024 10.1016/j.cmet.2008.07.005
43. Yang WS Regulation of ferroptotic cancer cell death by GPX4 Cell 2014 156 317 331 10.1016/j.cell.2013.12.010 24439385
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).24439385 10.1016/j.cell.2013.12.010
44. Yang WS Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis Proc. Natl Acad. Sci. USA 2016 113 E4966 E4975 10.1073/pnas.1603244113 27506793
Yang, W. S. et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl Acad. Sci. USA 113, E4966–E4975 (2016).27506793 10.1073/pnas.1603244113
45. Shimada K Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis Nat. Chem. Biol. 2016 12 497 503 10.1038/nchembio.2079 27159577
Shimada, K. et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497–503 (2016).27159577 10.1038/nchembio.2079
46. Doll S ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition Nat. Chem. Biol. 2017 13 91 98 10.1038/nchembio.2239 27842070
Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98 (2017).27842070 10.1038/nchembio.2239
47. Wu J Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling Nature 2019 572 402 406 10.1038/s41586-019-1426-6 31341276
Wu, J. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 572, 402–406 (2019).31341276 10.1038/s41586-019-1426-6
48. Bersuker K The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis Nature 2019 575 688 692 10.1038/s41586-019-1705-2 31634900
Bersuker, K. et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688–692 (2019).31634900 10.1038/s41586-019-1705-2
49. Doll S FSP1 is a glutathione-independent ferroptosis suppressor Nature 2019 575 693 698 10.1038/s41586-019-1707-0 31634899
Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693–698 (2019).31634899 10.1038/s41586-019-1707-0
50. Kraft VAN GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling ACS Cent. Sci. 2020 6 41 53 10.1021/acscentsci.9b01063 31989025
Kraft, V. A. N. et al. GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling. ACS Cent. Sci. 6, 41–53 (2020).31989025 10.1021/acscentsci.9b01063
51. Soula M Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers Nat. Chem. Biol. 2020 16 1351 1360 10.1038/s41589-020-0613-y 32778843
Soula, M. et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat. Chem. Biol. 16, 1351–1360 (2020).32778843 10.1038/s41589-020-0613-y
52. Zou Y Plasticity of ether lipids promotes ferroptosis susceptibility and evasion Nature 2020 585 603 608 10.1038/s41586-020-2732-8 32939090
Zou, Y. et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 585, 603–608 (2020).32939090 10.1038/s41586-020-2732-8
53. Badgley MA Cysteine depletion induces pancreatic tumor ferroptosis in mice Science 2020 368 85 89 10.1126/science.aaw9872 32241947
Badgley, M. A. et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85–89 (2020).32241947 10.1126/science.aaw9872
54. Ubellacker JM Lymph protects metastasizing melanoma cells from ferroptosis Nature 2020 585 113 118 10.1038/s41586-020-2623-z 32814895
Ubellacker, J. M. et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585, 113–118 (2020).32814895 10.1038/s41586-020-2623-z
55. Mishima E DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition Nature 2023 619 E9 E18 10.1038/s41586-023-06269-0 37407687
Mishima, E. et al. DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition. Nature 619, E9–E18 (2023).37407687 10.1038/s41586-023-06269-0
56. Mishima E A non-canonical vitamin K cycle is a potent ferroptosis suppressor Nature 2022 608 778 783 10.1038/s41586-022-05022-3 35922516
Mishima, E. et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature 608, 778–783 (2022).35922516 10.1038/s41586-022-05022-3
57. Nakamura T Phase separation of FSP1 promotes ferroptosis Nature 2023 619 371 377 10.1038/s41586-023-06255-6 37380771
Nakamura, T. et al. Phase separation of FSP1 promotes ferroptosis. Nature 619, 371–377 (2023).37380771 10.1038/s41586-023-06255-6
58. Zhao J Human hematopoietic stem cell vulnerability to ferroptosis Cell 2023 186 732 747 e716 10.1016/j.cell.2023.01.020 36803603
Zhao, J. et al. Human hematopoietic stem cell vulnerability to ferroptosis. Cell 186, 732–747 e716 (2023).36803603 10.1016/j.cell.2023.01.020
59. Liang D Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones Cell 2023 186 2748 2764 e2722 10.1016/j.cell.2023.05.003 37267948
Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186, 2748–2764 e2722 (2023).37267948 10.1016/j.cell.2023.05.003
60. Lei G Zhuang L Gan B Targeting ferroptosis as a vulnerability in cancer Nat. Rev. Cancer 2022 22 381 396 10.1038/s41568-022-00459-0 35338310
Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381–396 (2022).35338310 10.1038/s41568-022-00459-0
61. Sun S Targeting ferroptosis opens new avenues for the development of novel therapeutics Signal Transduct. Target Ther. 2023 8 372 10.1038/s41392-023-01606-1 37735472
Sun, S. et al. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct. Target Ther. 8, 372 (2023).37735472 10.1038/s41392-023-01606-1
62. Dixon SJ Pratt DA Ferroptosis: A flexible constellation of related biochemical mechanisms Mol. Cell 2023 83 1030 1042 10.1016/j.molcel.2023.03.005 36977413
Dixon, S. J. & Pratt, D. A. Ferroptosis: A flexible constellation of related biochemical mechanisms. Mol. Cell 83, 1030–1042 (2023).36977413 10.1016/j.molcel.2023.03.005
63. Dos Santos AF Fazeli G Xavier da Silva TN Friedmann Angeli JP Ferroptosis: mechanisms and implications for cancer development and therapy response Trends Cell Biol. 2023 33 1062 1076 10.1016/j.tcb.2023.04.005 37230924
Dos Santos, A. F., Fazeli, G., Xavier da Silva, T. N., & Friedmann Angeli, J. P. Ferroptosis: mechanisms and implications for cancer development and therapy response. Trends Cell Biol. 33, 1062–1076 (2023).37230924 10.1016/j.tcb.2023.04.005
64. Pope LE Dixon SJ Regulation of ferroptosis by lipid metabolism Trends Cell Biol. 2023 33 1077 1087 10.1016/j.tcb.2023.05.003 37407304
Pope, L. E. & Dixon, S. J. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 33, 1077–1087 (2023).37407304 10.1016/j.tcb.2023.05.003
65. Porter NA Wolf RA Yarbro EM Weenen H The autoxidation of arachidonic acid: formation of the proposed SRS-A intermediate Biochem Biophys. Res Commun. 1979 89 1058 1064 10.1016/0006-291X(79)92115-6 496937
Porter, N. A., Wolf, R. A., Yarbro, E. M. & Weenen, H. The autoxidation of arachidonic acid: formation of the proposed SRS-A intermediate. Biochem Biophys. Res Commun. 89, 1058–1064 (1979).496937 10.1016/0006-291X(79)92115-6
66. Gill I Valivety R Polyunsaturated fatty acids, Part 2: Biotransformations and biotechnological applications Trends Biotechnol. 1997 15 470 478 10.1016/S0167-7799(97)01077-9 9369030
Gill, I. & Valivety, R. Polyunsaturated fatty acids, Part 2: Biotransformations and biotechnological applications. Trends Biotechnol. 15, 470–478 (1997).9369030 10.1016/S0167-7799(97)01077-9
67. Gill I Valivety R Polyunsaturated fatty acids, Part 1: Occurrence, biological activities and applications Trends Biotechnol. 1997 15 401 409 10.1016/S0167-7799(97)01076-7 9351284
Gill, I. & Valivety, R. Polyunsaturated fatty acids, Part 1: Occurrence, biological activities and applications. Trends Biotechnol. 15, 401–409 (1997).9351284 10.1016/S0167-7799(97)01076-7
68. Kagan VE Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis Nat. Chem. Biol. 2017 13 81 90 10.1038/nchembio.2238 27842066
Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).27842066 10.1038/nchembio.2238
69. Dixon SJ Human Haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death ACS Chem. Biol. 2015 10 1604 1609 10.1021/acschembio.5b00245 25965523
Dixon, S. J. et al. Human Haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10, 1604–1609 (2015).25965523 10.1021/acschembio.5b00245
70. Cui W Liu D Gu W Chu B Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis Cell Death Differ. 2021 28 2536 2551 10.1038/s41418-021-00769-0 33731874
Cui, W., Liu, D., Gu, W. & Chu, B. Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis. Cell Death Differ. 28, 2536–2551 (2021).33731874 10.1038/s41418-021-00769-0
71. Chen D iPLA2beta-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4 Nat. Commun. 2021 12 3644 10.1038/s41467-021-23902-6 34131139
Chen, D. et al. iPLA2beta-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat. Commun. 12, 3644 (2021).34131139 10.1038/s41467-021-23902-6
72. Shah R Shchepinov MS Pratt DA Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis ACS Cent. Sci. 2018 4 387 396 10.1021/acscentsci.7b00589 29632885
Shah, R., Shchepinov, M. S. & Pratt, D. A. Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent. Sci. 4, 387–396 (2018).29632885 10.1021/acscentsci.7b00589
73. Zou Y Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis Nat. Chem. Biol. 2020 16 302 309 10.1038/s41589-020-0472-6 32080622
Zou, Y. et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat. Chem. Biol. 16, 302–309 (2020).32080622 10.1038/s41589-020-0472-6
74. Wenzel SE PEBP1 Wardens ferroptosis by enabling lipoxygenase generation of lipid death signals Cell 2017 171 628 641 e626 10.1016/j.cell.2017.09.044 29053969
Wenzel, S. E. et al. PEBP1 Wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171, 628–641 e626 (2017).29053969 10.1016/j.cell.2017.09.044
75. Wang J PM(2.5) caused ferroptosis in spermatocyte via overloading iron and disrupting redox homeostasis Sci. Total Environ. 2023 872 162089 10.1016/j.scitotenv.2023.162089 36781135
Wang, J. et al. PM(2.5) caused ferroptosis in spermatocyte via overloading iron and disrupting redox homeostasis. Sci. Total Environ. 872, 162089 (2023).36781135 10.1016/j.scitotenv.2023.162089
76. Yang X miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities Oncogenesis 2021 10 15 10.1038/s41389-021-00304-3 33579899
Yang, X. et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis 10, 15 (2021).33579899 10.1038/s41389-021-00304-3
77. Wang M ALOX5 promotes autophagy-dependent ferroptosis by activating the AMPK/mTOR pathway in melanoma Biochem Pharm. 2023 212 115554 10.1016/j.bcp.2023.115554 37080437
Wang, M. et al. ALOX5 promotes autophagy-dependent ferroptosis by activating the AMPK/mTOR pathway in melanoma. Biochem Pharm. 212, 115554 (2023).37080437 10.1016/j.bcp.2023.115554
78. Li C Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death Autophagy 2021 17 948 960 10.1080/15548627.2020.1739447 32186434
Li, C. et al. Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. Autophagy 17, 948–960 (2021).32186434 10.1080/15548627.2020.1739447
79. Matsushita M T cell lipid peroxidation induces ferroptosis and prevents immunity to infection J. Exp. Med. 2015 212 555 568 10.1084/jem.20140857 25824823
Matsushita, M. et al. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J. Exp. Med. 212, 555–568 (2015).25824823 10.1084/jem.20140857
80. Ghosh MK Mukhopadhyay M Chatterjee IB NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid Mol. Cell Biochem. 1997 166 35 44 10.1023/A:1006841228483 9046019
Ghosh, M. K., Mukhopadhyay, M. & Chatterjee, I. B. NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: specific prevention by ascorbic acid. Mol. Cell Biochem. 166, 35–44 (1997).9046019 10.1023/A:1006841228483
81. Gaschler MM Stockwell BR Lipid peroxidation in cell death Biochem. Biophys. Res Commun. 2017 482 419 425 10.1016/j.bbrc.2016.10.086 28212725
Gaschler, M. M. & Stockwell, B. R. Lipid peroxidation in cell death. Biochem. Biophys. Res Commun. 482, 419–425 (2017).28212725 10.1016/j.bbrc.2016.10.086
82. Milne GL Dai Q Roberts LJ 2nd The isoprostanes-25 years later Biochim Biophys. Acta 2015 1851 433 445 10.1016/j.bbalip.2014.10.007 25449649
Milne, G. L., Dai, Q. & Roberts, L. J. 2nd The isoprostanes-25 years later. Biochim Biophys. Acta 1851, 433–445 (2015).25449649 10.1016/j.bbalip.2014.10.007
83. Conrad M Pratt DA The chemical basis of ferroptosis Nat. Chem. Biol. 2019 15 1137 1147 10.1038/s41589-019-0408-1 31740834
Conrad, M. & Pratt, D. A. The chemical basis of ferroptosis. Nat. Chem. Biol. 15, 1137–1147 (2019).31740834 10.1038/s41589-019-0408-1
84. Andrews NC Schmidt PJ Iron homeostasis Annu Rev. Physiol. 2007 69 69 85 10.1146/annurev.physiol.69.031905.164337 17014365
Andrews, N. C. & Schmidt, P. J. Iron homeostasis. Annu Rev. Physiol. 69, 69–85 (2007).17014365 10.1146/annurev.physiol.69.031905.164337
85. Richardson DR Ponka P The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells Biochim Biophys. Acta 1997 1331 1 40 10.1016/S0304-4157(96)00014-7 9325434
Richardson, D. R. & Ponka, P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys. Acta 1331, 1–40 (1997).9325434 10.1016/S0304-4157(96)00014-7
86. Feng H Transferrin receptor is a specific ferroptosis marker Cell Rep. 2020 30 3411 3423 e3417 10.1016/j.celrep.2020.02.049 32160546
Feng, H. et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 30, 3411–3423 e3417 (2020).32160546 10.1016/j.celrep.2020.02.049
87. El Hout M Dos Santos L Hamaï A Mehrpour M A promising new approach to cancer therapy: Targeting iron metabolism in cancer stem cells Semin. Cancer Biol. 2018 53 125 138 10.1016/j.semcancer.2018.07.009 30071257
El Hout, M., Dos Santos, L., Hamaï, A. & Mehrpour, M. A promising new approach to cancer therapy: Targeting iron metabolism in cancer stem cells. Semin. Cancer Biol. 53, 125–138 (2018).30071257 10.1016/j.semcancer.2018.07.009
88. Gao M Ferroptosis is an autophagic cell death process Cell Res 2016 26 1021 1032 10.1038/cr.2016.95 27514700
Gao, M. et al. Ferroptosis is an autophagic cell death process. Cell Res. 26, 1021–1032 (2016).27514700 10.1038/cr.2016.95
89. Yambire KF Impaired lysosomal acidification triggers iron deficiency and inflammation in vivo Elife 2019 8 e51031 10.7554/eLife.51031 31793879
Yambire, K. F. et al. Impaired lysosomal acidification triggers iron deficiency and inflammation in vivo. Elife 8, e51031 (2019).31793879 10.7554/eLife.51031
90. Donovan A The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis Cell Metab. 2005 1 191 200 10.1016/j.cmet.2005.01.003 16054062
Donovan, A. et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1, 191–200 (2005).16054062 10.1016/j.cmet.2005.01.003
91. Chen X Yu C Kang R Tang D Iron metabolism in ferroptosis Front. Cell Dev. Biol. 2020 8 590226 10.3389/fcell.2020.590226 33117818
Chen, X., Yu, C., Kang, R. & Tang, D. Iron metabolism in ferroptosis. Front. Cell Dev. Biol. 8, 590226 (2020).33117818 10.3389/fcell.2020.590226
92. Battaglia AM Ferroptosis and cancer: Mitochondria Meet the “Iron Maiden” cell death Cells 2020 9 1505 10.3390/cells9061505 32575749
Battaglia, A. M. et al. Ferroptosis and cancer: Mitochondria Meet the “Iron Maiden” cell death. Cells 9, 1505 (2020).32575749 10.3390/cells9061505
93. Galy, B., Conrad, M. & Muckenthaler, M. Mechanisms controlling cellular and systemic iron homeostasis. Nature reviews. Molecular cell biology. 10.1038/s41580-023-00648-1, (2023).
94. Wolff NA A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron and manganese Sci. Rep. 2018 8 211 10.1038/s41598-017-18584-4 29317744
Wolff, N. A. et al. A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron and manganese. Sci. Rep. 8, 211 (2018).29317744 10.1038/s41598-017-18584-4
95. Shaw GC Mitoferrin is essential for erythroid iron assimilation Nature 2006 440 96 100 10.1038/nature04512 16511496
Shaw, G. C. et al. Mitoferrin is essential for erythroid iron assimilation. Nature 440, 96–100 (2006).16511496 10.1038/nature04512
96. Paradkar PN Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2 Mol. Cell Biol. 2009 29 1007 1016 10.1128/MCB.01685-08 19075006
Paradkar, P. N. et al. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol. Cell Biol. 29, 1007–1016 (2009).19075006 10.1128/MCB.01685-08
97. Wu JR Tuo QZ Lei P Ferroptosis, a recent defined form of critical cell death in neurological disorders J. Mol. Neurosci. 2018 66 197 206 10.1007/s12031-018-1155-6 30145632
Wu, J. R., Tuo, Q. Z. & Lei, P. Ferroptosis, a recent defined form of critical cell death in neurological disorders. J. Mol. Neurosci. 66, 197–206 (2018).30145632 10.1007/s12031-018-1155-6
98. Nechushtai R The balancing act of NEET proteins: Iron, ROS, calcium and metabolism Biochim. Biophys. Acta Mol. Cell Res. 2020 1867 118805 10.1016/j.bbamcr.2020.118805 32745723
Nechushtai, R. et al. The balancing act of NEET proteins: Iron, ROS, calcium and metabolism. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118805 (2020).32745723 10.1016/j.bbamcr.2020.118805
99. Tamir S Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease Biochim. Biophys. Acta 2015 1853 1294 1315 10.1016/j.bbamcr.2014.10.014 25448035
Tamir, S. et al. Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease. Biochim. Biophys. Acta 1853, 1294–1315 (2015).25448035 10.1016/j.bbamcr.2014.10.014
100. Yuan H CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation Biochem. Biophys. Res Commun. 2016 478 838 844 10.1016/j.bbrc.2016.08.034 27510639
Yuan, H. et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem. Biophys. Res Commun. 478, 838–844 (2016).27510639 10.1016/j.bbrc.2016.08.034
101. Lipper CH Redox-dependent gating of VDAC by mitoNEET Proc. Natl Acad. Sci. USA 2019 116 19924 19929 10.1073/pnas.1908271116 31527235
Lipper, C. H. et al. Redox-dependent gating of VDAC by mitoNEET. Proc. Natl Acad. Sci. USA 116, 19924–19929 (2019).31527235 10.1073/pnas.1908271116
102. Yang Y Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma Nat. Commun. 2020 11 433 10.1038/s41467-020-14324-x 31974380
Yang, Y. et al. Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. Nat. Commun. 11, 433 (2020).31974380 10.1038/s41467-020-14324-x
103. Huang F Hedyotis diffusa injection induces ferroptosis via the Bax/Bcl2/VDAC2/3 axis in lung adenocarcinoma Phytomedicine 2022 104 154319 10.1016/j.phymed.2022.154319 35853302
Huang, F. et al. Hedyotis diffusa injection induces ferroptosis via the Bax/Bcl2/VDAC2/3 axis in lung adenocarcinoma. Phytomedicine 104, 154319 (2022).35853302 10.1016/j.phymed.2022.154319
104. Fuhrmann DC Hypoxia inhibits ferritinophagy, increases mitochondrial ferritin, and protects from ferroptosis Redox Biol. 2020 36 101670 10.1016/j.redox.2020.101670 32810738
Fuhrmann, D. C. et al. Hypoxia inhibits ferritinophagy, increases mitochondrial ferritin, and protects from ferroptosis. Redox Biol. 36, 101670 (2020).32810738 10.1016/j.redox.2020.101670
105. Wang YQ The protective role of mitochondrial ferritin on erastin-induced ferroptosis Front. Aging Neurosci. 2016 8 308 10.3389/fnagi.2016.00308 28066232
Wang, Y. Q. et al. The protective role of mitochondrial ferritin on erastin-induced ferroptosis. Front. Aging Neurosci. 8, 308 (2016).28066232 10.3389/fnagi.2016.00308
106. Wang X Mitochondrial Ferritin deficiency promotes osteoblastic ferroptosis via mitophagy in Type 2 diabetic Osteoporosis Biol. Trace Elem. Res 2022 200 298 307 10.1007/s12011-021-02627-z 33594527
Wang, X. et al. Mitochondrial Ferritin deficiency promotes osteoblastic ferroptosis via mitophagy in Type 2 diabetic Osteoporosis. Biol. Trace Elem. Res 200, 298–307 (2022).33594527 10.1007/s12011-021-02627-z
107. Cavadini P RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload Blood 2007 109 3552 3559 10.1182/blood-2006-08-041632 17192393
Cavadini, P. et al. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 109, 3552–3559 (2007).17192393 10.1182/blood-2006-08-041632
108. Li, P. et al. Structures of Atm1 provide insight into [2Fe-2S] cluster export from mitochondria. Nat Commun 13, 4339 (2022).
109. Srinivasan V Pierik AJ Lill R Crystal structures of nucleotide-free and glutathione-bound mitochondrial ABC transporter Atm1 Science 2014 343 1137 1140 10.1126/science.1246729 24604199
Srinivasan, V., Pierik, A. J. & Lill, R. Crystal structures of nucleotide-free and glutathione-bound mitochondrial ABC transporter Atm1. Science 343, 1137–1140 (2014).24604199 10.1126/science.1246729
110. Lehrke MJ The mitochondrial iron transporter ABCB7 is required for B cell development, proliferation, and class switch recombination in mice Elife 2021 10 e69621 10.7554/eLife.69621 34762046
Lehrke, M. J. et al. The mitochondrial iron transporter ABCB7 is required for B cell development, proliferation, and class switch recombination in mice. Elife 10, e69621 (2021).34762046 10.7554/eLife.69621
111. Ichikawa Y Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export Proc. Natl Acad. Sci. USA 2012 109 4152 4157 10.1073/pnas.1119338109 22375032
Ichikawa, Y. et al. Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc. Natl Acad. Sci. USA 109, 4152–4157 (2012).22375032 10.1073/pnas.1119338109
112. Chang HC Augmenter of liver regeneration regulates cellular iron homeostasis by modulating mitochondrial transport of ATP-binding cassette B8 Elife 2021 10 e65158 10.7554/eLife.65158 33835027
Chang, H. C. et al. Augmenter of liver regeneration regulates cellular iron homeostasis by modulating mitochondrial transport of ATP-binding cassette B8. Elife 10, e65158 (2021).33835027 10.7554/eLife.65158
113. Chang HC Reduction in mitochondrial iron alleviates cardiac damage during injury EMBO Mol. Med. 2016 8 247 267 10.15252/emmm.201505748 26896449
Chang, H. C. et al. Reduction in mitochondrial iron alleviates cardiac damage during injury. EMBO Mol. Med. 8, 247–267 (2016).26896449 10.15252/emmm.201505748
114. Ichikawa Y Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation J. Clin. Invest 2014 124 617 630 10.1172/JCI72931 24382354
Ichikawa, Y. et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 124, 617–630 (2014).24382354 10.1172/JCI72931
115. Bannai S Sato H Ishii T Sugita Y Induction of cystine transport activity in human fibroblasts by oxygen J. Biol. Chem. 1989 264 18480 18484 10.1016/S0021-9258(18)51491-5 2808385
Bannai, S., Sato, H., Ishii, T. & Sugita, Y. Induction of cystine transport activity in human fibroblasts by oxygen. J. Biol. Chem. 264, 18480–18484 (1989).2808385 10.1016/S0021-9258(18)51491-5
116. Liu X Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer Nat. Cell Biol. 2020 22 476 486 10.1038/s41556-020-0496-x 32231310
Liu, X. et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat. Cell Biol. 22, 476–486 (2020).32231310 10.1038/s41556-020-0496-x
117. Lu SC Regulation of glutathione synthesis Mol. Asp. Med. 2009 30 42 59 10.1016/j.mam.2008.05.005
Lu, S. C. Regulation of glutathione synthesis. Mol. Asp. Med. 30, 42–59 (2009).10.1016/j.mam.2008.05.005
118. Parker JL Molecular basis for redox control by the human cystine/glutamate antiporter system xc Nat. Commun. 2021 12 7147 10.1038/s41467-021-27414-1 34880232
Parker, J. L. et al. Molecular basis for redox control by the human cystine/glutamate antiporter system xc. Nat. Commun. 12, 7147 (2021).34880232 10.1038/s41467-021-27414-1
119. Ursini F Maiorino M Lipid peroxidation and ferroptosis: The role of GSH and GPx4 Free Radic. Biol. Med. 2020 152 175 185 10.1016/j.freeradbiomed.2020.02.027 32165281
Ursini, F. & Maiorino, M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic. Biol. Med. 152, 175–185 (2020).32165281 10.1016/j.freeradbiomed.2020.02.027
120. Chen X Ferroptosis: machinery and regulation Autophagy 2021 17 2054 2081 10.1080/15548627.2020.1810918 32804006
Chen, X. et al. Ferroptosis: machinery and regulation. Autophagy 17, 2054–2081 (2021).32804006 10.1080/15548627.2020.1810918
121. Seibt TM Proneth B Conrad M Role of GPX4 in ferroptosis and its pharmacological implication Free Radic. Biol. Med. 2019 133 144 152 10.1016/j.freeradbiomed.2018.09.014 30219704
Seibt, T. M., Proneth, B. & Conrad, M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic. Biol. Med. 133, 144–152 (2019).30219704 10.1016/j.freeradbiomed.2018.09.014
122. Forcina GC Dixon SJ GPX4 at the crossroads of lipid homeostasis and ferroptosis Proteomics 2019 19 e1800311 10.1002/pmic.201800311 30888116
Forcina, G. C. & Dixon, S. J. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics 19, e1800311 (2019).30888116 10.1002/pmic.201800311
123. Brigelius-Flohé R Maiorino M Glutathione peroxidases Biochim. Biophys. Acta 2013 1830 3289 3303 10.1016/j.bbagen.2012.11.020 23201771
Brigelius-Flohé, R. & Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta 1830, 3289–3303 (2013).23201771 10.1016/j.bbagen.2012.11.020
124. Borchert A Crystal structure and functional characterization of selenocysteine-containing glutathione peroxidase 4 suggests an alternative mechanism of peroxide reduction Biochim Biophys. Acta Mol. Cell Biol. Lipids 2018 1863 1095 1107 10.1016/j.bbalip.2018.06.006 29883798
Borchert, A. et al. Crystal structure and functional characterization of selenocysteine-containing glutathione peroxidase 4 suggests an alternative mechanism of peroxide reduction. Biochim Biophys. Acta Mol. Cell Biol. Lipids 1863, 1095–1107 (2018).29883798 10.1016/j.bbalip.2018.06.006
125. Ingold I Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis Cell 2018 172 409 422 e421 10.1016/j.cell.2017.11.048 29290465
Ingold, I. et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell 172, 409–422 e421 (2018).29290465 10.1016/j.cell.2017.11.048
126. Pushpa-Rekha TR Rat phospholipid-hydroperoxide glutathione peroxidase. cDNA cloning and identification of multiple transcription and translation start sites J. Biol. Chem. 1995 270 26993 26999 10.1074/jbc.270.45.26993 7592947
Pushpa-Rekha, T. R. et al. Rat phospholipid-hydroperoxide glutathione peroxidase. cDNA cloning and identification of multiple transcription and translation start sites. J. Biol. Chem. 270, 26993–26999 (1995).7592947 10.1074/jbc.270.45.26993
127. Moreno SG Testis-specific expression of the nuclear form of phospholipid hydroperoxide glutathione peroxidase (PHGPx) Biol. Chem. 2003 384 635 643 10.1515/BC.2003.070 12751792
Moreno, S. G. et al. Testis-specific expression of the nuclear form of phospholipid hydroperoxide glutathione peroxidase (PHGPx). Biol. Chem. 384, 635–643 (2003).12751792 10.1515/BC.2003.070
128. Maiorino M Distinct promoters determine alternative transcription of gpx-4 into phospholipid-hydroperoxide glutathione peroxidase variants J. Biol. Chem. 2003 278 34286 34290 10.1074/jbc.M305327200 12819198
Maiorino, M. et al. Distinct promoters determine alternative transcription of gpx-4 into phospholipid-hydroperoxide glutathione peroxidase variants. J. Biol. Chem. 278, 34286–34290 (2003).12819198 10.1074/jbc.M305327200
129. Pfeifer H Identification of a specific sperm nuclei selenoenzyme necessary for protamine thiol cross-linking during sperm maturation FASEB J. 2001 15 1236 1238 10.1096/fj.00-0655fje 11344099
Pfeifer, H. et al. Identification of a specific sperm nuclei selenoenzyme necessary for protamine thiol cross-linking during sperm maturation. FASEB J. 15, 1236–1238 (2001).11344099 10.1096/fj.00-0655fje
130. Schneider M Mitochondrial glutathione peroxidase 4 disruption causes male infertility FASEB J. 2009 23 3233 3242 10.1096/fj.09-132795 19417079
Schneider, M. et al. Mitochondrial glutathione peroxidase 4 disruption causes male infertility. FASEB J. 23, 3233–3242 (2009).19417079 10.1096/fj.09-132795
131. Liang H Short form glutathione peroxidase 4 is the essential isoform required for survival and somatic mitochondrial functions J. Biol. Chem. 2009 284 30836 30844 10.1074/jbc.M109.032839 19744930
Liang, H. et al. Short form glutathione peroxidase 4 is the essential isoform required for survival and somatic mitochondrial functions. J. Biol. Chem. 284, 30836–30844 (2009).19744930 10.1074/jbc.M109.032839
132. Yant LJ The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults Free Radic. Biol. Med 2003 34 496 502 10.1016/S0891-5849(02)01360-6 12566075
Yant, L. J. et al. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic. Biol. Med 34, 496–502 (2003).12566075 10.1016/S0891-5849(02)01360-6
133. Conrad M The nuclear form of phospholipid hydroperoxide glutathione peroxidase is a protein thiol peroxidase contributing to sperm chromatin stability Mol. Cell Biol. 2005 25 7637 7644 10.1128/MCB.25.17.7637-7644.2005 16107710
Conrad, M. et al. The nuclear form of phospholipid hydroperoxide glutathione peroxidase is a protein thiol peroxidase contributing to sperm chromatin stability. Mol. Cell Biol. 25, 7637–7644 (2005).16107710 10.1128/MCB.25.17.7637-7644.2005
134. Mao C DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer Nature 2021 593 586 590 10.1038/s41586-021-03539-7 33981038
Mao, C. et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586–590 (2021).33981038 10.1038/s41586-021-03539-7
135. Wu S A ferroptosis defense mechanism mediated by glycerol-3-phosphate dehydrogenase 2 in mitochondria Proc. Natl Acad. Sci. USA 2022 119 e2121987119 10.1073/pnas.2121987119 35749365
Wu, S. et al. A ferroptosis defense mechanism mediated by glycerol-3-phosphate dehydrogenase 2 in mitochondria. Proc. Natl Acad. Sci. USA 119, e2121987119 (2022).35749365 10.1073/pnas.2121987119
136. Gaschler MM FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation Nat. Chem. Biol. 2018 14 507 515 10.1038/s41589-018-0031-6 29610484
Gaschler, M. M. et al. FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol. 14, 507–515 (2018).29610484 10.1038/s41589-018-0031-6
137. Muller T Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure Cell Mol. Life Sci. 2017 74 3631 3645 10.1007/s00018-017-2547-4 28551825
Muller, T. et al. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cell Mol. Life Sci. 74, 3631–3645 (2017).28551825 10.1007/s00018-017-2547-4
138. Zhu S HSPA5 regulates ferroptotic cell death in cancer cells Cancer Res. 2017 77 2064 2077 10.1158/0008-5472.CAN-16-1979 28130223
Zhu, S. et al. HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res. 77, 2064–2077 (2017).28130223 10.1158/0008-5472.CAN-16-1979
139. Deshwal S Mitochondria regulate intracellular coenzyme Q transport and ferroptotic resistance via STARD7 Nat. Cell Biol. 2023 25 246 257 36658222
Deshwal, S. et al. Mitochondria regulate intracellular coenzyme Q transport and ferroptotic resistance via STARD7. Nat. Cell Biol. 25, 246–257 (2023).36658222
140. Zeng F Chen X Deng G The anti-ferroptotic role of FSP1: current molecular mechanism and therapeutic approach Mol. Biomed. 2022 3 37 10.1186/s43556-022-00105-z 36445538
Zeng, F., Chen, X. & Deng, G. The anti-ferroptotic role of FSP1: current molecular mechanism and therapeutic approach. Mol. Biomed. 3, 37 (2022).36445538 10.1186/s43556-022-00105-z
141. Magtanong L Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state Cell Chem. Biol. 2019 26 420 432 e429 10.1016/j.chembiol.2018.11.016 30686757
Magtanong, L. et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem. Biol. 26, 420–432 e429 (2019).30686757 10.1016/j.chembiol.2018.11.016
142. Tesfay L Stearoyl-CoA Desaturase 1 protects ovarian cancer cells from ferroptotic cell death Cancer Res. 2019 79 5355 5366 10.1158/0008-5472.CAN-19-0369 31270077
Tesfay, L. et al. Stearoyl-CoA Desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 79, 5355–5366 (2019).31270077 10.1158/0008-5472.CAN-19-0369
143. Papsdorf K Lipid droplets and peroxisomes are co-regulated to drive lifespan extension in response to mono-unsaturated fatty acids Nat. Cell Biol. 2023 25 672 684 10.1038/s41556-023-01136-6 37127715
Papsdorf, K. et al. Lipid droplets and peroxisomes are co-regulated to drive lifespan extension in response to mono-unsaturated fatty acids. Nat. Cell Biol. 25, 672–684 (2023).37127715 10.1038/s41556-023-01136-6
144. Gong YN ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences Cell 2017 169 286 300 e216 10.1016/j.cell.2017.03.020 28388412
Gong, Y. N. et al. ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. Cell 169, 286–300 e216 (2017).28388412 10.1016/j.cell.2017.03.020
145. Ruhl S ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation Science 2018 362 956 960 10.1126/science.aar7607 30467171
Ruhl, S. et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science 362, 956–960 (2018).30467171 10.1126/science.aar7607
146. Dai E ESCRT-III-dependent membrane repair blocks ferroptosis Biochem Biophys. Res. Commun. 2020 522 415 421 10.1016/j.bbrc.2019.11.110 31761326
Dai, E. et al. ESCRT-III-dependent membrane repair blocks ferroptosis. Biochem Biophys. Res. Commun. 522, 415–421 (2020).31761326 10.1016/j.bbrc.2019.11.110
147. Pedrera L Ferroptotic pores induce Ca(2+) fluxes and ESCRT-III activation to modulate cell death kinetics Cell Death Differ. 2021 28 1644 1657 10.1038/s41418-020-00691-x 33335287
Pedrera, L. et al. Ferroptotic pores induce Ca(2+) fluxes and ESCRT-III activation to modulate cell death kinetics. Cell Death Differ. 28, 1644–1657 (2021).33335287 10.1038/s41418-020-00691-x
148. Dai E AIFM2 blocks ferroptosis independent of ubiquinol metabolism Biochem Biophys. Res. Commun. 2020 523 966 971 10.1016/j.bbrc.2020.01.066 31964528
Dai, E. et al. AIFM2 blocks ferroptosis independent of ubiquinol metabolism. Biochem Biophys. Res. Commun. 523, 966–971 (2020).31964528 10.1016/j.bbrc.2020.01.066
149. David LA Alm EJ Rapid evolutionary innovation during an Archaean genetic expansion Nature 2011 469 93 96 10.1038/nature09649 21170026
David, L. A. & Alm, E. J. Rapid evolutionary innovation during an Archaean genetic expansion. Nature 469, 93–96 (2011).21170026 10.1038/nature09649
150. Wang Y Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53 EMBO Rep. 2019 20 e47563 10.15252/embr.201847563 31267712
Wang, Y. et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 20, e47563 (2019).31267712 10.15252/embr.201847563
151. Chu B ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway Nat. Cell Biol. 2019 21 579 591 10.1038/s41556-019-0305-6 30962574
Chu, B. et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat. Cell Biol. 21, 579–591 (2019).30962574 10.1038/s41556-019-0305-6
152. Jennis M An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model Genes Dev. 2016 30 918 930 10.1101/gad.275891.115 27034505
Jennis, M. et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 30, 918–930 (2016).27034505 10.1101/gad.275891.115
153. Wang SJ Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression Cell Rep. 2016 17 366 373 10.1016/j.celrep.2016.09.022 27705786
Wang, S. J. et al. Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression. Cell Rep. 17, 366–373 (2016).27705786 10.1016/j.celrep.2016.09.022
154. Leu JI Murphy ME George DL Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53 Proc. Natl Acad. Sci. USA 2019 116 8390 8396 10.1073/pnas.1821277116 30962386
Leu, J. I., Murphy, M. E. & George, D. L. Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53. Proc. Natl Acad. Sci. USA 116, 8390–8396 (2019).30962386 10.1073/pnas.1821277116
155. Jensen DE BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression Oncogene 1998 16 1097 1112 10.1038/sj.onc.1201861 9528852
Jensen, D. E. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097–1112 (1998).9528852 10.1038/sj.onc.1201861
156. Zhang Y BAP1 links metabolic regulation of ferroptosis to tumour suppression Nat. Cell Biol. 2018 20 1181 1192 10.1038/s41556-018-0178-0 30202049
Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181–1192 (2018).30202049 10.1038/s41556-018-0178-0
157. Tomlinson IP Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer Nat. Genet. 2002 30 406 410 10.1038/ng849 11865300
Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406–410 (2002).11865300 10.1038/ng849
158. Alam NA Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer J. Mol. Diagn. 2005 7 437 443 10.1016/S1525-1578(10)60574-0 16237213
Alam, N. A. et al. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J. Mol. Diagn. 7, 437–443 (2005).16237213 10.1016/S1525-1578(10)60574-0
159. Chuang GS Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata J. Am. Acad. Dermatol. 2005 52 410 416 10.1016/j.jaad.2004.08.051 15761418
Chuang, G. S. et al. Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. J. Am. Acad. Dermatol. 52, 410–416 (2005).15761418 10.1016/j.jaad.2004.08.051
160. Gao M Role of Mitochondria in Ferroptosis Mol. Cell 2019 73 354 363 e353 10.1016/j.molcel.2018.10.042 30581146
Gao, M. et al. Role of Mitochondria in Ferroptosis. Mol. Cell 73, 354–363 e353 (2019).30581146 10.1016/j.molcel.2018.10.042
161. Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 489 519 525 10.1038/nature11404 22960745
Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).22960745 10.1038/nature11404
162. Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma Nature 2014 511 543 550 10.1038/nature13385 25079552
Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).25079552 10.1038/nature13385
163. Scalera S KEAP1-mutant NSCLC: The catastrophic failure of a cell-protecting hub J. Thorac. Oncol. 2022 17 751 757 10.1016/j.jtho.2022.03.011 35351670
Scalera, S. et al. KEAP1-mutant NSCLC: The catastrophic failure of a cell-protecting hub. J. Thorac. Oncol. 17, 751–757 (2022).35351670 10.1016/j.jtho.2022.03.011
164. Romero R Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis Nat. Med 2017 23 1362 1368 10.1038/nm.4407 28967920
Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med 23, 1362–1368 (2017).28967920 10.1038/nm.4407
165. Koppula P A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers Nat. Commun. 2022 13 2206 10.1038/s41467-022-29905-1 35459868
Koppula, P. et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat. Commun. 13, 2206 (2022).35459868 10.1038/s41467-022-29905-1
166. Fan Z Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis Oncogenesis 2017 6 e371 10.1038/oncsis.2017.65 28805788
Fan, Z. et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 6, e371 (2017).28805788 10.1038/oncsis.2017.65
167. Bartha I di Iulio J Venter JC Telenti A Human gene essentiality Nat. Rev. Genet 2018 19 51 62 10.1038/nrg.2017.75 29082913
Bartha, I., di Iulio, J., Venter, J. C. & Telenti, A. Human gene essentiality. Nat. Rev. Genet 19, 51–62 (2018).29082913 10.1038/nrg.2017.75
168. Lee JE H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation Elife 2013 2 e01503 10.7554/eLife.01503 24368734
Lee, J. E. et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife 2, e01503 (2013).24368734 10.7554/eLife.01503
169. Egolf S MLL4 mediates differentiation and tumor suppression through ferroptosis Sci. Adv. 2021 7 eabj9141 10.1126/sciadv.abj9141 34890228
Egolf, S. et al. MLL4 mediates differentiation and tumor suppression through ferroptosis. Sci. Adv. 7, eabj9141 (2021).34890228 10.1126/sciadv.abj9141
170. Gorrini C Harris IS Mak TW Modulation of oxidative stress as an anticancer strategy Nat. Rev. Drug Discov. 2013 12 931 947 10.1038/nrd4002 24287781
Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013).24287781 10.1038/nrd4002
171. Koppula P Zhang Y Zhuang L Gan B Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer Cancer Commun. 2018 38 12 10.1186/s40880-018-0288-x
Koppula, P., Zhang, Y., Zhuang, L. & Gan, B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 38, 12 (2018).10.1186/s40880-018-0288-x
172. Koppula P Zhuang L Gan B Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy Protein Cell 2021 12 599 620 10.1007/s13238-020-00789-5 33000412
Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12, 599–620 (2021).33000412 10.1007/s13238-020-00789-5
173. Chen D NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression Mol. Cell 2017 68 224 232 e224 10.1016/j.molcel.2017.09.009 28985506
Chen, D. et al. NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. Mol. Cell 68, 224–232 e224 (2017).28985506 10.1016/j.molcel.2017.09.009
174. Hu K Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma J. Clin. Invest 2020 130 1752 1766 10.1172/JCI124049 31874110
Hu, K. et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J. Clin. Invest. 130, 1752–1766 (2020).31874110 10.1172/JCI124049
175. Harris IS Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression Cancer Cell 2015 27 211 222 10.1016/j.ccell.2014.11.019 25620030
Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211–222 (2015).25620030 10.1016/j.ccell.2014.11.019
176. Xiong Y Xiao C Li Z Yang X Engineering nanomedicine for glutathione depletion-augmented cancer therapy Chem. Soc. Rev. 2021 50 6013 6041 10.1039/D0CS00718H 34027953
Xiong, Y., Xiao, C., Li, Z. & Yang, X. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem. Soc. Rev. 50, 6013–6041 (2021).34027953 10.1039/D0CS00718H
177. Anasagasti MJ Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature Hepatology 1998 27 1249 1256 10.1002/hep.510270510 9581678
Anasagasti, M. J. et al. Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 27, 1249–1256 (1998).9581678 10.1002/hep.510270510
178. Estrela JM Glutathione in metastases: From mechanisms to clinical applications Crit. Rev. Clin. Lab. Sci. 2016 53 253 267 10.3109/10408363.2015.1136259 26754151
Estrela, J. M. et al. Glutathione in metastases: From mechanisms to clinical applications. Crit. Rev. Clin. Lab. Sci. 53, 253–267 (2016).26754151 10.3109/10408363.2015.1136259
179. Yang C A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance J. Control. Rel. 2023 357 20 30 10.1016/j.jconrel.2023.03.030
Yang, C. et al. A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance. J. Control. Rel. 357, 20–30 (2023).10.1016/j.jconrel.2023.03.030
180. Yu L WIPI2 enhances the vulnerability of colorectal cancer cells to erastin via bioinformatics analysis and experimental verification Front. Oncol. 2023 13 1146617 10.3389/fonc.2023.1146617 37207153
Yu, L. et al. WIPI2 enhances the vulnerability of colorectal cancer cells to erastin via bioinformatics analysis and experimental verification. Front. Oncol. 13, 1146617 (2023).37207153 10.3389/fonc.2023.1146617
181. Zhang L Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11 Proc. Natl Acad. Sci. USA 2022 119 e2122840119 10.1073/pnas.2122840119 35867762
Zhang, L. et al. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. Proc. Natl Acad. Sci. USA 119, e2122840119 (2022).35867762 10.1073/pnas.2122840119
182. Hangauer MJ Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition Nature 2017 551 247 250 10.1038/nature24297 29088702
Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247–250 (2017).29088702 10.1038/nature24297
183. Rojo de la Vega M Chapman E Zhang DD NRF2 and the Hallmarks of Cancer Cancer Cell 2018 34 21 43 10.1016/j.ccell.2018.03.022 29731393
Rojo de la Vega, M., Chapman, E. & Zhang, D. D. NRF2 and the Hallmarks of Cancer. Cancer Cell 34, 21–43 (2018).29731393 10.1016/j.ccell.2018.03.022
184. Liu S Tubastatin A potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis Redox Biol. 2023 62 102677 10.1016/j.redox.2023.102677 36989572
Liu, S. et al. Tubastatin A potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis. Redox Biol. 62, 102677 (2023).36989572 10.1016/j.redox.2023.102677
185. Dodson M Castro-Portuguez R Zhang DD NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis Redox Biol. 2019 23 101107 10.1016/j.redox.2019.101107 30692038
Dodson, M., Castro-Portuguez, R. & Zhang, D. D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 23, 101107 (2019).30692038 10.1016/j.redox.2019.101107
186. Sun R AADAC protects colorectal cancer liver colonization from ferroptosis through SLC7A11-dependent inhibition of lipid peroxidation J. Exp. Clin. Cancer Res. 2022 41 284 10.1186/s13046-022-02493-0 36163032
Sun, R. et al. AADAC protects colorectal cancer liver colonization from ferroptosis through SLC7A11-dependent inhibition of lipid peroxidation. J. Exp. Clin. Cancer Res. 41, 284 (2022).36163032 10.1186/s13046-022-02493-0
187. Chang K DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib resistance in clear cell renal cell carcinoma Cancer Res. 2023 83 3940 3955 10.1158/0008-5472.CAN-22-4001 37713596
Chang, K. et al. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib resistance in clear cell renal cell carcinoma. Cancer Res. 83, 3940–3955 (2023).37713596 10.1158/0008-5472.CAN-22-4001
188. Wang X Mitochondrial calcium uniporter drives metastasis and confers a targetable cystine dependency in pancreatic cancer Cancer Res. 2022 82 2254 2268 10.1158/0008-5472.CAN-21-3230 35413105
Wang, X. et al. Mitochondrial calcium uniporter drives metastasis and confers a targetable cystine dependency in pancreatic cancer. Cancer Res. 82, 2254–2268 (2022).35413105 10.1158/0008-5472.CAN-21-3230
189. Sun WY Phospholipase iPLA(2)β averts ferroptosis by eliminating a redox lipid death signal Nat. Chem. Biol. 2021 17 465 476 10.1038/s41589-020-00734-x 33542532
Sun, W. Y. et al. Phospholipase iPLA(2)β averts ferroptosis by eliminating a redox lipid death signal. Nat. Chem. Biol. 17, 465–476 (2021).33542532 10.1038/s41589-020-00734-x
190. Chen D iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4 Nat. Commun. 2021 12 3644 10.1038/s41467-021-23902-6 34131139
Chen, D. et al. iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat. Commun. 12, 3644 (2021).34131139 10.1038/s41467-021-23902-6
191. Hong X The Lipogenic Regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis Cancer Discov. 2021 11 678 695 10.1158/2159-8290.CD-19-1500 33203734
Hong, X. et al. The Lipogenic Regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis. Cancer Discov. 11, 678–695 (2021).33203734 10.1158/2159-8290.CD-19-1500
192. Alvarez SW NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis Nature 2017 551 639 643 10.1038/nature24637 29168506
Alvarez, S. W. et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature 551, 639–643 (2017).29168506 10.1038/nature24637
193. Du J Identification of Frataxin as a regulator of ferroptosis Redox Biol. 2020 32 101483 10.1016/j.redox.2020.101483 32169822
Du, J. et al. Identification of Frataxin as a regulator of ferroptosis. Redox Biol. 32, 101483 (2020).32169822 10.1016/j.redox.2020.101483
194. Kim EH CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer Cancer Lett. 2018 432 180 190 10.1016/j.canlet.2018.06.018 29928961
Kim, E. H. et al. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Cancer Lett. 432, 180–190 (2018).29928961 10.1016/j.canlet.2018.06.018
195. Brown CW Prominin2 drives ferroptosis resistance by stimulating iron export Dev. Cell 2019 51 575 586 e574 10.1016/j.devcel.2019.10.007 31735663
Brown, C. W. et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev. Cell 51, 575–586 e574 (2019).31735663 10.1016/j.devcel.2019.10.007
196. Xie Y Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis J. Hematol. Oncol. 2022 15 72 10.1186/s13045-022-01297-1 35659320
Xie, Y. et al. Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis. J. Hematol. Oncol. 15, 72 (2022).35659320 10.1186/s13045-022-01297-1
197. Belavgeni A Tonnus W Linkermann A Cancer cells evade ferroptosis: sex hormone-driven membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) expression Signal Transduct. Target Ther. 2023 8 336 10.1038/s41392-023-01593-3 37679313
Belavgeni, A., Tonnus, W. & Linkermann, A. Cancer cells evade ferroptosis: sex hormone-driven membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) expression. Signal Transduct. Target Ther. 8, 336 (2023).37679313 10.1038/s41392-023-01593-3
198. Murugan AK Grieco M Tsuchida N RAS mutations in human cancers: Roles in precision medicine Semin Cancer Biol. 2019 59 23 35 10.1016/j.semcancer.2019.06.007 31255772
Murugan, A. K., Grieco, M. & Tsuchida, N. RAS mutations in human cancers: Roles in precision medicine. Semin Cancer Biol. 59, 23–35 (2019).31255772 10.1016/j.semcancer.2019.06.007
199. Prior IA Hood FE Hartley JL The frequency of Ras Mutations in cancer Cancer Res 2020 80 2969 2974 10.1158/0008-5472.CAN-19-3682 32209560
Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras Mutations in cancer. Cancer Res 80, 2969–2974 (2020).32209560 10.1158/0008-5472.CAN-19-3682
200. Poursaitidis I Oncogene-selective sensitivity to synchronous cell death following modulation of the amino acid nutrient cystine Cell Rep. 2017 18 2547 2556 10.1016/j.celrep.2017.02.054 28297659
Poursaitidis, I. et al. Oncogene-selective sensitivity to synchronous cell death following modulation of the amino acid nutrient cystine. Cell Rep. 18, 2547–2556 (2017).28297659 10.1016/j.celrep.2017.02.054
201. Bartolacci C Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer Nat. Commun. 2022 13 4327 10.1038/s41467-022-31963-4 35882862
Bartolacci, C. et al. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat. Commun. 13, 4327 (2022).35882862 10.1038/s41467-022-31963-4
202. Muller F Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation Cell Death Differ. 2023 30 442 456 10.1038/s41418-022-01096-8 36443441
Muller, F. et al. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Cell Death Differ. 30, 442–456 (2023).36443441 10.1038/s41418-022-01096-8
203. Padanad MS Fatty acid oxidation mediated by Acyl-CoA Synthetase Long Chain 3 is required for mutant KRAS Lung Tumorigenesis Cell Rep. 2016 16 1614 1628 10.1016/j.celrep.2016.07.009 27477280
Padanad, M. S. et al. Fatty acid oxidation mediated by Acyl-CoA Synthetase Long Chain 3 is required for mutant KRAS Lung Tumorigenesis. Cell Rep. 16, 1614–1628 (2016).27477280 10.1016/j.celrep.2016.07.009
204. Itoh K Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain Genes Dev. 1999 13 76 86 10.1101/gad.13.1.76 9887101
Itoh, K. et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13, 76–86 (1999).9887101 10.1101/gad.13.1.76
205. Tao S The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer Mol. Carcinog. 2018 57 182 192 10.1002/mc.22745 28976703
Tao, S. et al. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol. Carcinog. 57, 182–192 (2018).28976703 10.1002/mc.22745
206. Alam J Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 1999 274 26071 26078 10.1074/jbc.274.37.26071 10473555
Alam, J. et al. Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274, 26071–26078 (1999).10473555 10.1074/jbc.274.37.26071
207. Liby K The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice Cancer Res. 2007 67 2414 2419 10.1158/0008-5472.CAN-06-4534 17363558
Liby, K. et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 67, 2414–2419 (2007).17363558 10.1158/0008-5472.CAN-06-4534
208. DeNicola GM Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 2011 475 106 109 10.1038/nature10189 21734707
DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109 (2011).21734707 10.1038/nature10189
209. Chio IIC NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer Cell 2016 166 963 976 10.1016/j.cell.2016.06.056 27477511
Chio, I. I. C. et al. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166, 963–976 (2016).27477511 10.1016/j.cell.2016.06.056
210. Chen X Kang R Kroemer G Tang D Broadening horizons: the role of ferroptosis in cancer Nat. Rev. Clin. Oncol. 2021 18 280 296 10.1038/s41571-020-00462-0 33514910
Chen, X., Kang, R., Kroemer, G. & Tang, D. Broadening horizons: the role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 18, 280–296 (2021).33514910 10.1038/s41571-020-00462-0
211. Yang Z ACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis Nat. Commun. 2023 14 4193 10.1038/s41467-023-39901-8 37443154
Yang, Z. et al. ACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis. Nat. Commun. 14, 4193 (2023).37443154 10.1038/s41467-023-39901-8
212. Kobayashi A Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2 Mol. Cell Biol. 2004 24 7130 7139 10.1128/MCB.24.16.7130-7139.2004 15282312
Kobayashi, A. et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell Biol. 24, 7130–7139 (2004).15282312 10.1128/MCB.24.16.7130-7139.2004
213. Wang Z PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis J. Immunother. Cancer 2023 11 e006890 10.1136/jitc-2023-006890 37380368
Wang, Z. et al. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. J. Immunother. Cancer 11, e006890 (2023).37380368 10.1136/jitc-2023-006890
214. Sun X Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells Hepatology 2016 63 173 184 10.1002/hep.28251 26403645
Sun, X. et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63, 173–184 (2016).26403645 10.1002/hep.28251
215. Zhang D Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion Adv. Sci. 2023 10 e2206669 10.1002/advs.202206669
Zhang, D. et al. Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion. Adv. Sci. 10, e2206669 (2023).10.1002/advs.202206669
216. Ren X Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis Redox Biol. 2021 46 102122 10.1016/j.redox.2021.102122 34482117
Ren, X. et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol. 46, 102122 (2021).34482117 10.1016/j.redox.2021.102122
217. Yi J Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis Proc. Natl Acad. Sci. USA 2020 117 31189 31197 10.1073/pnas.2017152117 33229547
Yi, J. et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc. Natl Acad. Sci. USA 117, 31189–31197 (2020).33229547 10.1073/pnas.2017152117
218. Saxton RA Sabatini DM mTOR signaling in growth, metabolism, and disease Cell 2017 168 960 976 10.1016/j.cell.2017.02.004 28283069
Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).28283069 10.1016/j.cell.2017.02.004
219. Glaviano A PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Mol. Cancer 2023 22 138 10.1186/s12943-023-01827-6 37596643
Glaviano, A. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).37596643 10.1186/s12943-023-01827-6
220. Lei G Zhuang L Gan B mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential Bioessays 2021 43 e2100093 10.1002/bies.202100093 34121197
Lei, G., Zhuang, L. & Gan, B. mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential. Bioessays 43, e2100093 (2021).34121197 10.1002/bies.202100093
221. Gan W LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control Nat. Cell Biol. 2020 22 246 256 10.1038/s41556-020-0463-6 32015438
Gan, W. et al. LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat. Cell Biol. 22, 246–256 (2020).32015438 10.1038/s41556-020-0463-6
222. Zhang Y mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation Nat. Commun. 2021 12 1589 10.1038/s41467-021-21841-w 33707434
Zhang, Y. et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat. Commun. 12, 1589 (2021).33707434 10.1038/s41467-021-21841-w
223. Zeng F Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis Redox Biol. 2023 61 102653 10.1016/j.redox.2023.102653 36889082
Zeng, F. et al. Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis. Redox Biol. 61, 102653 (2023).36889082 10.1016/j.redox.2023.102653
224. Hu Q ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells Cancer Res. 2023 83 1646 1665 10.1158/0008-5472.CAN-22-1999 36892426
Hu, Q. et al. ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells. Cancer Res. 83, 1646–1665 (2023).36892426 10.1158/0008-5472.CAN-22-1999
225. Ye Y Characterization of Hypoxia-associated molecular features to aid hypoxia-targeted therapy Nat. Metab. 2019 1 431 444 10.1038/s42255-019-0045-8 31984309
Ye, Y. et al. Characterization of Hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat. Metab. 1, 431–444 (2019).31984309 10.1038/s42255-019-0045-8
226. Bristow RG Hill RP Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability Nat. Rev. Cancer 2008 8 180 192 10.1038/nrc2344 18273037
Bristow, R. G. & Hill, R. P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180–192 (2008).18273037 10.1038/nrc2344
227. Gilkes DM Semenza GL Wirtz D Hypoxia and the extracellular matrix: drivers of tumour metastasis Nat. Rev. Cancer 2014 14 430 439 10.1038/nrc3726 24827502
Gilkes, D. M., Semenza, G. L. & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430–439 (2014).24827502 10.1038/nrc3726
228. Rohwer N Cramer T Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways Drug Resist. Updat 2011 14 191 201 10.1016/j.drup.2011.03.001 21466972
Rohwer, N. & Cramer, T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat 14, 191–201 (2011).21466972 10.1016/j.drup.2011.03.001
229. Gordan JD Thompson CB Simon MC HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation Cancer Cell 2007 12 108 113 10.1016/j.ccr.2007.07.006 17692803
Gordan, J. D., Thompson, C. B. & Simon, M. C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12, 108–113 (2007).17692803 10.1016/j.ccr.2007.07.006
230. Chen Z Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions Signal Transduct. Target Ther. 2023 8 70 10.1038/s41392-023-01332-8 36797231
Chen, Z. et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct. Target Ther. 8, 70 (2023).36797231 10.1038/s41392-023-01332-8
231. Yang M Clockophagy is a novel selective autophagy process favoring ferroptosis Sci. Adv. 2019 5 eaaw2238 10.1126/sciadv.aaw2238 31355331
Yang, M. et al. Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci. Adv. 5, eaaw2238 (2019).31355331 10.1126/sciadv.aaw2238
232. Yang Z HIF-1alpha drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1 Cell Rep. 2023 42 112945 10.1016/j.celrep.2023.112945 37542723
Yang, Z. et al. HIF-1alpha drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1. Cell Rep. 42, 112945 (2023).37542723 10.1016/j.celrep.2023.112945
233. Zhang Q Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma Oncogene 2023 42 1509 1523 10.1038/s41388-023-02665-y 36932115
Zhang, Q. et al. Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. Oncogene 42, 1509–1523 (2023).36932115 10.1038/s41388-023-02665-y
234. Li Y Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis J. Exp. Clin. Cancer Res. 2023 42 6 10.1186/s13046-022-02567-z 36604718
Li, Y. et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J. Exp. Clin. Cancer Res. 42, 6 (2023).36604718 10.1186/s13046-022-02567-z
235. Singhal R HIF-2alpha activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron J. Clin. Invest 2021 131 e143691 10.1172/JCI143691 33914705
Singhal, R. et al. HIF-2alpha activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron. J. Clin. Invest 131, e143691 (2021).33914705 10.1172/JCI143691
236. Zou Y A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis Nat. Commun. 2019 10 1617 10.1038/s41467-019-09277-9 30962421
Zou, Y. et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun. 10, 1617 (2019).30962421 10.1038/s41467-019-09277-9
237. Yang J Guidelines and definitions for research on epithelial-mesenchymal transition Nat. Rev. Mol. Cell Biol. 2020 21 341 352 10.1038/s41580-020-0237-9 32300252
Yang, J. et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341–352 (2020).32300252 10.1038/s41580-020-0237-9
238. Dongre A Weinberg RA New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer Nat. Rev. Mol. Cell Biol. 2019 20 69 84 10.1038/s41580-018-0080-4 30459476
Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019).30459476 10.1038/s41580-018-0080-4
239. Pastushenko I Identification of the tumour transition states occurring during EMT Nature 2018 556 463 468 10.1038/s41586-018-0040-3 29670281
Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018).29670281 10.1038/s41586-018-0040-3
240. Lee J You JH Kim MS Roh JL Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer Redox Biol. 2020 37 101697 10.1016/j.redox.2020.101697 32896720
Lee, J., You, J. H., Kim, M. S. & Roh, J. L. Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer. Redox Biol. 37, 101697 (2020).32896720 10.1016/j.redox.2020.101697
241. Zheng X Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer Nature 2015 527 525 530 10.1038/nature16064 26560028
Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).26560028 10.1038/nature16064
242. Fischer KR Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance Nature 2015 527 472 476 10.1038/nature15748 26560033
Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015).26560033 10.1038/nature15748
243. Marcucci F Stassi G De Maria R Epithelial-mesenchymal transition: a new target in anticancer drug discovery Nat. Rev. Drug Discov. 2016 15 311 325 10.1038/nrd.2015.13 26822829
Marcucci, F., Stassi, G. & De Maria, R. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat. Rev. Drug Discov. 15, 311–325 (2016).26822829 10.1038/nrd.2015.13
244. Vucetic M Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis Cell Death Dis. 2020 11 789 10.1038/s41419-020-02994-w 32968052
Vucetic, M. et al. Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis. Cell Death Dis. 11, 789 (2020).32968052 10.1038/s41419-020-02994-w
245. Sun L Lipid Peroxidation, GSH depletion, and SLC7A11 inhibition are common causes of EMT and ferroptosis in A549 cells, but different in specific mechanisms DNA Cell Biol. 2021 40 172 183 10.1089/dna.2020.5730 33351681
Sun, L. et al. Lipid Peroxidation, GSH depletion, and SLC7A11 inhibition are common causes of EMT and ferroptosis in A549 cells, but different in specific mechanisms. DNA Cell Biol. 40, 172–183 (2021).33351681 10.1089/dna.2020.5730
246. Joseph JV TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion Cell Death Dis. 2014 5 e1443 10.1038/cddis.2014.395 25275602
Joseph, J. V. et al. TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis. 5, e1443 (2014).25275602 10.1038/cddis.2014.395
247. Viswanathan VS Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway Nature 2017 547 453 457 10.1038/nature23007 28678785
Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).28678785 10.1038/nature23007
248. Muller S CD44 regulates epigenetic plasticity by mediating iron endocytosis Nat. Chem. 2020 12 929 938 10.1038/s41557-020-0513-5 32747755
Muller, S. et al. CD44 regulates epigenetic plasticity by mediating iron endocytosis. Nat. Chem. 12, 929–938 (2020).32747755 10.1038/s41557-020-0513-5
249. Oliveira T HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells Redox Biol. 2021 47 102149 10.1016/j.redox.2021.102149 34600336
Oliveira, T. et al. HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells. Redox Biol. 47, 102149 (2021).34600336 10.1016/j.redox.2021.102149
250. You JH Lee J Roh JL Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition Cancer Lett. 2021 507 40 54 10.1016/j.canlet.2021.03.013 33741422
You, J. H., Lee, J. & Roh, J. L. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition. Cancer Lett. 507, 40–54 (2021).33741422 10.1016/j.canlet.2021.03.013
251. Chen L GINS4 suppresses ferroptosis by antagonizing p53 acetylation with Snail Proc. Natl Acad. Sci. USA 2023 120 e2219585120 10.1073/pnas.2219585120 37018198
Chen, L. et al. GINS4 suppresses ferroptosis by antagonizing p53 acetylation with Snail. Proc. Natl Acad. Sci. USA 120, e2219585120 (2023).37018198 10.1073/pnas.2219585120
252. Hassin O Oren M Drugging p53 in cancer: one protein, many targets Nat. Rev. Drug Discov. 2023 22 127 144 10.1038/s41573-022-00571-8 36216888
Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug Discov. 22, 127–144 (2023).36216888 10.1038/s41573-022-00571-8
253. Wang CK MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis Cancer Res. 2023 83 251 263 10.1158/0008-5472.CAN-22-1159 36354374
Wang, C. K. et al. MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis. Cancer Res. 83, 251–263 (2023).36354374 10.1158/0008-5472.CAN-22-1159
254. Zhang X ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation J. Exp. Clin. cancer Res. 2022 41 79 10.1186/s13046-022-02288-3 35227287
Zhang, X. et al. ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation. J. Exp. Clin. cancer Res. 41, 79 (2022).35227287 10.1186/s13046-022-02288-3
255. Maddocks OD Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells Nature 2013 493 542 546 10.1038/nature11743 23242140
Maddocks, O. D. et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542–546 (2013).23242140 10.1038/nature11743
256. Tarangelo A p53 suppresses metabolic stress-induced ferroptosis in cancer cells Cell Rep. 2018 22 569 575 10.1016/j.celrep.2017.12.077 29346757
Tarangelo, A. et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 22, 569–575 (2018).29346757 10.1016/j.celrep.2017.12.077
257. Xie Y The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity Cell Rep. 2017 20 1692 1704 10.1016/j.celrep.2017.07.055 28813679
Xie, Y. et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 20, 1692–1704 (2017).28813679 10.1016/j.celrep.2017.07.055
258. Gan Y UTP11 deficiency suppresses cancer development via nucleolar stress and ferroptosis Redox Biol. 2023 62 102705 10.1016/j.redox.2023.102705 37087976
Gan, Y. et al. UTP11 deficiency suppresses cancer development via nucleolar stress and ferroptosis. Redox Biol. 62, 102705 (2023).37087976 10.1016/j.redox.2023.102705
259. Sun T Chi JT Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications Genes Dis. 2021 8 241 249 10.1016/j.gendis.2020.05.004 33997171
Sun, T. & Chi, J. T. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications. Genes Dis. 8, 241–249 (2021).33997171 10.1016/j.gendis.2020.05.004
260. Magesh S Cai D Roles of YAP/TAZ in ferroptosis Trends Cell Biol. 2022 32 729 732 10.1016/j.tcb.2022.05.005 35701310
Magesh, S. & Cai, D. Roles of YAP/TAZ in ferroptosis. Trends Cell Biol. 32, 729–732 (2022).35701310 10.1016/j.tcb.2022.05.005
261. Lv M CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties Signal Transduct. Target Ther. 2023 8 302 10.1038/s41392-023-01555-9 37582812
Lv, M. et al. CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties. Signal Transduct. Target Ther. 8, 302 (2023).37582812 10.1038/s41392-023-01555-9
262. Zhang X Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma Theranostics 2021 11 5650 5674 10.7150/thno.55482 33897873
Zhang, X. et al. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. Theranostics 11, 5650–5674 (2021).33897873 10.7150/thno.55482
263. Yang WH A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer Mol. Cancer Res. 2020 18 79 90 10.1158/1541-7786.MCR-19-0691 31641008
Yang, W. H. et al. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer. Mol. Cancer Res. 18, 79–90 (2020).31641008 10.1158/1541-7786.MCR-19-0691
264. Yang WH The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma Cell Rep. 2019 28 2501 2508 e2504 10.1016/j.celrep.2019.07.107 31484063
Yang, W. H. et al. The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep. 28, 2501–2508 e2504 (2019).31484063 10.1016/j.celrep.2019.07.107
265. Zhou B Ferroptosis is a type of autophagy-dependent cell death Semin. Cancer Biol. 2020 66 89 100 10.1016/j.semcancer.2019.03.002 30880243
Zhou, B. et al. Ferroptosis is a type of autophagy-dependent cell death. Semin. Cancer Biol. 66, 89–100 (2020).30880243 10.1016/j.semcancer.2019.03.002
266. Mancias JD Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy Nature 2014 509 105 109 10.1038/nature13148 24695223
Mancias, J. D. et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509, 105–109 (2014).24695223 10.1038/nature13148
267. Wu H ATM orchestrates ferritinophagy and ferroptosis by phosphorylating NCOA4 Autophagy 2023 19 2062 2077 10.1080/15548627.2023.2170960 36752571
Wu, H. et al. ATM orchestrates ferritinophagy and ferroptosis by phosphorylating NCOA4. Autophagy 19, 2062–2077 (2023).36752571 10.1080/15548627.2023.2170960
268. Li K TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells Redox Biol. 2022 56 102451 10.1016/j.redox.2022.102451 36067704
Li, K. et al. TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells. Redox Biol. 56, 102451 (2022).36067704 10.1016/j.redox.2022.102451
269. Bai Y Lipid storage and lipophagy regulates ferroptosis Biochem. Biophys. Res Commun. 2019 508 997 1003 10.1016/j.bbrc.2018.12.039 30545638
Bai, Y. et al. Lipid storage and lipophagy regulates ferroptosis. Biochem. Biophys. Res Commun. 508, 997–1003 (2019).30545638 10.1016/j.bbrc.2018.12.039
270. Schroeder B The small GTPase Rab7 as a central regulator of hepatocellular lipophagy Hepatology 2015 61 1896 1907 10.1002/hep.27667 25565581
Schroeder, B. et al. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. Hepatology 61, 1896–1907 (2015).25565581 10.1002/hep.27667
271. You JH Lee J Roh JL PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells J. Exp. Clin. Cancer Res. 2021 40 350 10.1186/s13046-021-02168-2 34749765
You, J. H., Lee, J. & Roh, J. L. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells. J. Exp. Clin. Cancer Res. 40, 350 (2021).34749765 10.1186/s13046-021-02168-2
272. Chang LC Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis Cancer Lett. 2018 416 124 137 10.1016/j.canlet.2017.12.025 29274359
Chang, L. C. et al. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett. 416, 124–137 (2018).29274359 10.1016/j.canlet.2017.12.025
273. Rademaker G Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells Redox Biol. 2022 53 102324 10.1016/j.redox.2022.102324 35533575
Rademaker, G. et al. Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biol. 53, 102324 (2022).35533575 10.1016/j.redox.2022.102324
274. Kaushik S Cuervo AM The coming of age of chaperone-mediated autophagy Nat. Rev. Mol. Cell Biol. 2018 19 365 381 10.1038/s41580-018-0001-6 29626215
Kaushik, S. & Cuervo, A. M. The coming of age of chaperone-mediated autophagy. Nat. Rev. Mol. Cell Biol. 19, 365–381 (2018).29626215 10.1038/s41580-018-0001-6
275. Wu Z Chaperone-mediated autophagy is involved in the execution of ferroptosis Proc. Natl Acad. Sci. USA 2019 116 2996 3005 10.1073/pnas.1819728116 30718432
Wu, Z. et al. Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc. Natl Acad. Sci. USA 116, 2996–3005 (2019).30718432 10.1073/pnas.1819728116
276. Wu K Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function Nat. Cell Biol. 2023 25 714 725 10.1038/s41556-023-01133-9 37156912
Wu, K. et al. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function. Nat. Cell Biol. 25, 714–725 (2023).37156912 10.1038/s41556-023-01133-9
277. Ott M Gogvadze V Orrenius S Zhivotovsky B Mitochondria, oxidative stress and cell death Apoptosis 2007 12 913 922 10.1007/s10495-007-0756-2 17453160
Ott, M., Gogvadze, V., Orrenius, S. & Zhivotovsky, B. Mitochondria, oxidative stress and cell death. Apoptosis 12, 913–922 (2007).17453160 10.1007/s10495-007-0756-2
278. Shindo R Critical contribution of oxidative stress to TNFalpha-induced necroptosis downstream of RIPK1 activation Biochem. Biophys. Res Commun. 2013 436 212 216 10.1016/j.bbrc.2013.05.075 23727581
Shindo, R. et al. Critical contribution of oxidative stress to TNFalpha-induced necroptosis downstream of RIPK1 activation. Biochem. Biophys. Res Commun. 436, 212–216 (2013).23727581 10.1016/j.bbrc.2013.05.075
279. Zhang Z RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells Autophagy 2020 16 1482 1505 10.1080/15548627.2019.1687985 31679460
Zhang, Z. et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy 16, 1482–1505 (2020).31679460 10.1080/15548627.2019.1687985
280. Li J Tumor heterogeneity in autophagy-dependent ferroptosis Autophagy 2021 17 3361 3374 10.1080/15548627.2021.1872241 33404288
Li, J. et al. Tumor heterogeneity in autophagy-dependent ferroptosis. Autophagy 17, 3361–3374 (2021).33404288 10.1080/15548627.2021.1872241
281. Lee WC Guntur AR Long F Rosen CJ Energy metabolism of the Osteoblast: Implications for Osteoporosis Endocr. Rev. 2017 38 255 266 10.1210/er.2017-00064 28472361
Lee, W. C., Guntur, A. R., Long, F. & Rosen, C. J. Energy metabolism of the Osteoblast: Implications for Osteoporosis. Endocr. Rev. 38, 255–266 (2017).28472361 10.1210/er.2017-00064
282. Chen YR Zweier JL Cardiac mitochondria and reactive oxygen species generation Circ. Res. 2014 114 524 537 10.1161/CIRCRESAHA.114.300559 24481843
Chen, Y. R. & Zweier, J. L. Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 114, 524–537 (2014).24481843 10.1161/CIRCRESAHA.114.300559
283. Gao M Glutaminolysis and Transferrin regulate ferroptosis Mol. Cell 2015 59 298 308 10.1016/j.molcel.2015.06.011 26166707
Gao, M. et al. Glutaminolysis and Transferrin regulate ferroptosis. Mol. Cell 59, 298–308 (2015).26166707 10.1016/j.molcel.2015.06.011
284. Wang YQ Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner Nat. Commun. 2018 9 545 10.1038/s41467-018-02951-4 29416026
Wang, Y. Q. et al. Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner. Nat. Commun. 9, 545 (2018).29416026 10.1038/s41467-018-02951-4
285. Oka S Hsu CP Sadoshima J Regulation of cell survival and death by pyridine nucleotides Circ. Res. 2012 111 611 627 10.1161/CIRCRESAHA.111.247932 22904041
Oka, S., Hsu, C. P. & Sadoshima, J. Regulation of cell survival and death by pyridine nucleotides. Circ. Res. 111, 611–627 (2012).22904041 10.1161/CIRCRESAHA.111.247932
286. Llabani E Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis Nat. Chem. 2019 11 521 532 10.1038/s41557-019-0261-6 31086302
Llabani, E. et al. Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis. Nat. Chem. 11, 521–532 (2019).31086302 10.1038/s41557-019-0261-6
287. Lee H Energy-stress-mediated AMPK activation inhibits ferroptosis Nat. Cell Biol. 2020 22 225 234 10.1038/s41556-020-0461-8 32029897
Lee, H. et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat. Cell Biol. 22, 225–234 (2020).32029897 10.1038/s41556-020-0461-8
288. Li C LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis Signal Transduct. Target Ther. 2020 5 187 10.1038/s41392-020-00297-2 32883948
Li, C. et al. LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis. Signal Transduct. Target Ther. 5, 187 (2020).32883948 10.1038/s41392-020-00297-2
289. Zhang Y High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma Biol. Direct 2021 16 10 10.1186/s13062-021-00294-7 34053456
Zhang, Y. et al. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma. Biol. Direct 16, 10 (2021).34053456 10.1186/s13062-021-00294-7
290. Liu W Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer Nat. Commun. 2021 12 5103 10.1038/s41467-021-25354-4 34429409
Liu, W. et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat. Commun. 12, 5103 (2021).34429409 10.1038/s41467-021-25354-4
291. Tan SK Obesity-dependent adipokine chemerin suppresses fatty acid oxidation to confer ferroptosis resistance Cancer Discov. 2021 11 2072 2093 10.1158/2159-8290.CD-20-1453 33757970
Tan, S. K. et al. Obesity-dependent adipokine chemerin suppresses fatty acid oxidation to confer ferroptosis resistance. Cancer Discov. 11, 2072–2093 (2021).33757970 10.1158/2159-8290.CD-20-1453
292. Shi Z Naowarojna N Pan Z Zou Y Multifaceted mechanisms mediating cystine starvation-induced ferroptosis Nat. Commun. 2021 12 4792 10.1038/s41467-021-25159-5 34373463
Shi, Z., Naowarojna, N., Pan, Z. & Zou, Y. Multifaceted mechanisms mediating cystine starvation-induced ferroptosis. Nat. Commun. 12, 4792 (2021).34373463 10.1038/s41467-021-25159-5
293. Jin J Byun JK Choi YK Park KG Targeting glutamine metabolism as a therapeutic strategy for cancer Exp. Mol. Med. 2023 55 706 715 10.1038/s12276-023-00971-9 37009798
Jin, J., Byun, J. K., Choi, Y. K. & Park, K. G. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp. Mol. Med. 55, 706–715 (2023).37009798 10.1038/s12276-023-00971-9
294. Xue Y Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade Nat. Commun. 2023 14 4758 10.1038/s41467-023-40518-0 37553341
Xue, Y. et al. Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade. Nat. Commun. 14, 4758 (2023).37553341 10.1038/s41467-023-40518-0
295. Liu D Tryptophan Metabolism Acts as a New Anti-Ferroptotic Pathway to Mediate Tumor Growth Adv. Sci. 2023 10 e2204006 10.1002/advs.202204006
Liu, D. et al. Tryptophan Metabolism Acts as a New Anti-Ferroptotic Pathway to Mediate Tumor Growth. Adv. Sci. 10, e2204006 (2023).10.1002/advs.202204006
296. Fiore A Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling Mol. Cell 2022 82 920 932 e927 10.1016/j.molcel.2022.02.007 35245456
Fiore, A. et al. Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling. Mol. Cell 82, 920–932 e927 (2022).35245456 10.1016/j.molcel.2022.02.007
297. Panda SK Repression of the aryl-hydrocarbon receptor prevents oxidative stress and ferroptosis of intestinal intraepithelial lymphocytes Immunity 2023 56 797 812 e794 10.1016/j.immuni.2023.01.023 36801011
Panda, S. K. et al. Repression of the aryl-hydrocarbon receptor prevents oxidative stress and ferroptosis of intestinal intraepithelial lymphocytes. Immunity 56, 797–812 e794 (2023).36801011 10.1016/j.immuni.2023.01.023
298. Hu Q GPX4 and vitamin E cooperatively protect hematopoietic stem and progenitor cells from lipid peroxidation and ferroptosis Cell Death Dis. 2021 12 706 10.1038/s41419-021-04008-9 34267193
Hu, Q. et al. GPX4 and vitamin E cooperatively protect hematopoietic stem and progenitor cells from lipid peroxidation and ferroptosis. Cell Death Dis. 12, 706 (2021).34267193 10.1038/s41419-021-04008-9
299. Yang X Regulation of VKORC1L1 is critical for p53-mediated tumor suppression through vitamin K metabolism Cell Metab. 2023 35 1474 1490 e1478 10.1016/j.cmet.2023.06.014 37467745
Yang, X. et al. Regulation of VKORC1L1 is critical for p53-mediated tumor suppression through vitamin K metabolism. Cell Metab. 35, 1474–1490 e1478 (2023).37467745 10.1016/j.cmet.2023.06.014
300. Dai E Epigenetic modulation of antitumor immunity for improved cancer immunotherapy Mol. Cancer 2021 20 171 10.1186/s12943-021-01464-x 34930302
Dai, E. et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol. Cancer 20, 171 (2021).34930302 10.1186/s12943-021-01464-x
301. Quail DF Joyce JA Microenvironmental regulation of tumor progression and metastasis Nat. Med. 2013 19 1423 1437 10.1038/nm.3394 24202395
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).24202395 10.1038/nm.3394
302. Drijvers JM Pharmacologic screening identifies metabolic vulnerabilities of CD8(+) T Cells Cancer Immunol. Res. 2021 9 184 199 10.1158/2326-6066.CIR-20-0384 33277233
Drijvers, J. M. et al. Pharmacologic screening identifies metabolic vulnerabilities of CD8(+) T Cells. Cancer Immunol. Res. 9, 184–199 (2021).33277233 10.1158/2326-6066.CIR-20-0384
303. Kroemer G Galassi C Zitvogel L Galluzzi L Immunogenic cell stress and death Nat. Immunol. 2022 23 487 500 10.1038/s41590-022-01132-2 35145297
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).35145297 10.1038/s41590-022-01132-2
304. Shen D PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer Cancer Lett. 2022 550 215919 10.1016/j.canlet.2022.215919 36116741
Shen, D. et al. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. Cancer Lett. 550, 215919 (2022).36116741 10.1016/j.canlet.2022.215919
305. Liang JL Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy Sci. Bull. 2023 68 622 636 10.1016/j.scib.2023.02.027
Liang, J. L. et al. Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Sci. Bull. 68, 622–636 (2023).10.1016/j.scib.2023.02.027
306. Ding Q Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer J. Control Rel. 2023 363 221 234 10.1016/j.jconrel.2023.09.024
Ding, Q. et al. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer. J. Control Rel. 363, 221–234 (2023).10.1016/j.jconrel.2023.09.024
307. Yu B Choi B Li W Kim DH Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy Nat. Commun. 2020 11 3637 10.1038/s41467-020-17380-5 32686685
Yu, B., Choi, B., Li, W. & Kim, D. H. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat. Commun. 11, 3637 (2020).32686685 10.1038/s41467-020-17380-5
308. Yu Y Iron-based nanoscale coordination polymers synergistically induce immunogenic ferroptosis by blocking dihydrofolate reductase for cancer immunotherapy Biomaterials 2022 288 121724 10.1016/j.biomaterials.2022.121724 36038420
Yu, Y. et al. Iron-based nanoscale coordination polymers synergistically induce immunogenic ferroptosis by blocking dihydrofolate reductase for cancer immunotherapy. Biomaterials 288, 121724 (2022).36038420 10.1016/j.biomaterials.2022.121724
309. Luo X Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2 Cell Death Differ. 2021 28 1971 1989 10.1038/s41418-020-00719-2 33432112
Luo, X. et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 28, 1971–1989 (2021).33432112 10.1038/s41418-020-00719-2
310. Efimova I Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity J. Immunother. Cancer 2020 8 e001369 10.1136/jitc-2020-001369 33188036
Efimova, I. et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 8, e001369 (2020).33188036 10.1136/jitc-2020-001369
311. Bianchi ME High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair Immunol. Rev. 2017 280 74 82 10.1111/imr.12601 29027228
Bianchi, M. E. et al. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol. Rev. 280, 74–82 (2017).29027228 10.1111/imr.12601
312. Liu P Inhibition of ALG3 stimulates cancer cell immunogenic ferroptosis to potentiate immunotherapy Cell Mol. Life Sci. 2022 79 352 10.1007/s00018-022-04365-4 35676564
Liu, P. et al. Inhibition of ALG3 stimulates cancer cell immunogenic ferroptosis to potentiate immunotherapy. Cell Mol. Life Sci. 79, 352 (2022).35676564 10.1007/s00018-022-04365-4
313. Kim KS Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer J. Nanobiotechnol. 2022 20 428 10.1186/s12951-022-01635-y
Kim, K. S. et al. Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer. J. Nanobiotechnol. 20, 428 (2022).10.1186/s12951-022-01635-y
314. Hinshaw DC Shevde LA The tumor microenvironment innately modulates cancer progression Cancer Res. 2019 79 4557 4566 10.1158/0008-5472.CAN-18-3962 31350295
Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79, 4557–4566 (2019).31350295 10.1158/0008-5472.CAN-18-3962
315. Peng D Targeting TGF-beta signal transduction for fibrosis and cancer therapy Mol. Cancer 2022 21 104 10.1186/s12943-022-01569-x 35461253
Peng, D. et al. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).35461253 10.1186/s12943-022-01569-x
316. Shi X TGF-beta signaling in the tumor metabolic microenvironment and targeted therapies J. Hematol. Oncol. 2022 15 135 10.1186/s13045-022-01349-6 36115986
Shi, X. et al. TGF-beta signaling in the tumor metabolic microenvironment and targeted therapies. J. Hematol. Oncol. 15, 135 (2022).36115986 10.1186/s13045-022-01349-6
317. Jiang F ANO1-mediated inhibition of cancer ferroptosis confers immunotherapeutic resistance through recruiting cancer-associated fibroblasts Adv. Sci. 2023 10 e2300881 10.1002/advs.202300881
Jiang, F. et al. ANO1-mediated inhibition of cancer ferroptosis confers immunotherapeutic resistance through recruiting cancer-associated fibroblasts. Adv. Sci. 10, e2300881 (2023).10.1002/advs.202300881
318. Hernandez C Huebener P Schwabe RF Damage-associated molecular patterns in cancer: a double-edged sword Oncogene 2016 35 5931 5941 10.1038/onc.2016.104 27086930
Hernandez, C., Huebener, P. & Schwabe, R. F. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35, 5931–5941 (2016).27086930 10.1038/onc.2016.104
319. Dai E Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway Nat. Commun. 2020 11 6339 10.1038/s41467-020-20154-8 33311482
Dai, E. et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat. Commun. 11, 6339 (2020).33311482 10.1038/s41467-020-20154-8
320. Fang C Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine Cell Mol. Immunol. 2021 18 2211 2223 10.1038/s41423-020-0456-1 32398808
Fang, C. et al. Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cell Mol. Immunol. 18, 2211–2223 (2021).32398808 10.1038/s41423-020-0456-1
321. Dai E Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein Autophagy 2020 16 2069 2083 10.1080/15548627.2020.1714209 31920150
Dai, E. et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy 16, 2069–2083 (2020).31920150 10.1080/15548627.2020.1714209
322. Conche C Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade Gut 2023 72 1774 1782 10.1136/gutjnl-2022-327909 36707233
Conche, C. et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut 72, 1774–1782 (2023).36707233 10.1136/gutjnl-2022-327909
323. Bottcher JP NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control Cell 2018 172 1022 1037 e1014 10.1016/j.cell.2018.01.004 29429633
Bottcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037 e1014 (2018).29429633 10.1016/j.cell.2018.01.004
324. Zelenay S Cyclooxygenase-dependent tumor growth through evasion of immunity Cell 2015 162 1257 1270 10.1016/j.cell.2015.08.015 26343581
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).26343581 10.1016/j.cell.2015.08.015
325. Kalinski P Regulation of immune responses by prostaglandin E2 J. Immunol. 2012 188 21 28 10.4049/jimmunol.1101029 22187483
Kalinski, P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188, 21–28 (2012).22187483 10.4049/jimmunol.1101029
326. Wang D DuBois RN Immunosuppression associated with chronic inflammation in the tumor microenvironment Carcinogenesis 2015 36 1085 1093 10.1093/carcin/bgv123 26354776
Wang, D. & DuBois, R. N. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 36, 1085–1093 (2015).26354776 10.1093/carcin/bgv123
327. Lang X Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11 Cancer Discov. 2019 9 1673 1685 10.1158/2159-8290.CD-19-0338 31554642
Lang, X. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9, 1673–1685 (2019).31554642 10.1158/2159-8290.CD-19-0338
328. Zitvogel L Kroemer G Interferon-gamma induces cancer cell ferroptosis Cell Res 2019 29 692 693 10.1038/s41422-019-0186-z 31160718
Zitvogel, L. & Kroemer, G. Interferon-gamma induces cancer cell ferroptosis. Cell Res 29, 692–693 (2019).31160718 10.1038/s41422-019-0186-z
329. Stockwell BR Jiang X A physiological function for ferroptosis in tumor suppression by the immune system Cell Metab. 2019 30 14 15 10.1016/j.cmet.2019.06.012 31269423
Stockwell, B. R. & Jiang, X. A physiological function for ferroptosis in tumor suppression by the immune system. Cell Metab. 30, 14–15 (2019).31269423 10.1016/j.cmet.2019.06.012
330. Liao P CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4 Cancer Cell 2022 40 365 378 e366 10.1016/j.ccell.2022.02.003 35216678
Liao, P. et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40, 365–378 e366 (2022).35216678 10.1016/j.ccell.2022.02.003
331. Friedmann Angeli JP Xavier da Silva TN Schilling B CD8(+) T cells PUF(A)ing the flames of cancer ferroptotic cell death Cancer Cell 2022 40 346 348 10.1016/j.ccell.2022.03.003 35334204
Friedmann Angeli, J. P., Xavier da Silva, T. N. & Schilling, B. CD8(+) T cells PUF(A)ing the flames of cancer ferroptotic cell death. Cancer Cell 40, 346–348 (2022).35334204 10.1016/j.ccell.2022.03.003
332. Gan B ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity Signal Transduct. Target Ther. 2022 7 128 10.1038/s41392-022-01004-z 35459217
Gan, B. ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity. Signal Transduct. Target Ther. 7, 128 (2022).35459217 10.1038/s41392-022-01004-z
333. Kepp O Kroemer G Pro-ferroptotic fatty acid metabolism renders cancer cells immunogenic Trends Cancer 2022 8 785 787 10.1016/j.trecan.2022.04.002 35469799
Kepp, O. & Kroemer, G. Pro-ferroptotic fatty acid metabolism renders cancer cells immunogenic. Trends Cancer 8, 785–787 (2022).35469799 10.1016/j.trecan.2022.04.002
334. Gocher AM Workman CJ Vignali DAA Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 2022 22 158 172 10.1038/s41577-021-00566-3 34155388
Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 22, 158–172 (2022).34155388 10.1038/s41577-021-00566-3
335. Wu L The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death Cancer Commun. 2022 42 768 783 10.1002/cac2.12321
Wu, L. et al. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death. Cancer Commun. 42, 768–783 (2022).10.1002/cac2.12321
336. Li H HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk J. Hematol. Oncol. 2022 15 2 10.1186/s13045-021-01223-x 34991659
Li, H. et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J. Hematol. Oncol. 15, 2 (2022).34991659 10.1186/s13045-021-01223-x
337. Bansal A Gamma-Glutamyltransferase 1 promotes clear cell renal cell carcinoma initiation and progression Mol. Cancer Res. 2019 17 1881 1892 10.1158/1541-7786.MCR-18-1204 31151999
Bansal, A. et al. Gamma-Glutamyltransferase 1 promotes clear cell renal cell carcinoma initiation and progression. Mol. Cancer Res. 17, 1881–1892 (2019).31151999 10.1158/1541-7786.MCR-18-1204
338. Luo Y The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes Acta Pharm. Sin. B 2023 13 2645 2662 10.1016/j.apsb.2023.03.025 37425043
Luo, Y. et al. The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. Acta Pharm. Sin. B 13, 2645–2662 (2023).37425043 10.1016/j.apsb.2023.03.025
339. Bouche C Quail DF Fueling the tumor microenvironment with cancer-associated adipocytes Cancer Res. 2023 83 1170 1172 10.1158/0008-5472.CAN-23-0505 37057599
Bouche, C. & Quail, D. F. Fueling the tumor microenvironment with cancer-associated adipocytes. Cancer Res. 83, 1170–1172 (2023).37057599 10.1158/0008-5472.CAN-23-0505
340. Wang R Liu Z Fan Z Zhan H Lipid metabolism reprogramming of CD8(+) T cell and therapeutic implications in cancer Cancer Lett. 2023 567 216267 10.1016/j.canlet.2023.216267 37315709
Wang, R., Liu, Z., Fan, Z. & Zhan, H. Lipid metabolism reprogramming of CD8(+) T cell and therapeutic implications in cancer. Cancer Lett. 567, 216267 (2023).37315709 10.1016/j.canlet.2023.216267
341. Ma X CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability Cell Metab. 2021 33 1001 1012 e1005 10.1016/j.cmet.2021.02.015 33691090
Ma, X. et al. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 33, 1001–1012 e1005 (2021).33691090 10.1016/j.cmet.2021.02.015
342. Xu S Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors Immunity 2021 54 1561 1577 e1567 10.1016/j.immuni.2021.05.003 34102100
Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity 54, 1561–1577 e1567 (2021).34102100 10.1016/j.immuni.2021.05.003
343. Xiao L IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity J. Clin. Invest 2022 132 e153247 10.1172/JCI153247 35192544
Xiao, L. et al. IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity. J. Clin. Invest. 132, e153247 (2022).35192544 10.1172/JCI153247
344. Downs-Canner SM Meier J Vincent BG Serody JS B cell function in the tumor microenvironment Annu Rev. Immunol. 2022 40 169 193 10.1146/annurev-immunol-101220-015603 35044794
Downs-Canner, S. M., Meier, J., Vincent, B. G. & Serody, J. S. B cell function in the tumor microenvironment. Annu Rev. Immunol. 40, 169–193 (2022).35044794 10.1146/annurev-immunol-101220-015603
345. Muri, J., Thut, H., Bornkamm, G. W. & Kopf, M. B1 and marginal zone B Cells but not follicular B2 cells require Gpx4 to prevent lipid peroxidation and ferroptosis. Cell Rep. 29, 2731-2744 e2734, (2019).
346. Chen Q The role of B-cell ferroptosis in the pathogenesis of systemic lupus erythematosus Clin. Immunol. 2023 256 109778 10.1016/j.clim.2023.109778 37730009
Chen, Q. et al. The role of B-cell ferroptosis in the pathogenesis of systemic lupus erythematosus. Clin. Immunol. 256, 109778 (2023).37730009 10.1016/j.clim.2023.109778
347. Zhu S Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy Pharm. Res. 2020 159 104980 10.1016/j.phrs.2020.104980
Zhu, S. et al. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy. Pharm. Res. 159, 104980 (2020).10.1016/j.phrs.2020.104980
348. Cubillos-Ruiz JR ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis Cell 2015 161 1527 1538 10.1016/j.cell.2015.05.025 26073941
Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538 (2015).26073941 10.1016/j.cell.2015.05.025
349. Garris CS Pittet MJ ER stress in dendritic cells promotes Cancer Cell. 2015 161 1492 1493
Garris, C. S. & Pittet, M. J. ER stress in dendritic cells promotes. Cancer Cell. 161, 1492–1493 (2015).
350. Merad M Salmon H Cancer: A dendritic-cell brake on antitumour immunity Nature 2015 523 294 295 10.1038/523294a 26178959
Merad, M. & Salmon, H. Cancer: A dendritic-cell brake on antitumour immunity. Nature 523, 294–295 (2015).26178959 10.1038/523294a
351. Han L PPARG-mediated ferroptosis in dendritic cells limits antitumor immunity Biochem Biophys. Res. Commun. 2021 576 33 39 10.1016/j.bbrc.2021.08.082 34478917
Han, L. et al. PPARG-mediated ferroptosis in dendritic cells limits antitumor immunity. Biochem Biophys. Res. Commun. 576, 33–39 (2021).34478917 10.1016/j.bbrc.2021.08.082
352. Rothe T 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function J. Clin. Invest 2015 125 1944 1954 10.1172/JCI78490 25844901
Rothe, T. et al. 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J. Clin. Invest 125, 1944–1954 (2015).25844901 10.1172/JCI78490
353. Zhou Y Cheng L Liu L Li X NK cells are never alone: crosstalk and communication in tumour microenvironments Mol. Cancer 2023 22 34 10.1186/s12943-023-01737-7 36797782
Zhou, Y., Cheng, L., Liu, L. & Li, X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol. Cancer 22, 34 (2023).36797782 10.1186/s12943-023-01737-7
354. Cui JX L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis J. Exp. Clin. Cancer Res. 2023 42 52 10.1186/s13046-023-02629-w 36855135
Cui, J. X. et al. L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis. J. Exp. Clin. Cancer Res. 42, 52 (2023).36855135 10.1186/s13046-023-02629-w
355. Tan S Exosomal miRNAs in tumor microenvironment J. Exp. Clin. Cancer Res. 2020 39 67 10.1186/s13046-020-01570-6 32299469
Tan, S. et al. Exosomal miRNAs in tumor microenvironment. J. Exp. Clin. Cancer Res. 39, 67 (2020).32299469 10.1186/s13046-020-01570-6
356. Kapralov AA Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death Nat. Chem. Biol. 2020 16 278 290 10.1038/s41589-019-0462-8 32080625
Kapralov, A. A. et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat. Chem. Biol. 16, 278–290 (2020).32080625 10.1038/s41589-019-0462-8
357. Hao X Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing Redox Biol. 2022 56 102463 10.1016/j.redox.2022.102463 36108528
Hao, X. et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 56, 102463 (2022).36108528 10.1016/j.redox.2022.102463
358. Tang B Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against hcc and enhances the efficacy of the anti-PD-1/L1 response Adv. Sci. 2023 10 e2203973 10.1002/advs.202203973
Tang, B. et al. Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against hcc and enhances the efficacy of the anti-PD-1/L1 response. Adv. Sci. 10, e2203973 (2023).10.1002/advs.202203973
359. Gu Z Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal activities Nano Lett. 2021 21 6471 6479 10.1021/acs.nanolett.1c01401 34292757
Gu, Z. et al. Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal activities. Nano Lett. 21, 6471–6479 (2021).34292757 10.1021/acs.nanolett.1c01401
360. Li LG A Dihydroartemisinin-loaded nanoreactor motivates anti-cancer immunotherapy by synergy-induced ferroptosis to activate Cgas/STING for reprogramming of macrophage Adv. Health. Mater. 2023 12 e2301561 10.1002/adhm.202301561
Li, L. G. et al. A Dihydroartemisinin-loaded nanoreactor motivates anti-cancer immunotherapy by synergy-induced ferroptosis to activate Cgas/STING for reprogramming of macrophage. Adv. Health. Mater. 12, e2301561 (2023).10.1002/adhm.202301561
361. Shi Z Multifunctional nanomaterials for ferroptotic cancer therapy Front Chem. 2022 10 868630 10.3389/fchem.2022.868630 35402376
Shi, Z. et al. Multifunctional nanomaterials for ferroptotic cancer therapy. Front Chem. 10, 868630 (2022).35402376 10.3389/fchem.2022.868630
362. Li LG Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage Front. Pharm. 2022 13 949835 10.3389/fphar.2022.949835
Li, L. G. et al. Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage. Front. Pharm. 13, 949835 (2022).10.3389/fphar.2022.949835
363. Yan Y Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity J. Hematol. Oncol. 2022 15 104 10.1186/s13045-022-01322-3 35948909
Yan, Y. et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J. Hematol. Oncol. 15, 104 (2022).35948909 10.1186/s13045-022-01322-3
364. Xu C The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity Cell Rep. 2021 35 109235 10.1016/j.celrep.2021.109235 34133924
Xu, C. et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 35, 109235 (2021).34133924 10.1016/j.celrep.2021.109235
365. Li K Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer Signal Transduct. Target Ther. 2021 6 362 10.1038/s41392-021-00670-9 34620838
Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target Ther. 6, 362 (2021).34620838 10.1038/s41392-021-00670-9
366. Wu Y Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy Mol. Cancer 2022 21 184 10.1186/s12943-022-01657-y 36163047
Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).36163047 10.1186/s12943-022-01657-y
367. Du S Zeng F Deng G Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy Signal Transduct. Target Ther. 2023 8 77 10.1038/s41392-023-01357-z 36813764
Du, S., Zeng, F. & Deng, G. Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy. Signal Transduct. Target Ther. 8, 77 (2023).36813764 10.1038/s41392-023-01357-z
368. Torti SV Torti FM Iron and cancer: more ore to be mined Nat. Rev. Cancer 2013 13 342 355 10.1038/nrc3495 23594855
Torti, S. V. & Torti, F. M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13, 342–355 (2013).23594855 10.1038/nrc3495
369. Manz DH Iron and cancer: recent insights Ann. N. Y Acad. Sci. 2016 1368 149 161 10.1111/nyas.13008 26890363
Manz, D. H. et al. Iron and cancer: recent insights. Ann. N. Y Acad. Sci. 1368, 149–161 (2016).26890363 10.1111/nyas.13008
370. Tsoi J Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress Cancer Cell 2018 33 890 904 e895 10.1016/j.ccell.2018.03.017 29657129
Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890–904 e895 (2018).29657129 10.1016/j.ccell.2018.03.017
371. Koeberle SC Kipp AP Stuppner H Koeberle A Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling Med. Res. Rev. 2023 43 614 682 10.1002/med.21933 36658724
Koeberle, S. C., Kipp, A. P., Stuppner, H. & Koeberle, A. Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling. Med. Res. Rev. 43, 614–682 (2023).36658724 10.1002/med.21933
372. Lei G The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression Cell Res. 2020 30 146 162 10.1038/s41422-019-0263-3 31949285
Lei, G. et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 30, 146–162 (2020).31949285 10.1038/s41422-019-0263-3
373. Guo J Ferroptosis: A novel anti-tumor action for Cisplatin Cancer Res. Treat. 2018 50 445 460 10.4143/crt.2016.572 28494534
Guo, J. et al. Ferroptosis: A novel anti-tumor action for Cisplatin. Cancer Res. Treat. 50, 445–460 (2018).28494534 10.4143/crt.2016.572
374. Wang J RNF2 promotes the progression of colon cancer by regulating ubiquitination and degradation of IRF4 Biochim Biophys. Acta Mol. Cell Res 2022 1869 119162 10.1016/j.bbamcr.2021.119162 34670117
Wang, J. et al. RNF2 promotes the progression of colon cancer by regulating ubiquitination and degradation of IRF4. Biochim Biophys. Acta Mol. Cell Res 1869, 119162 (2022).34670117 10.1016/j.bbamcr.2021.119162
375. Yao X Simvastatin induced ferroptosis for triple-negative breast cancer therapy J. Nanobiotechnol. 2021 19 311 10.1186/s12951-021-01058-1
Yao, X. et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J. Nanobiotechnol. 19, 311 (2021).10.1186/s12951-021-01058-1
376. Gout PW Buckley AR Simms CR Bruchovsky N Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug Leukemia 2001 15 1633 1640 10.1038/sj.leu.2402238 11587223
Gout, P. W., Buckley, A. R., Simms, C. R. & Bruchovsky, N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15, 1633–1640 (2001).11587223 10.1038/sj.leu.2402238
377. Chipurupalli S Three-dimensional growth sensitizes breast cancer cells to treatment with ferroptosis-promoting drugs Cell Death Dis. 2023 14 580 10.1038/s41419-023-06106-2 37658069
Chipurupalli, S. et al. Three-dimensional growth sensitizes breast cancer cells to treatment with ferroptosis-promoting drugs. Cell Death Dis. 14, 580 (2023).37658069 10.1038/s41419-023-06106-2
378. Philip M Schietinger A CD8(+) T cell differentiation and dysfunction in cancer Nat. Rev. Immunol. 2022 22 209 223 10.1038/s41577-021-00574-3 34253904
Philip, M. & Schietinger, A. CD8(+) T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209–223 (2022).34253904 10.1038/s41577-021-00574-3
379. Carlino MS Larkin J Long GV Immune checkpoint inhibitors in melanoma Lancet 2021 398 1002 1014 10.1016/S0140-6736(21)01206-X 34509219
Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002–1014 (2021).34509219 10.1016/S0140-6736(21)01206-X
380. Kong R IFNgamma-mediated repression of system xc(-) drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells J. Leukoc. Biol. 2021 110 301 314 10.1002/JLB.3MA1220-815RRR 34318944
Kong, R. et al. IFNgamma-mediated repression of system xc(-) drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells. J. Leukoc. Biol. 110, 301–314 (2021).34318944 10.1002/JLB.3MA1220-815RRR
381. Jiang Z TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis J. Clin. Investig. 2021 131 e139434 10.1172/JCI139434 33855973
Jiang, Z. et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J. Clin. Investig. 131, e139434 (2021).33855973 10.1172/JCI139434
382. Yang F Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy Cell Metab. 2023 35 84 100.e108 10.1016/j.cmet.2022.09.021 36257316
Yang, F. et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 35, 84–100.e108 (2023).36257316 10.1016/j.cmet.2022.09.021
383. Han Y IL-1β-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance Mol. Cell 2023 83 1887 1902.e1888 10.1016/j.molcel.2023.05.011 37244254
Han, Y. et al. IL-1β-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance. Mol. Cell 83, 1887–1902.e1888 (2023).37244254 10.1016/j.molcel.2023.05.011
384. Meng Y BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition Mil. Med. Res. 2023 10 61 38049916
Meng, Y. et al. BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition. Mil. Med. Res. 10, 61 (2023).38049916
385. Wu Y Song Y Wang R Wang T Molecular mechanisms of tumor resistance to radiotherapy Mol. Cancer 2023 22 96 10.1186/s12943-023-01801-2 37322433
Wu, Y., Song, Y., Wang, R. & Wang, T. Molecular mechanisms of tumor resistance to radiotherapy. Mol. Cancer 22, 96 (2023).37322433 10.1186/s12943-023-01801-2
386. Jaffray DA Image-guided radiotherapy: from current concept to future perspectives Nat. Rev. Clin. Oncol. 2012 9 688 699 10.1038/nrclinonc.2012.194 23165124
Jaffray, D. A. Image-guided radiotherapy: from current concept to future perspectives. Nat. Rev. Clin. Oncol. 9, 688–699 (2012).23165124 10.1038/nrclinonc.2012.194
387. Baidoo KE Yong K Brechbiel MW Molecular pathways: targeted alpha-particle radiation therapy Clin. Cancer Res. 2013 19 530 537 10.1158/1078-0432.CCR-12-0298 23230321
Baidoo, K. E., Yong, K. & Brechbiel, M. W. Molecular pathways: targeted alpha-particle radiation therapy. Clin. Cancer Res. 19, 530–537 (2013).23230321 10.1158/1078-0432.CCR-12-0298
388. Wan C Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming Sci. Adv. 2020 6 eaay9789 10.1126/sciadv.aay9789 32232155
Wan, C. et al. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci. Adv. 6, eaay9789 (2020).32232155 10.1126/sciadv.aay9789
389. Chandra RA Keane FK Voncken FEM Thomas CR Jr. Contemporary radiotherapy: present and future Lancet 2021 398 171 184 10.1016/S0140-6736(21)00233-6 34166607
Chandra, R. A., Keane, F. K., Voncken, F. E. M. & Thomas, C. R. Jr. Contemporary radiotherapy: present and future. Lancet 398, 171–184 (2021).34166607 10.1016/S0140-6736(21)00233-6
390. Jiang K STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma Redox Biol. 2023 60 102626 10.1016/j.redox.2023.102626 36764215
Jiang, K. et al. STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma. Redox Biol. 60, 102626 (2023).36764215 10.1016/j.redox.2023.102626
391. Chen Q SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma Cell Death Differ. 2023 30 137 151 10.1038/s41418-022-01051-7 35995846
Chen, Q. et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 30, 137–151 (2023).35995846 10.1038/s41418-022-01051-7
392. Yang M COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma J. Hepatol. 2022 76 1138 1150 10.1016/j.jhep.2022.01.009 35101526
Yang, M. et al. COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J. Hepatol. 76, 1138–1150 (2022).35101526 10.1016/j.jhep.2022.01.009
393. Mou Y Ferroptosis, a new form of cell death: opportunities and challenges in cancer J. Hematol. Oncol. 2019 12 34 10.1186/s13045-019-0720-y 30925886
Mou, Y. et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J. Hematol. Oncol. 12, 34 (2019).30925886 10.1186/s13045-019-0720-y
394. Dixon SJ Stockwell BR The role of iron and reactive oxygen species in cell death Nat. Chem. Biol. 2014 10 9 17 10.1038/nchembio.1416 24346035
Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9–17 (2014).24346035 10.1038/nchembio.1416
395. Li Q Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy Eur. J. Pharm. 2023 955 175913 10.1016/j.ejphar.2023.175913
Li, Q. et al. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy. Eur. J. Pharm. 955, 175913 (2023).10.1016/j.ejphar.2023.175913
396. Xu X Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer Redox Biol. 2023 59 102564 10.1016/j.redox.2022.102564 36473315
Xu, X. et al. Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox Biol. 59, 102564 (2023).36473315 10.1016/j.redox.2022.102564
397. Gao R YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis EMBO Mol. Med 2021 13 e14351 10.15252/emmm.202114351 34664408
Gao, R. et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol. Med 13, e14351 (2021).34664408 10.15252/emmm.202114351
398. Li B CISD2 promotes resistance to sorafenib-induced ferroptosis by regulating autophagy in hepatocellular carcinoma Front Oncol. 2021 11 657723 10.3389/fonc.2021.657723 34485112
Li, B. et al. CISD2 promotes resistance to sorafenib-induced ferroptosis by regulating autophagy in hepatocellular carcinoma. Front Oncol. 11, 657723 (2021).34485112 10.3389/fonc.2021.657723
399. Yang H The PTBP1‑NCOA4 axis promotes ferroptosis in liver cancer cells Oncol. Rep. 2023 49 45 10.3892/or.2023.8482 36660932
Yang, H. et al. The PTBP1‑NCOA4 axis promotes ferroptosis in liver cancer cells. Oncol. Rep. 49, 45 (2023).36660932 10.3892/or.2023.8482
400. Zheng J Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines Cell Death Dis. 2021 12 698 10.1038/s41419-021-03998-w 34257282
Zheng, J. et al. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 12, 698 (2021).34257282 10.1038/s41419-021-03998-w
401. Ni J Chen K Zhang J Zhang X Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells Biochem Biophys. Res Commun. 2021 567 154 160 10.1016/j.bbrc.2021.06.051 34157442
Ni, J., Chen, K., Zhang, J. & Zhang, X. Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells. Biochem Biophys. Res Commun. 567, 154–160 (2021).34157442 10.1016/j.bbrc.2021.06.051
402. Ma S Henson ES Chen Y Gibson SB Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells Cell Death Dis. 2016 7 e2307 10.1038/cddis.2016.208 27441659
Ma, S., Henson, E. S., Chen, Y. & Gibson, S. B. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 7, e2307 (2016).27441659 10.1038/cddis.2016.208
403. Ma S Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells PLoS One 2017 12 e0182921 10.1371/journal.pone.0182921 28827805
Ma, S. et al. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One 12, e0182921 (2017).28827805 10.1371/journal.pone.0182921
404. Nagpal A Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis Breast Cancer Res. 2019 21 94 10.1186/s13058-019-1177-1 31409375
Nagpal, A. et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis. Breast Cancer Res. 21, 94 (2019).31409375 10.1186/s13058-019-1177-1
405. Ma H Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy-dependent ferroptosis Drug Dev. Res. 2022 83 1641 1653 10.1002/ddr.21983 36031759
Ma, H. et al. Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy-dependent ferroptosis. Drug Dev. Res. 83, 1641–1653 (2022).36031759 10.1002/ddr.21983
406. Park SY Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer Cell Death Dis. 2023 14 532 10.1038/s41419-023-06042-1 37596261
Park, S. Y. et al. Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death Dis. 14, 532 (2023).37596261 10.1038/s41419-023-06042-1
407. Rottenberg S Disler C Perego P The rediscovery of platinum-based cancer therapy Nat. Rev. Cancer 2021 21 37 50 10.1038/s41568-020-00308-y 33128031
Rottenberg, S., Disler, C. & Perego, P. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer 21, 37–50 (2021).33128031 10.1038/s41568-020-00308-y
408. Han Y Wen P Li J Kataoka K Targeted nanomedicine in cisplatin-based cancer therapeutics J. Control. Rel. 2022 345 709 720 10.1016/j.jconrel.2022.03.049
Han, Y., Wen, P., Li, J. & Kataoka, K. Targeted nanomedicine in cisplatin-based cancer therapeutics. J. Control. Rel. 345, 709–720 (2022).10.1016/j.jconrel.2022.03.049
409. Zamble DB Lippard SJ Cisplatin and D. N. A. repair in cancer chemotherapy Trends Biochem Sci. 1995 20 435 439 10.1016/S0968-0004(00)89095-7 8533159
Zamble, D. B. & Lippard, S. J. Cisplatin and D. N. A. repair in cancer chemotherapy. Trends Biochem Sci. 20, 435–439 (1995).8533159 10.1016/S0968-0004(00)89095-7
410. Roh JL Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer Cancer Lett. 2016 381 96 103 10.1016/j.canlet.2016.07.035 27477897
Roh, J. L. et al. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 381, 96–103 (2016).27477897 10.1016/j.canlet.2016.07.035
411. Fu D Wang C Yu L Yu R Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling Cell Mol. Biol. Lett. 2021 26 26 10.1186/s11658-021-00271-y 34098867
Fu, D., Wang, C., Yu, L. & Yu, R. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cell Mol. Biol. Lett. 26, 26 (2021).34098867 10.1186/s11658-021-00271-y
412. Han L Li L Wu G Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells Mol. Cell Probes 2022 64 101821 10.1016/j.mcp.2022.101821 35490795
Han, L., Li, L. & Wu, G. Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells. Mol. Cell Probes 64, 101821 (2022).35490795 10.1016/j.mcp.2022.101821
413. Roh JL Kim EH Jang H Shin D Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis Redox Biol. 2017 11 254 262 10.1016/j.redox.2016.12.010 28012440
Roh, J. L., Kim, E. H., Jang, H. & Shin, D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11, 254–262 (2017).28012440 10.1016/j.redox.2016.12.010
414. Sato M The ferroptosis inducer erastin irreversibly inhibits system x(c)- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells Sci. Rep. 2018 8 968 10.1038/s41598-018-19213-4 29343855
Sato, M. et al. The ferroptosis inducer erastin irreversibly inhibits system x(c)- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells. Sci. Rep. 8, 968 (2018).29343855 10.1038/s41598-018-19213-4
415. Wang Y Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer Cell Death Differ. 2022 29 2190 2202 10.1038/s41418-022-01008-w 35534546
Wang, Y. et al. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 29, 2190–2202 (2022).35534546 10.1038/s41418-022-01008-w
416. Zhou Z Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils Front. Pharmacol. 2022 13 870178 10.3389/fphar.2022.870178 35784745
Zhou, Z. et al. Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils. Front. Pharmacol. 13, 870178 (2022).35784745 10.3389/fphar.2022.870178
417. Mini E Cellular pharmacology of gemcitabine Ann. Oncol. 2006 17 v7 12, 10.1093/annonc/mdj941 16807468
Mini, E. et al. Cellular pharmacology of gemcitabine. Ann. Oncol. 17, v7–12, (2006).16807468 10.1093/annonc/mdj941
418. He H KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma Front. Pharm. 2022 13 1007429 10.3389/fphar.2022.1007429
He, H. et al. KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma. Front. Pharm. 13, 1007429 (2022).10.3389/fphar.2022.1007429
419. Qi R Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs Drug Resist. Updat. 2023 68 100960 10.1016/j.drup.2023.100960 37003125
Qi, R. et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist. Updat. 68, 100960 (2023).37003125 10.1016/j.drup.2023.100960
420. Combe B Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Ann. Rheum. Dis. 2009 68 1146 1152 10.1136/ard.2007.087106 18794178
Combe, B. et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann. Rheum. Dis. 68, 1146–1152 (2009).18794178 10.1136/ard.2007.087106
421. Pardieu B Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia Leukemia 2022 36 1585 1595 10.1038/s41375-022-01573-6 35474100
Pardieu, B. et al. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia 36, 1585–1595 (2022).35474100 10.1038/s41375-022-01573-6
422. Idei U Mechanism of cell death by combined treatment with an xCT Inhibitor and Paclitaxel: An alternative therapeutic strategy for patients with ovarian clear cell carcinoma Int J. Mol. Sci. 2023 24 11781 10.3390/ijms241411781 37511540
Idei, U. et al. Mechanism of cell death by combined treatment with an xCT Inhibitor and Paclitaxel: An alternative therapeutic strategy for patients with ovarian clear cell carcinoma. Int J. Mol. Sci. 24, 11781 (2023).37511540 10.3390/ijms241411781
423. Kerkhove L Repurposing Sulfasalazine as a radiosensitizer in hypoxic human colorectal cancer Cancers 2023 15 2363 10.3390/cancers15082363 37190291
Kerkhove, L. et al. Repurposing Sulfasalazine as a radiosensitizer in hypoxic human colorectal cancer. Cancers 15, 2363 (2023).37190291 10.3390/cancers15082363
424. Ruiz de Galarreta M beta-Catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma Cancer Discov. 2019 9 1124 1141 10.1158/2159-8290.CD-19-0074 31186238
Ruiz de Galarreta, M. et al. beta-Catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 9, 1124–1141 (2019).31186238 10.1158/2159-8290.CD-19-0074
425. Jin H EGFR activation limits the response of liver cancer to lenvatinib Nature 2021 595 730 734 10.1038/s41586-021-03741-7 34290403
Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730–734 (2021).34290403 10.1038/s41586-021-03741-7
426. Meng J Ferroptosis-enhanced immunotherapy with an injectable dextran-chitosan hydrogel for the treatment of malignant ascites in hepatocellular carcinoma Adv. Sci. (Weinh.) 2023 10 e2300517 37132587
Meng, J. et al. Ferroptosis-enhanced immunotherapy with an injectable dextran-chitosan hydrogel for the treatment of malignant ascites in hepatocellular carcinoma. Adv. Sci. (Weinh.) 10, e2300517 (2023).37132587
427. Mach F 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur. Heart J. 2020 41 111 188 10.1093/eurheartj/ehz455 31504418
Mach, F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020).31504418 10.1093/eurheartj/ehz455
428. Li Q Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner Exp. Ther. Med. 2021 22 1275 10.3892/etm.2021.10710 34594412
Li, Q. et al. Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner. Exp. Ther. Med. 22, 1275 (2021).34594412 10.3892/etm.2021.10710
429. Zhang Q Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of Nrf2-xCT/GPx4 Axis Front. Cell Dev. Biol. 2022 10 806081 10.3389/fcell.2022.806081 35309902
Zhang, Q. et al. Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of Nrf2-xCT/GPx4 Axis. Front. Cell Dev. Biol. 10, 806081 (2022).35309902 10.3389/fcell.2022.806081
430. Sahebkar A Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? Metab.: Clin. Exp. 2023 146 155659 10.1016/j.metabol.2023.155659 37442270
Sahebkar, A. et al. Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? Metab.: Clin. Exp. 146, 155659 (2023).37442270 10.1016/j.metabol.2023.155659
431. Mao W Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer JCI insight 2022 7 e161940 10.1172/jci.insight.161940 35943796
Mao, W. et al. Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer. JCI insight 7, e161940 (2022).35943796 10.1172/jci.insight.161940
432. Klayman DL Qinghaosu (artemisinin): an antimalarial drug from China Science 1985 228 1049 1055 10.1126/science.3887571 3887571
Klayman, D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049–1055 (1985).3887571 10.1126/science.3887571
433. Li J Zhou B Biological actions of artemisinin: insights from medicinal chemistry studies Molecules 2010 15 1378 1397 10.3390/molecules15031378 20335987
Li, J. & Zhou, B. Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules 15, 1378–1397 (2010).20335987 10.3390/molecules15031378
434. Ooko E Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells Phytomedicine 2015 22 1045 1054 10.1016/j.phymed.2015.08.002 26407947
Ooko, E. et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22, 1045–1054 (2015).26407947 10.1016/j.phymed.2015.08.002
435. Markowitsch SD Artesunate Inhibits Growth Of Sunitinib-resistant Renal Cell Carcinoma Cells Through Cell Cycle Arrest And Induction Of Ferroptosis Cancers 2020 12 3150 10.3390/cancers12113150 33121039
Markowitsch, S. D. et al. Artesunate Inhibits Growth Of Sunitinib-resistant Renal Cell Carcinoma Cells Through Cell Cycle Arrest And Induction Of Ferroptosis. Cancers 12, 3150 (2020).33121039 10.3390/cancers12113150
436. Li ZJ Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma Acta Pharm. Sin. 2021 42 301 310 10.1038/s41401-020-0478-3
Li, Z. J. et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharm. Sin. 42, 301–310 (2021).10.1038/s41401-020-0478-3
437. Chen Y Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway Oncol. Rep. 2023 50 147 10.3892/or.2023.8584 37326033
Chen, Y. et al. Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway. Oncol. Rep. 50, 147 (2023).37326033 10.3892/or.2023.8584
438. Crespo-Ortiz MP Wei MQ Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug J. Biomed. Biotechnol. 2012 2012 247597 10.1155/2012/247597 22174561
Crespo-Ortiz, M. P. & Wei, M. Q. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J. Biomed. Biotechnol. 2012, 247597 (2012).22174561 10.1155/2012/247597
439. Yuan B Dihydroartemisinin Inhibits The Proliferation, Colony Formation And Induces Ferroptosis Of Lung Cancer Cells By Inhibiting PRIM2/SLC7A11 Axis Oncol Targets Ther. 2020 13 10829 10840 10.2147/OTT.S248492
Yuan, B. et al. Dihydroartemisinin Inhibits The Proliferation, Colony Formation And Induces Ferroptosis Of Lung Cancer Cells By Inhibiting PRIM2/SLC7A11 Axis. Oncol Targets Ther. 13, 10829–10840 (2020).10.2147/OTT.S248492
440. Lai XY Shi YM Zhou MM Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis Kaohsiung J. Med. Sci. 2023 39 699 709 10.1002/kjm2.12684 37057810
Lai, X. Y., Shi, Y. M. & Zhou, M. M. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis. Kaohsiung J. Med. Sci. 39, 699–709 (2023).37057810 10.1002/kjm2.12684
441. Cui Z Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism J. Pharm. Sci. 2022 148 73 85 10.1016/j.jphs.2021.09.008
Cui, Z. et al. Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism. J. Pharm. Sci. 148, 73–85 (2022).10.1016/j.jphs.2021.09.008
442. Du J DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism Cell Death Dis. 2021 12 705 10.1038/s41419-021-03996-y 34262021
Du, J. et al. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism. Cell Death Dis. 12, 705 (2021).34262021 10.1038/s41419-021-03996-y
443. Froemming JS Lam YW Jann MW Davis CM Pharmacokinetics of haloperidol Clin. Pharmacokinet. 1989 17 396 423 10.2165/00003088-198917060-00004 2689040
Froemming, J. S., Lam, Y. W., Jann, M. W. & Davis, C. M. Pharmacokinetics of haloperidol. Clin. Pharmacokinet. 17, 396–423 (1989).2689040 10.2165/00003088-198917060-00004
444. Bakadlag R Jandaghi P Hoheisel JD Riazalhosseini Y The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer Expert Opin. Ther. Targets 2019 23 365 367 10.1080/14728222.2019.1606904 30986128
Bakadlag, R., Jandaghi, P., Hoheisel, J. D. & Riazalhosseini, Y. The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. Expert Opin. Ther. Targets 23, 365–367 (2019).30986128 10.1080/14728222.2019.1606904
445. Liu Z Synergistic suppression of glioblastoma cell growth by combined application of Temozolomide and Dopamine D2 receptor antagonists World Neurosurg. 2019 128 e468 e477 10.1016/j.wneu.2019.04.180 31048057
Liu, Z. et al. Synergistic suppression of glioblastoma cell growth by combined application of Temozolomide and Dopamine D2 receptor antagonists. World Neurosurg. 128, e468–e477 (2019).31048057 10.1016/j.wneu.2019.04.180
446. Shi L The DRD2 antagonist Haloperidol mediates autophagy-induced ferroptosis to increase Temozolomide sensitivity by promoting endoplasmic reticulum stress in Glioblastoma Clin. Cancer Res. 2023 29 3172 3188 10.1158/1078-0432.CCR-22-3971 37249604
Shi, L. et al. The DRD2 antagonist Haloperidol mediates autophagy-induced ferroptosis to increase Temozolomide sensitivity by promoting endoplasmic reticulum stress in Glioblastoma. Clin. Cancer Res. 29, 3172–3188 (2023).37249604 10.1158/1078-0432.CCR-22-3971
447. Bai T Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells Biochem. Biophys. Res. Commun. 2017 491 919 925 10.1016/j.bbrc.2017.07.136 28756230
Bai, T. et al. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 491, 919–925 (2017).28756230 10.1016/j.bbrc.2017.07.136
448. Adkins JC Peters DH Faulds D Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection Drugs 1997 53 1054 1080 10.2165/00003495-199753060-00009 9179531
Adkins, J. C., Peters, D. H. & Faulds, D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 53, 1054–1080 (1997).9179531 10.2165/00003495-199753060-00009
449. Ma X CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability Cell Metab. 2021 33 1001 1012.e1005 10.1016/j.cmet.2021.02.015 33691090
Ma, X. et al. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 33, 1001–1012.e1005 (2021).33691090 10.1016/j.cmet.2021.02.015
450. Zhai B Drug delivery systems for elemene, its main active ingredient beta-elemene, and its derivatives in cancer therapy Int J. Nanomed. 2018 13 6279 6296 10.2147/IJN.S174527
Zhai, B. et al. Drug delivery systems for elemene, its main active ingredient beta-elemene, and its derivatives in cancer therapy. Int J. Nanomed. 13, 6279–6296 (2018).10.2147/IJN.S174527
451. Zhao, L. P. et al. beta-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer. J. Adv. Res. 10.1016/j.jare.2023.08.018, (2023).
452. Tang Q Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis Cell Prolif. 2020 53 e12706 10.1111/cpr.12706 31642559
Tang, Q. et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis. Cell Prolif. 53, e12706 (2020).31642559 10.1111/cpr.12706
453. Hassannia B Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma J. Clin. Investig. 2018 128 3341 3355 10.1172/JCI99032 29939160
Hassannia, B. et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J. Clin. Investig. 128, 3341–3355 (2018).29939160 10.1172/JCI99032
454. Zhang Y Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis Toxicol. Mech. Methods 2023 33 47 55 10.1080/15376516.2022.2075297 35592903
Zhang, Y. et al. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol. Mech. Methods 33, 47–55 (2023).35592903 10.1080/15376516.2022.2075297
455. Rao Z Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination J. Nanobiotechnology 2023 21 265 10.1186/s12951-023-01998-w 37563614
Rao, Z. et al. Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination. J. Nanobiotechnology 21, 265 (2023).37563614 10.1186/s12951-023-01998-w
456. Lippmann J Petri K Fulda S Liese J Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma Transl. Oncol. 2020 13 100785 10.1016/j.tranon.2020.100785 32416440
Lippmann, J., Petri, K., Fulda, S. & Liese, J. Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma. Transl. Oncol. 13, 100785 (2020).32416440 10.1016/j.tranon.2020.100785
457. Zeng L A MOF-based potent ferroptosis inducer for enhanced radiotherapy of triple negative breast cancer ACS Nano 2023 17 13195 13210 10.1021/acsnano.3c00048 37256771
Zeng, L. et al. A MOF-based potent ferroptosis inducer for enhanced radiotherapy of triple negative breast cancer. ACS Nano 17, 13195–13210 (2023).37256771 10.1021/acsnano.3c00048
458. Yang C De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence Nat. Cell Biol. 2023 25 836 847 10.1038/s41556-023-01146-4 37291265
Yang, C. et al. De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. Nat. Cell Biol. 25, 836–847 (2023).37291265 10.1038/s41556-023-01146-4
459. Zhang R Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR-19b-3p/FTH1 axis Bioact. Mater. 2022 13 23 36 35224289
Zhang, R. et al. Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR-19b-3p/FTH1 axis. Bioact. Mater. 13, 23–36 (2022).35224289
460. Feng H Stockwell BR Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol. 2018 16 e2006203 10.1371/journal.pbio.2006203 29795546
Feng, H. & Stockwell, B. R. Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol. 16, e2006203 (2018).29795546 10.1371/journal.pbio.2006203
461. Hassannia B Vandenabeele P Vanden Berghe T Targeting Ferroptosis to Iron Out Cancer Cancer Cell 2019 35 830 849 10.1016/j.ccell.2019.04.002 31105042
Hassannia, B., Vandenabeele, P. & Vanden Berghe, T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 35, 830–849 (2019).31105042 10.1016/j.ccell.2019.04.002
462. Zeng F Ferroptosis detection: from approaches to applications Angew. Chem. (Int. ed. Engl.) 2023 62 e202300379 10.1002/anie.202300379 36828775
Zeng, F. et al. Ferroptosis detection: from approaches to applications. Angew. Chem. (Int. ed. Engl.) 62, e202300379 (2023).36828775 10.1002/anie.202300379
463. Yan R The structure of erastin-bound xCT-4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis Cell Res. 2022 32 687 690 10.1038/s41422-022-00642-w 35352032
Yan, R. et al. The structure of erastin-bound xCT-4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis. Cell Res. 32, 687–690 (2022).35352032 10.1038/s41422-022-00642-w
464. Gan B How erastin assassinates cells by ferroptosis revealed Protein Cell 2023 14 84 86 36929006
Gan, B. How erastin assassinates cells by ferroptosis revealed. Protein Cell 14, 84–86 (2023).36929006
465. Cramer SL Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth Nat. Med. 2017 23 120 127 10.1038/nm.4232 27869804
Cramer, S. L. et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat. Med. 23, 120–127 (2017).27869804 10.1038/nm.4232
466. Sun Y Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells Cell Death Dis. 2021 12 1028 10.1038/s41419-021-04306-2 34716292
Sun, Y. et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis. 12, 1028 (2021).34716292 10.1038/s41419-021-04306-2
467. Zhang X Guo Y Li H Han L FIN56, a novel ferroptosis inducer, triggers lysosomal membrane permeabilization in a TFEB-dependent manner in glioblastoma J. Cancer 2021 12 6610 6619 10.7150/jca.58500 34659551
Zhang, X., Guo, Y., Li, H. & Han, L. FIN56, a novel ferroptosis inducer, triggers lysosomal membrane permeabilization in a TFEB-dependent manner in glioblastoma. J. Cancer 12, 6610–6619 (2021).34659551 10.7150/jca.58500
468. Zhao LX Graphdiyne nanoplatforms for photothermal-ferroptosis combination therapy against glioblastoma J. Control Rel. 2023 359 12 25 10.1016/j.jconrel.2023.05.035
Zhao, L. X. et al. Graphdiyne nanoplatforms for photothermal-ferroptosis combination therapy against glioblastoma. J. Control Rel. 359, 12–25 (2023).10.1016/j.jconrel.2023.05.035
469. Liu X Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis Exp. Hematol. Oncol. 2023 12 47 10.1186/s40164-023-00411-4 37198609
Liu, X. et al. Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis. Exp. Hematol. Oncol. 12, 47 (2023).37198609 10.1186/s40164-023-00411-4
470. Song R Acidity-activatable dynamic nanoparticles boosting ferroptotic cell death for immunotherapy of cancer Adv. Mater. 2021 33 e2101155 10.1002/adma.202101155 34170581
Song, R. et al. Acidity-activatable dynamic nanoparticles boosting ferroptotic cell death for immunotherapy of cancer. Adv. Mater. 33, e2101155 (2021).34170581 10.1002/adma.202101155
471. Chen K Injectable alginate hydrogel promotes antitumor immunity through glucose oxidase and Fe(3+) amplified RSL3-induced ferroptosis Carbohydr. Polym. 2024 326 121643 10.1016/j.carbpol.2023.121643 38142082
Chen, K. et al. Injectable alginate hydrogel promotes antitumor immunity through glucose oxidase and Fe(3+) amplified RSL3-induced ferroptosis. Carbohydr. Polym. 326, 121643 (2024).38142082 10.1016/j.carbpol.2023.121643
472. Anstee QM From NASH to HCC: current concepts and future challenges Nat. Rev. Gastroenterol. Hepatol. 2019 16 411 428 10.1038/s41575-019-0145-7 31028350
Anstee, Q. M. et al. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411–428 (2019).31028350 10.1038/s41575-019-0145-7
473. Umemura A p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells Cancer Cell 2016 29 935 948 10.1016/j.ccell.2016.04.006 27211490
Umemura, A. et al. p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29, 935–948 (2016).27211490 10.1016/j.ccell.2016.04.006
474. Yao L Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation Redox Biol. 2023 67 102923 10.1016/j.redox.2023.102923 37832398
Yao, L. et al. Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation. Redox Biol. 67, 102923 (2023).37832398 10.1016/j.redox.2023.102923
475. Zhang S Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis Cell Death Dis. 2023 14 340 10.1038/s41419-023-05859-0 37225709
Zhang, S. et al. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis. 14, 340 (2023).37225709 10.1038/s41419-023-05859-0
476. Mishima E Drugs repurposed as antiferroptosis agents suppress organ damage, including AKI, by functioning as lipid peroxyl radical scavengers J. Am. Soc. Nephrol. 2020 31 280 296 10.1681/ASN.2019060570 31767624
Mishima, E. et al. Drugs repurposed as antiferroptosis agents suppress organ damage, including AKI, by functioning as lipid peroxyl radical scavengers. J. Am. Soc. Nephrol. 31, 280–296 (2020).31767624 10.1681/ASN.2019060570
477. Fang X Ferroptosis as a target for protection against cardiomyopathy Proc. Natl Acad. Sci. USA 2019 116 2672 2680 10.1073/pnas.1821022116 30692261
Fang, X. et al. Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl Acad. Sci. USA 116, 2672–2680 (2019).30692261 10.1073/pnas.1821022116
478. Kong P Ferroptosis triggered by STAT1- IRF1-ACSL4 pathway was involved in radiation-induced intestinal injury Redox Biol. 2023 66 102857 10.1016/j.redox.2023.102857 37611494
Kong, P. et al. Ferroptosis triggered by STAT1- IRF1-ACSL4 pathway was involved in radiation-induced intestinal injury. Redox Biol. 66, 102857 (2023).37611494 10.1016/j.redox.2023.102857
479. Wang D LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia J. Hematol. Oncol. 2023 16 30 10.1186/s13045-023-01429-1 36973755
Wang, D. et al. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. J. Hematol. Oncol. 16, 30 (2023).36973755 10.1186/s13045-023-01429-1
480. Wang D Antiferroptotic activity of non-oxidative dopamine Biochem. Biophys. Res. Commun. 2016 480 602 607 10.1016/j.bbrc.2016.10.099 27793671
Wang, D. et al. Antiferroptotic activity of non-oxidative dopamine. Biochem. Biophys. Res. Commun. 480, 602–607 (2016).27793671 10.1016/j.bbrc.2016.10.099
481. Gaschler MM Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis ACS Chem. Biol. 2018 13 1013 1020 10.1021/acschembio.8b00199 29512999
Gaschler, M. M. et al. Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis. ACS Chem. Biol. 13, 1013–1020 (2018).29512999 10.1021/acschembio.8b00199
482. Hao L Zhong YM Tan CP Mao ZW Quantitative tracking of endoplasmic reticulum viscosity during ferroptosis by an iridium complex via TPPLM Chem. Commun. 2021 57 5040 5042 10.1039/D1CC01062J
Hao, L., Zhong, Y. M., Tan, C. P. & Mao, Z. W. Quantitative tracking of endoplasmic reticulum viscosity during ferroptosis by an iridium complex via TPPLM. Chem. Commun. 57, 5040–5042 (2021).10.1039/D1CC01062J
483. Dixon SJ Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis Elife 2014 3 e02523 10.7554/eLife.02523 24844246
Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).24844246 10.7554/eLife.02523
484. Hong SH Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression Oncotarget 2017 8 115164 115178 10.18632/oncotarget.23046 29383150
Hong, S. H. et al. Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression. Oncotarget 8, 115164–115178 (2017).29383150 10.18632/oncotarget.23046
485. Saito A Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2 J. Biol. Chem. 2011 286 4809 4818 10.1074/jbc.M110.152900 21135100
Saito, A. et al. Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J. Biol. Chem. 286, 4809–4818 (2011).21135100 10.1074/jbc.M110.152900
486. Su N Kilberg MS C/EBP homology protein (CHOP) interacts with activating transcription factor 4 (ATF4) and negatively regulates the stress-dependent induction of the asparagine synthetase gene J. Biol. Chem. 2008 283 35106 35117 10.1074/jbc.M806874200 18940792
Su, N. & Kilberg, M. S. C/EBP homology protein (CHOP) interacts with activating transcription factor 4 (ATF4) and negatively regulates the stress-dependent induction of the asparagine synthetase gene. J. Biol. Chem. 283, 35106–35117 (2008).18940792 10.1074/jbc.M806874200
487. Lee AS Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential Nat. Rev. Cancer 2014 14 263 276 10.1038/nrc3701 24658275
Lee, A. S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 14, 263–276 (2014).24658275 10.1038/nrc3701
488. Gao H Ferroptosis is a lysosomal cell death process Biochem. Biophys. Res Commun. 2018 503 1550 1556 10.1016/j.bbrc.2018.07.078 30031610
Gao, H. et al. Ferroptosis is a lysosomal cell death process. Biochem. Biophys. Res Commun. 503, 1550–1556 (2018).30031610 10.1016/j.bbrc.2018.07.078
489. Hou W Autophagy promotes ferroptosis by degradation of ferritin Autophagy 2016 12 1425 1428 10.1080/15548627.2016.1187366 27245739
Hou, W. et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12, 1425–1428 (2016).27245739 10.1080/15548627.2016.1187366
490. Kang R Tang D Autophagy and Ferroptosis - What’s the connection? Curr. Pathobiol. Rep. 2017 5 153 159 10.1007/s40139-017-0139-5 29038744
Kang, R. & Tang, D. Autophagy and Ferroptosis - What’s the connection? Curr. Pathobiol. Rep. 5, 153–159 (2017).29038744 10.1007/s40139-017-0139-5
491. Torii S An essential role for functional lysosomes in ferroptosis of cancer cells Biochem. J. 2016 473 769 777 10.1042/BJ20150658 26759376
Torii, S. et al. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem. J. 473, 769–777 (2016).26759376 10.1042/BJ20150658
492. Wu Y The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression Mol. Cancer 2020 19 39 10.1186/s12943-020-01157-x 32103754
Wu, Y. et al. The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. Mol. Cancer 19, 39 (2020).32103754 10.1186/s12943-020-01157-x
493. Chen X Kang R Kroemer G Tang D Organelle-specific regulation of ferroptosis Cell Death Differ. 2021 28 2843 2856 10.1038/s41418-021-00859-z 34465893
Chen, X., Kang, R., Kroemer, G. & Tang, D. Organelle-specific regulation of ferroptosis. Cell Death Differ. 28, 2843–2856 (2021).34465893 10.1038/s41418-021-00859-z
494. Stockwell BR Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease Cell 2017 171 273 285 10.1016/j.cell.2017.09.021 28985560
Stockwell, B. R. et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285 (2017).28985560 10.1016/j.cell.2017.09.021
495. Cui S Identification of hyperoxidized PRDX3 as a ferroptosis marker reveals ferroptotic damage in chronic liver diseases Mol. Cell 2023 83 3931 3939.e3935 10.1016/j.molcel.2023.09.025 37863053
Cui, S. et al. Identification of hyperoxidized PRDX3 as a ferroptosis marker reveals ferroptotic damage in chronic liver diseases. Mol. Cell 83, 3931–3939.e3935 (2023).37863053 10.1016/j.molcel.2023.09.025
496. Zhang Y Imidazole Ketone Erastin Induces ferroptosis and slows tumor growth in a mouse lymphoma model Cell Chem. Biol. 2019 26 623 633.e629 10.1016/j.chembiol.2019.01.008 30799221
Zhang, Y. et al. Imidazole Ketone Erastin Induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 26, 623–633.e629 (2019).30799221 10.1016/j.chembiol.2019.01.008
497. Chen X A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma Cancer Res. 2006 66 11323 11330 10.1158/0008-5472.CAN-06-1536 17145878
Chen, X. et al. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res. 66, 11323–11330 (2006).17145878 10.1158/0008-5472.CAN-06-1536
498. Zeng F Prognostic implications of metabolism related gene signature in cutaneous melanoma Front. Oncol. 2020 10 1710 10.3389/fonc.2020.01710 33014847
Zeng, F. et al. Prognostic implications of metabolism related gene signature in cutaneous melanoma. Front. Oncol. 10, 1710 (2020).33014847 10.3389/fonc.2020.01710
499. Ding Y Fei Y Lu B Emerging new concepts of degrader technologies Trends Pharm. Sci. 2020 41 464 474 10.1016/j.tips.2020.04.005 32416934
Ding, Y., Fei, Y. & Lu, B. Emerging new concepts of degrader technologies. Trends Pharm. Sci. 41, 464–474 (2020).32416934 10.1016/j.tips.2020.04.005
500. Luo T Intracellular delivery of glutathione peroxidase degrader induces ferroptosis in vivo Angew. Chem. Int Ed. Engl. 2022 61 e202206277 10.1002/anie.202206277 35924720
Luo, T. et al. Intracellular delivery of glutathione peroxidase degrader induces ferroptosis in vivo. Angew. Chem. Int Ed. Engl. 61, e202206277 (2022).35924720 10.1002/anie.202206277
501. Banik SM Lysosome-targeting chimaeras for degradation of extracellular proteins Nature 2020 584 291 297 10.1038/s41586-020-2545-9 32728216
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).32728216 10.1038/s41586-020-2545-9
